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Abstract  
 
Perturbation of androgen signalling drives progression of human prostate cancer (CaP) to 
castration-resistant prostate cancer (CRPC). Additionally, CaP is initiated and maintained 
by cancer stem cells (CSC)s which are analogous to normal prostate stem cells (SC)s. This 
study presents a qPCR assay to detect androgen receptor gene amplification (GAAR), 
which is the most common mechanism of castration resistance (>30%). Also, the 
epigenetic regulation and function of two SC-silenced genes with tumour-suppressive 
activity (Latexin (LXN) and Retinoic Acid Receptor Responder 1 (RARRES1)) were 
interrogated using micro-ChIP, transcriptional profiling and mass spectrometry.  
Traditionally, GAAR is detected using FISH which is labour-intensive and semi-
quantitative, limiting clinical applicability. The mechanism of action of LXN or RARRES1 in 
CaP is unknown, and epigenetic regulation by DNA methylation has been ruled-out in 
primary CaP.  
The qPCR assay can detect GAAR in minor cell populations (~1%) within a heterogeneous 
sample and also quantifies X chromosome aneuploidy (XCA) - a predictor of poor-
prognosis in CaP. GAAR and XCA were detected in near-patient xenografts derived from 
CRPC-tissue indicating that these abnormalities are present in cells capable of in vivo 
tumour-reconstitution.  
Micro-ChIP analysis of fractionated primary CaP cultures identified bivalent chromatin at 
LXN and RARRES1 promoters. Transcriptomic profiling failed to reveal significant changes 
in gene expression after transduction with LXN or RARRES1. However, an interactome for 
LXN and RARRES1 was successfully generated in PC3 cells. Additionally, confocal 
microscopy of mVenus-tagged LXN revealed a pan-cellular distribution which is reflected 
in the interactome.  
Screening for GAAR and XCA, using a high-throughput qPCR assay, could facilitate a 
targeted-medicine strategy in the treatment of CaP and CRPC. Further investigation of 
the LXN and RARRES1 interactomes may identify their mechanism(s) of action and the 
micro-ChIP assay could be used to identify epigenetic-inducers of LXN and RARRES1 which 
could provide a CSC-targeted strategy for CaP treatment. 
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  14                                  Chapter 1. Introduction 
1. General Introduction 
1.1. The Prostate  
The prostate is a male-specific organ located at the base of the bladder. This walnut sized 
and shaped glandular organ plays an important role in reproduction by producing 
prostatic fluid; a major constituent of semen (Huggins et al., 1942). Prostate fluid is 
alkaline and contains bio-available zinc as well as various proteins. Increased pH protects 
sperm from the acidic environment encountered in the vagina, while protein constituents 
of prostate fluid, which include: prostate specific antigen (PSA) and prostatic acid 
phosphatase (PAP), are essential for sperm function along with zinc (Carpino et al., 1994). 
Additionally, the prostate also has a contractile function acting as a ‘tap’ for bladder flow. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Zonal Anatomy of the Normal Prostate.  
 
The zonal anatomy of the prostate  showing the relative locations of the Transitional 
zone, Central zone, Anterior fibromuscular stroma and Peripheral zone. 
 
From: (Hammerich, 2009) 
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1.1.1. Topographical Anatomy of the Human Prostate 
In contrast to the murine prostate, which is composed of distinct anatomic lobes, the 
human gland can be divided into four anatomical zones, which were identified by McNeal 
in a comprehensive study of 500 prostates. McNeal used the relationship of each region 
to the urethra to provide a central reference point (McNeal, 1981). An anatomical 
diagram of the prostate is shown in (Fig. 1.) (Hammerich, 2009). 
These four zones are listed below: 
 Anterior fibromuscular stroma 
 Central zone 
 Peripheral zone 
 Transition zone 
 
A simplified two zone scheme is more often used, which comprises: 
 
 Inner section (transition zone) 
 Outer section (peripheral and central zones) 
 
Anterior fibromuscular stroma comprises one third of the prostate. This zone contains 
very few or no acini and is composed primarily of smooth muscle and dense fibrous tissue. 
A major function of this zone is in voluntary and involuntary sphincter functions. 
 
Approximately 20% of the glandular tissue is contained within the cone-shaped central 
zone. At the apex of the central zone is the verumontanum whilst at its base is the bladder 
neck.  It has been calculated that 5% of adenocarcinomas occur within the central zone. 
 
The peripheral zone is the largest, containing approximately 75% of the glandular tissue. 
It is distal to the central zone and has a horseshoe-shaped structure. Chronic prostatitis 
and post-inflammatory atrophy primarily afflict this zone, which is also the primary site 
for malignant transformations; ~70% of adenocarcinomas originate at this site (McNeal 
et al., 1988). 
The transitional zone is composed of two equal sections which surround the urethra. 
Whilst only representing 5% of the prostatic volume it has significant clinical importance, 
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as the location in which age-related benign prostatic hyperplasia (BPH) occurs (McNeal, 
1978). 
 
1.1.2. Histological Anatomy of the Human Prostate 
Glandular prostate tissue consists of epithelial and stromal cells, physically separated by 
a basement membrane (BM). Laminins and collagen are the primary constituents of the 
BM (Yurchenco and O'Rear, 1994, Navdaev and Eble, 2011) which is also composed of 
glycoproteins and proteoglycans which play an important role in fundamental cellular 
processes including proliferation and differentiation (Gonçalves et al., 2015). In the case 
of proteoglycans these functions are attributed to the glycosaminoglycan side chains such 
as chondroitin sulphate which has shown to be enriched in areas of active proliferation 
(Gonçalves et al., 2015).  The stroma is located beneath the BM and helps serve the 
metabolic needs of the epithelium (in which blood vessels are normally absent) in a 
paracrine manner (Hayward et al., 1997, Giri et al., 1999).  
 
Phenotypically the stromal compartment is composed of both smooth muscle cells and 
fibroblasts, which can be distinguished from each other immunohistochemically: The 
short and broad smooth muscle cells express high levels of alpha-smooth muscle actin 
and have very low expression of prolyl 4-hydroxylase (Goodpaster et al., 2008, Kooistra 
et al., 1995). In contrast, the fibroblasts show the reciprocal expression pattern for these 
two markers (Kooistra et al., 1995). 
 
Functionally the stroma plays a role in the survival, proliferation and differentiation of 
epithelial cells by secreting growth factors, which include fibroblast growth factor (FGF) 
and epidermal growth factor (EGF) (Berry et al., 2008, Giri et al., 1999). Of important note 
is that a proportion of the stromal cells express the androgen receptor (AR) and thus serve 
as an androgen signalling link to basal cells within the epithelium, in which AR expression 
is low or absent (Berry et al., 2008).  
 
The epithelial compartment is arranged in glands composed of ducts, which branch out 
from the urethra and terminate into acini. Several distinct types of epithelial cells exist 
within in the prostate: (a) secretory luminal cells, (b) basal cells, and (c) rare 
neuroendocrine cells (Liu and True, 2002). Architecturally, the epithelium is arranged in a 
bilayer, consisting of a basal layer which is in direct contact with the BM and an upper 
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luminal layer which is physically separated from the BM by the basal layer (Collins and 
Maitland, 2006) (Fig. 2.). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Organisation of the Prostate Gland.  
 
Cross-section of the ductal region of the prostate, with labels indicating cell types 
present in prostatic ducts, including luminal secretory cells and basal cells. 
 
From: (Collins and Maitland, 2006)  
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The luminal cell fraction is terminally differentiated, performing the highly specialised role 
of manufacturing and secreting proteins, such as PSA and PAP (Collins and Maitland, 
2006, Lang et al., 2009) into the glandular lumina. They can be distinguished from the 
basal cells by their columnar morphology and expression of PSA, PAP, cytokeratin 8 (CK8), 
CK18 and high expression AR (Yu et al., 2012, Wang et al., 2012). These cells are also 
dependent on androgens for their survival. 
 
In contrast, basal cells have a very low secretory activity (Collins and Maitland, 2006, Lang 
et al., 2009) and are relatively undifferentiated. Morphologically, they are small and 
flattened or cuboidal. In contrast to luminal cells, they are independent of androgens for 
their survival and they express CD44, α2β1 integrin (which facilitates there attachment to 
the BM via collagen type IV (Liu et al., 2009, Collins et al., 2005)) tumour protein p63 
(p63), CK5 and CK14 (Wang et al., 2012, Collins et al., 2005). A summary of prostate 
epithelial markers is shown in (Table. 1.). 
 
The basal cells also represent the proliferative compartment within the prostate 
epithelium as shown by the expression of markers of proliferation, such as tyrosine-
protein kinase Met (c-met), antigen KI-67 (Ki67) and proliferating cell nuclear antigen 
(PCNA) (Bonkhoff et al., 1994). For example, it has been shown that 70% of the Ki67 
positive cells are located within the basal layer (Bonkhoff et al., 1994).  
A third group of prostatic epithelial cells are the terminally differentiated, post-mitotic 
neuroendocrine cells. These cells represent a small proportion of cells within the prostate 
epithelium and stroma (Lang et al., 2009). They secrete neuropeptides such as bombesin, 
neurotensin, serotonin, chromogranin A, neuron-specific enolase, and calcitonin 
(Rumpold et al., 2002), and are devoid of both luminal and basal markers.  
 
 
 
 
 
 
Table. 1.  Common Antigenic Markers Used to Distinguish Prostate 
Epithelial Cells. 
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1.1.3. Development and Maturation of the Prostate 
By understanding the development and maturation of the prostate during embryogenesis 
and puberty respectively, one can elucidate important pathways, which may be pertinent 
to diseases of the prostate, including cancer. Due to ethical constraints the vast majority 
of evidence on prostate development comes from laboratory rodents. One major caveat 
in the translation of these findings is that the murine and human prostates have 
significant morphological differences. For example, murine acini have  a discontinuous 
epithelial bi-layer in which a proportion of luminal cells are in direct contact with the BM 
(Marker et al., 2003). 
The murine embryonic development of the prostate is dependent on androgens, namely 
5α-dihydrotestosterone which is synthesized from foetal testosterone by the action of 
5α-reductase (Hammerich, 2009). Androgens exert their effect directly upon the AR-
expressing urogenital sinus mesenchyme (USM). Prostate development occurs late in 
embryogenesis whereby the prostate gland develops from epithelial invaginations within 
the posterior USM (Bhavsar and Verma, 2014), resulting in a multi-layered epithelium 
encapsulated by stroma. As development continues the basal epithelium invades the 
surrounding stroma producing immature secretory structures. Apart from the well-
defined androgen axis there are several other signalling pathways that play an essential 
role in organogenesis of the prostate; including the wingless-related integration site 
protein (Wnt), retinoid, fibroblast growth factor (FGF), and Hedgehog pathways (Yu et al., 
2012, Maitland, 2013) (Fig. 3.). This figure also depicts both mesenchymal and epithelial 
stem cells (SC)s of the prostate, which persist in the adult organ. Importantly the diagram 
depicts the prostate epithelial stem cell as being located basally in close contact with the 
stromal compartment to facilitate ‘cross-talk’ between the two cell types. 
While AR mediated transcriptional activity is a requirement for prostate formation 
(patients with complete androgen insensitivity syndrome (CAIS) don’t develop a prostate 
(Quigley et al., 1995)), it is only essential within the USM (Cunha and Donjacour, 1987, 
Cunha et al., 1987). This was shown by grafting of AR-deficient murine urogenital sinus 
epithelium (UGE) in combination with wild type murine USM, which resulted in androgen-
dependent ductal morphogenesis (Fig. 4.). The complementary experiment i.e. AR- USM 
and wild type UGE resulted in vaginal-like differentiation (Cunha et al., 1987, Cunha and 
Donjacour, 1987). 
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Other key transcription factors involved in cell fate decisions during prostate 
embryogenesis include; p63 (deletion of which causes a complete absence of epithelial 
cells (Senoo et al., 2007), forkhead box protein A1 (Foxa1), and homeobox protein Nkx-
3.1 (Nkx3.1) (Bhatia-Gaur et al., 1999, Gao et al., 2005) (Fig. 4.). Knockout of Foxa1 in 
murine models results in a population of cells that individually express markers 
representative of both luminal and basal cell types namely co-expression of Ck8 (luminal 
marker), Ck5 and Ck14 (basal markers)  (Gao et al., 2005). Nkx3.1-deletion results in 
prostate epithelial cell hyperplasia and incomplete differentiation and curtailed secretory 
activity (Gao et al., 2005). 
Expansion of the prostate is induced by the testosterone surge that occurs during 
puberty, and consequent increase in 5α-dihydrotestosterone (DHT). A significant 
morphological feature of maturation is the differentiation of the multi-layered 
epithelium, to produce the mature epithelial bi-layer (Wang et al., 2012, Yu et al., 2012, 
Collins and Maitland, 2006, Liu et al., 2009, Lang et al., 2009, Collins et al., 2005). The 
prostate continuously enlarges, reaching the adult weight of approximately (mean 11g) 
by 25–30 years of age (Berry et al., 1984). 
 
Fig. 3. Development of the Normal Prostate. 
Stem cells in the epithelial and stromal compartments are shown in green, basal cells 
in blue, and luminal cells in pink, with cells positive for AR-expression depicted by red 
nuclei. Hormone-responsive stromal cells are also shown in pink.  
From: (Maitland, 2013) 
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Fig. 4. Elucidating the Roles of Key Transcription Factors (Foxa1, Nkx3.1 and AR) in 
Prostate Embryogenesis by Utilising Murine Knockout Models.  
Normal development of the adult murine prostate results in differentiation of the 
embryonic urogenital sinus (UGS) into fully differentiated basal and luminal 
compartments the latter exhibiting secretory activity of proteins such as PSA and 
PAP. 
The early growth and differentiation of the UGS is driven by androgen signalling, 
elevated Foxa1 and Nkx3.1 transcription factors.  
In the epithelium, knockout of Foxa1 results in a block of luminal cell differentiation 
with the luminal cell compartment exhibiting an cytokeratin expression profile 
consistent with a luminal-basal intermediate phenotype namely co expression of 
Ck5, Ck8 and Ck14. Another morphological abnormality of the Foxa-1 null mice is an 
unusually thick layer of smooth muscle cells which is a perturbation of normal 
differentiation of the mesenchyme. On a molecular level Foxa1 knockout results 
elevation of Bmp, Shh and Notch signalling and a reduction of Nkx3.1 signalling. 
Functionally the resulting prostate has an impaired secretory activity. 
The early prostate development in Nkx3.1 knockout mice is characterised by the 
accumulation of epithelial cells that show limited differentiation and secretory 
activity. As development continues, the Nkx3.1-null prostate exhibits prostatic 
intraepithelial neoplasia (PIN). 
Knockout of AR only in the prostate epithelium (stromal compartment retains AR 
expression) results in normal structural development and epithelial-
compartmentalisation. However, the luminal cell compartment fails to fully 
differentiate and secretory proteins are not expressed. 
 
From: (Gao et al., 2005) 
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1.2. Non-Malignant Disorders of the Prostate 
There are several disorders which affect the prostate including, prostatitis, benign 
prostatic hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and prostate cancer 
(CaP). 
 
1.2.1. Prostatitis 
Prostatitis is the most frequent disorder of the prostate with an incidence rate of 2-10% 
of males (Krieger et al., 2008). It is caused by inflammation and typically occurs in the 
central zone. Prostatitis is strongly implicated as a major contributory factor to the 
development of BPH (Nickel, 2008). 
This inflammatory response can be elicited by many factors including: 
 
 pathogenic infection 
 stress 
 autoimmunity 
 physical injury 
 
1.2.2. Benign Prostatic Hyperplasia 
Benign Prostatic Hyperplasia (BPH) is a non-malignant proliferative disease which affects 
the stromal and epithelial compartments of the transition zone. It is well established that 
BPH is an age-related disease (Berry et al., 1984). BPH leads to an enlargement of the 
prostate and subsequently obstruction of the urethra leading to increased resistance of 
urine flow and frequency of urination (Muruganandham et al., 2007). Palliative treatment 
of BPH typically involves trans-urethral resection of the prostate (TURP) to reduce the 
pressure on the bladder and obstruction of the urethra (Bozdar et al., 2010). 
 
1.2.3. Prostate Intraepithelial Neoplasia 
Prostate Intraepithelial Neoplasia (PIN) is a pre-invasive abnormal proliferation within 
pre-existing ducts and acini, most commonly affecting the peripheral zone (Bostwick et 
al., 2004). Cytological and histological abnormalities, such as nuclear and nucleolar 
enlargement as well as loss of stratification of the epithelial bilayer are also apparent.  
These abnormalities are also associated with CaP and therefore it is unsurprising that 
high-grade PIN (HGPIN) is considered to be a predictive precursor of malignant disease. A 
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molecular example of this is ERG rearrangement present in at least some HGPIN 
specimens (Morais et al., 2016). 
 
1.3. Prostate Cancer 
 
1.3.1. Epidemiology of Prostate Cancer  
The lifetime risk of developing prostate cancer is 1 in 8 for men in the UK. In 2013, there 
were 47,300 new cases of prostate cancer in the UK (Cancer Research UK, 2016) (Fig. 5.). 
The latest analysis of prostate cancer incidence shows that there is no statistically 
significant geographical variation in prostate cancer incidence within the UK (Cancer 
Research UK, 2016). In contrast, there is a significant correlation between prostate cancer 
incidence and age. For example, 54% of new cases of prostate cancer were diagnosed in 
men aged 70 years and over, whilst only 1% were diagnosed in the under-50s (Cancer 
Research UK, 2016). However, in men aged 75 and over (in the UK) incidence has 
decreased from 46% to 36% in the last 30 years (Cancer Research UK, 2016). This can be 
explained by the more efficient detection of early stage disease in relatively younger 
patients by PSA testing. 
Prostate cancer incidence rates have increased overall in the UK since the late-1970s and 
this finding is mirrored around the globe (Cancer Research UK, 2016). Much of the 
increase in incidence both in the UK and in many other countries worldwide can be 
attributed to incidental detection of prostate cancers following transurethral resection of 
the prostate (TURP) and PSA screening. In addition to more efficient detection of CaP, it 
is also likely that increased CaP incidence is rising alongside the average age of the 
population. 
The genetic background of the individual is also a major contributing factor to the 
development of CaP. This is evident when looking at the age-standardised rates of CaP 
for different racial profiles. These data show that white males have an incident rate of 
96.0 to 99.9 per 100,000 which is significantly greater than the rates for Asian males (28.7 
to 60.6 per 100,000) and significantly lower than the most at risk population – black males 
(120.8 to 247.9 per 100,000) (Cancer Research UK, 2016). 
In general CaP has a low mortality rate when compared to other cancers, such as 
pancreatic cancer (Carter and Nguyen, 2012). A demonstrative statistic of this is: in 2012 
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more than 181,000 men with prostate cancer were still alive ten years after diagnosis 
(Cancer Research UK, 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Prostate Cancer Statistics.  
A. The mean number of new CaP cases diagnosed (grouped by age) and 
age-specific incidence rates per 100,000 people of CaP diagnosed in the UK 
between 2011-2013. Modified from (Cancer Research UK). 
B. European age-standardised incidence rates per 100,000 plotted against 
year of diagnosis for several age groups. 
From: (Cancer Research UK, 2016) 
A 
B 
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1.3.2. Low Grade-Organ Confined CaP 
CaP is characterised by aberrant differentiation resulting in the accumulation of 
abnormally differentiated and replicating AR expressing luminal cells, (to >99% of all 
epithelial cells) (Nagle et al., 1987). Alongside this dramatic increase in luminal cells there 
is a concomitant decrease in the percentage of basal cells (Grisanzio and Signoretti, 2008) 
and a progressive loss of glandular structure as the disease progresses. These 
observations were originally made by Gleason, who classified them in the grading system 
for CaP that bears his name (Fig. 6.) (Gleason, 1966, Humphrey, 2004). Another gross 
histological change associated with invasive CaP is the destruction of the BM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Schematic of the Gleason Grading Criterion. 
 
Histology patterns of CaP corresponding to Gleason grade. All black depicts cancer, 
most cytological detail is omitted except in the right side of pattern 4, where tiny 
structures are intended to describe a hypernephroid pattern.  
 
From:  (Humphrey, 2004) 
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1.3.3. Cancer-Cell Invasion and Metastasis 
Escape of CaP from the prostate capsule is associated with a significant increase in 
mortality, i.e. the five-year survival rate for organ-confined CaP is 100%, whereas for 
metastatic disease, it is 30.6% (Schroder, 2012). Prostatectomy and radiotherapy are only 
effective in treating locally invasive lesions and as such they do not represent curative 
therapy once the tumour has disseminated (Lang et al., 2009, Schroder, 2012). Skeletal 
metastasis is the most significant cause of morbidity and mortality in CaP and is present 
in 90% of patients who die as a result of CaP. According to the ‘seed and soil hypothesis’ 
(proposed by Stephen Paget in 1889 as a means to explain the non-random distribution 
of breast cancer metastasis) disseminating tumour cells (seeds) will preferentially grow 
at sites with a compatible microenvironment (soil) (Langley and Fidler, 2011). This 
frequency indicates that the microenvironment of the bone is well suited to promote 
survival and expansion of CaP cells. Alternatively (or concomitantly) CaP may have the 
propensity to develop a homing ability specific to this site. Other common sites for 
metastatic spread of CaP are the lymphatic system, liver and lung (Schroder, 2012).  
 
Distant metastases are established through a complex cascade of events termed the 
invasion-metastasis cascade: The first step is local-invasion through the BM and stroma 
typically through epithelial-to-mesenchymal transition (EMT). Cancer cells may invade via 
mesenchymal or amoeboid invasion programs depending on the microenvironmental 
conditions (Valastyan and Weinberg, 2011). The best characterised change during EMT is 
loss of E-cadherin expression. After escape from the local-environment the disseminating 
cells enter lymphatic system or blood vessels by intravasation. Circulating tumour cells 
(CTC) can be isolated from liquid biopsies taken from patients with a range metastatic 
cancers including but not limited to breast, colon, and prostate cancer (Giuliano et al., 
2014, Danila et al., 2011, Nagrath et al., 2007). After transport the metastatic cells must 
then arrest at a compatible site. Individual primary tumours preferentially metastasise to 
specific secondary organs. In the case of CaP, the primary site of metastasis is the bone 
(90%) (Bubendorf et al., 2000). In order to enter the secondary tissue the metastatic 
carcinoma cells must escape the circulatory system. One mechanism by which 
extravasation can be achieved in a non-specific manner is by inducing capillary vessel 
failure by pressure exerted by colony expansion within the vessel, allowing the cancer 
cells to be in direct contact with the new tissue (Al-Mehdi et al., 2000, Stoletov et al., 
2010). Finally the metastatic cells must be able to survive and proliferate at the secondary 
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site in order to produce a secondary tumour.  The microenvironment of the metastatic 
site usually differs vastly from the primary site, but may have enough similarity or 
compensate with alternative growth/survival factors to allow outgrowth. Alternatively 
the new site may be co-opted to produce the necessary factors to allow survival and 
proliferation (Psaila and Lyden, 2009). After overcoming the challenges of a new 
microenvironment, a small fraction of disseminated cancer cells may form a clinically 
significant metastasis. Not every cell in a tumour possesses the ability to metastasise to 
distant organs, and the evidence suggests that metastases directly arise from cancer stem 
cells (CSC)s  (Hermann et al., 2007).  
 
1.3.4. Diagnostics in Prostate Cancer 
As with all cancers, prognosis is drastically improved if the disease is discovered at an 
early stage.  As such serum biomarker measurements have been developed to augment 
detection, via traditional digital rectal examination and symptomatic presentation. 
Serological biomarkers used in the screening of CaP include, but are not limited to, 
prostate cancer gene 3 (PCA3) and PSA (Schroder, 2012). However, the most prognostic 
diagnostic procedure is histological analysis of biopsied tissue according to the Gleason 
score (Gleason, 1966).  
 
1.3.4.1. PSA Testing  
Currently, diagnosis of CaP relies on the quantification of serum PSA levels (Placer and 
Morote, 2011). Increased PSA in the serum is linked to CaP progression. PSA testing (using 
>4 ng/ml as a cut-off) has a false positive rate of 34.5% and a false negative rate of 28.8%  
(Brawer, 1999). The false positive rate can be cut by approximately one third by increasing 
the cut-off to 10 ng/ml however this also comes with concomitant doubling in the false 
negative rate (Brawer, 1999). PSA occurs in blood as stable complexes with protease 
inhibitors (complexed PSA (cPSA)) or as free PSA (fPSA). Calculating the percentage of 
fPSA increases the diagnostic accuracy compared to total PSA levels, especially when cPSA 
is in the ‘grey area’ (4-10 ng/ml) (Catalona et al., 1998). Perhaps the biggest problem  of 
using  PSA as a diagnostic marker for CaP, is that PSA is detectable in other tissues, 
including: ovary, breast and lung (Smith et al., 1995). Moreover, high PSA levels are 
associated with other conditions including: inflammation or infection and PIN. Perhaps 
most importantly, it has been shown that many CaP patients have serum PSA levels within 
the ‘normal range’ i.e. less than 4 ng/ml (Thompson et al., 2004). Consequently, the use 
  29                                  Chapter 1. Introduction 
of PSA levels as a diagnostic test should be combined with further tests, to give an 
accurate diagnosis. 
1.3.4.2. Gleason Grading 
Once elevated serum PSA is detected, multiple biopsies are taken and the histological –
morphology of the tissue is graded according to the Gleason system (Fig. 7.) (Gleason, 
1992). Two areas of the tissue with the most prevalent disease are graded with a value of 
1-5. The grade of the two areas is then combined to give Gleason score between 2 and 
10. Towards the end of the last decade, the Gleason grading system was revisited with 
the major aim of reducing subjectivity (Epstein, 2010). Key updates included designating 
all cribiform cancers and poorly formed glands as Gleason grade 4 (Epstein, 2010). 
1.3.5. Current Treatments for Prostate Cancer  
 
1.3.5.1. Active Surveillance 
Some cases of low-grade CaP will not progress to a clinically relevant disease state, so 
active surveillance represents the most appropriate strategy. The aim of active 
surveillance is to omit treatment (which will negatively impact on quality of life) until the 
cancer is showing signs of progression. Upon which curative treatment strategies will be 
employed. Active surveillance involves monitoring PSA serum levels every 3 months and 
repeat-biopsies for histological analysis every 6-12 months 
 
1.3.5.2. Radical Prostatectomy 
Radical prostatectomy is the surgical removal of the prostate, and can be laparoscopic or 
via traditional open surgery (Walsh, 2005, Bill-Axelson et al., 2005). This form of 
intervention is the most common and most successful in treating organ confined CaP, but 
is obsolete when the cancer has disseminated (Bill-Axelson et al., 2005). Side-effects of 
this therapy include impotence (Catalona et al., 1999, Bill-Axelson et al., 2005). 
 
1.3.5.3. Radiotherapy 
Radiotherapy represents an alternative to prostatectomy (Duchesne, 2011). It involves 
the use of ionising radiation to destroy the malignant tissue based on the fact that cancer 
cells often have defects in DNA repair mechanisms which make them more susceptible to 
DNA damage. There are two main forms of radiotherapy namely, external beam radiation 
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therapy and brachytherapy (Duchesne, 2011). External beam radiotherapy, utilises an 
external source of radiation focused at the tumour mass. Brachytherapy involves the 
surgical implantation of small radioactive pellets as close as possible to the tumour mass. 
As such, brachytherapy is more invasive than the external beam method but has the 
advantage of fewer side-effects as normal surrounding tissue is exposed to much lower 
doses of radiation. 
 
1.3.5.4. Androgen Deprivation Therapy 
The treatment of choice for locally metastatic CaP and disseminated cancer is androgen 
deprivation therapy (ADT) which utilises the androgen dependent survival of luminal cells 
to cause dramatic reduction in tumour burden. This form of treatment was pioneered by 
Huggins in the 1940’s, using orchiectomy to dramatically reduce androgen production 
(Maitland et al., 2006, Huggins et al., 1941). Orchiectomy has since been largely replaced 
as a therapy by chemical blockade of AR-ligand binding. Today there are several 
therapeutic agents that act to disrupt the androgen axis at various points, this ranges 
from disruption of androgen biosynthesis via inhibition of the cytochrome P450 17A1 
(CYP17) enzyme (Abiraterone) to  suppression of testosterone production through the 
gonadotropin-releasing hormone (GnRH) agonist – Zoladex (de Bono et al., 2011, Peeling, 
1989).  
After the initial success of ADT there is an almost inevitable re-emergence of the disease, 
which returns with increased aggressiveness. As such ADT has been described as palliative 
rather than curative (Azzouni and Mohler, 2012, Lorente et al., 2015). 
 
1.3.6. Castration-Resistant Prostate Cancer  
CaP which has relapsed following ADT is termed castrate resistant CaP (CRPC). CRPC is 
incurable by current treatment strategies and is associated with dramatically increased 
mortality due to its highly aggressive nature. CRPC has an average survival rate of 2-3 
years. Even with the initiation of chemotherapy regimens, such as docetaxel (alone or as 
part of a combination therapy) median survival is only extended by a few months 
(Dubrovska et al., 2012).  
 
The prevailing model proposes that CRPC arises through neo-Darwinian evolution of CaP 
in response to ADT (Stanevsky et al., 2013, Gingrich et al., 1996, Saraon et al., 2011). In 
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this model, rare cells with an inherent survival advantage to low androgen levels are 
selected by ADT.  
 
Counter intuitively, CRPC remains dependent on AR function for maintenance and 
expansion (Shen and Abate-Shen, 2010). This can be explained by examining the common 
mechanisms by which castrate resistance has been shown to evolve. Genomic 
amplification of the AR gene (GAAR) (located on the X chromosome at Xq11-12) is the 
most frequent genetic alteration in CaP which results in increased AR expression 
(Waltering et al., 2012). It has been shown that amplification of the AR gene leads to 
increased AR expression at both the mRNA and protein levels (Waltering et al., 2012). 
Increasing AR expression sensitises CaP cells to very low levels of circulating androgens 
that persist during ADT (Waltering et al., 2012). GAAR has been detected in up to 80% of 
CRPCs, of which 30% have a high level amplification (≥3.8 copies per cell) (Visakorpi et al., 
1995, Waltering et al., 2012). In contrast, AR amplification represents a very rare event in 
hormone-naïve CaP.  
 
Gain of function mutations can result in a mutated-AR with increased affinity for 
androgens compared to wild type or relaxed ligand specificity (Nadiminty and Gao, 2012). 
In addition, constitutively active splice variants of AR also contribute to the development 
of a CRPC phenotype (Marcias et al., 2010, Hu et al., 2011, Hörnberg et al., 2011, Hu et 
al., 2012). Alternatively, mutation can result in a constitutively active AR which is 
independent of ligand binding for its function (Dubrovska et al., 2012, Céraline et al., 
2004, Lapouge et al., 2007).  
 
1.4. Cancer Stem Cells  
The initiation and development of prostate cancer can be described by two models, ‘the 
stochastic model’ and  the ‘hierarchy model’. 
The stochastic model views the tumour as a homogeneous cellular mass, with every cell 
possessing the ability to initiate tumour formation (Iyer and Saksena, 1970).  
Currently the most widely accepted model of cancer initiation and progression is the 
hierarchy model which is also referred to as the CSC model. The hierarchy model views 
the cancer as a heterogeneous population displaying a hierarchical organisation. Cancer 
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is proposed to be the outcome of aberrant organogenesis (Chandler and Lagasse, 2010). 
Within this hierarchy only a subset of cells are capable of founding and maintain a cancer, 
these cells are termed cancer CSCs (Chandler and Lagasse, 2010). 
 
The first discovery of CSCs was in acute myeloid leukaemia in the mid-1990s (Lapidot et 
al., 1994). These leukemic stem cells represented only a small fraction of leukaemia cells 
(0.2%) and shared key cell surface expression characteristics with normal hematopoietic 
stem cells (CD34+ CD38-) (Bonnet and Dick, 1997). Only those cells were able to 
recapitulate the original tumour when serially transplanted in non-obese diabetic severe 
combined immunodeficiency (NOD-SCID) mice (Bonnet and Dick, 1997). There is now a 
plethora of evidence for CSCs in many diverse solid cancers (Al-Hajj et al., 2003, Singh et 
al., 2004, Ricci-Vitiani et al., 2007, Eramo et al., 2008, He et al., 2009) including CaP (Collins 
et al., 2005). This explosion in CSC identification was facilitated by the identification of 
normal tissue stem cells and the markers used to isolate them.  A matter of debate within 
the CSC field is the origin of the CSC, which is proposed to be the normal stem cell or short 
lived progenitor cells that have acquired the ability to self-renew (Fig. 7.)  (Al-Hajj et al., 
2004) (Chandler and Lagasse, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Comparison of the Stochastic and Hierarchy Models of Cancer.  
Comparison of the two major models of cellular heterogeneity in cancer namely the 
stochastic model and the hierarchy model. In the stochastic model every cell has the 
potential for toumorigenisis. In the hierarchy model only the CSC compartment is 
tumuorigenic. 
      = self-renewal 
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There are two core properties of CSCs, which are shared with normal SCs, ‘property 1’ the 
ability to self-renew i.e. a proportion of the CSC-progeny are themselves CSCs and 
‘property 2’ is the ability to give rise to the various cells found in the original malignancy 
(Vermeulen et al., 2008). Experimentally, both properties are interrogated by serial-
xenotransplantation into immune-compromised mice. This experiment allows 
histological analysis of the resulting tumour allowing comparison to the original tumour. 
Additionally if the resulting tumour can be serially transplanted, this demonstrates the 
self-renewal capacity of the CSC population (Vermeulen et al., 2008). 
  
1.4.1. Therapeutic Implications of CSCs 
Conventional cancer therapy regimens specifically target rapidly dividing cells which is a 
hallmark of the majority of cells within a tumour. Such therapies can be very efficient at 
inducing clinical remission associated with a reduction in tumour-mass and disease 
biomarkers (Smith and Pienta, 1999, Tabarestani and Ghafouri-Fard, 2012). A major 
caveat of this form of intervention is that CSCs are inherently resistant to traditional 
chemotherapy and radiotherapy (Kim et al., 2009). They are therefore preferentially 
spared by these treatments, leading to a net enrichment (Gupta et al., 2009, Rich, 2007, 
Costello et al., 2000). After initial treatment success, relapse often occurs with the 
returning disease having a more invasive and resistant phenotype (Crawford et al., 1989, 
Scher et al., 2008). The development of resistance in the returning bulk tumour is due to 
the CSC population (accelerated by their genetic and epigenetic plasticity) resulting in the 
ability to produce resistant progeny (Vinogradova et al., 2015, Tabarestani and Ghafouri-
Fard, 2012, Yang et al., 2014).  
 
Mechanisms of CSC resistance include: low mitotic activity, resistance to DNA damage, 
efflux of cytotoxic compounds and an elevated apoptotic threshold. One of the reasons 
why normal SCs divide infrequently and cellular amplification is undertaken by 
intermediate cells on the path to differentiation is to minimise the potential for 
replication errors and hence mutation within the SC population.  This lack of proliferation 
confers resistance to drugs that induce cell-death by causing mitotic arrest e.g. taxanes 
(Murray et al., 2012). 
 
For normal homeostatic turnover and function of a tissue to be maintained throughout 
the lifetime of an organism, the SC compartment must be maintained. When non-stem 
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cells incur DNA damage that is beyond a threshold of repair they undergo senescence or 
apoptosis, preventing the propagation of mutations. The same is true for SCs however, 
the threshold is much greater due to increased expression of DNA repair pathways. CSCs 
also have augmented DNA repair systems which grants them increased resistance to 
genotoxic stress induced by radiotherapy (Bao et al., 2006, Rich, 2007, Ishii et al., 2008).  
 
Chemical agents must achieve a certain concentration to exert their effect on a particular 
system. A further mechanism by which normal SCs limit the potential for DNA damage is 
to actively pump cytotoxic compounds out of the cell (Dean, 2009). This is achieved by 
high expression of ATP-binding cassette (ABC) transporters (Dean, 2009, Elliott et al., 
2010). These pumps offer multi-drug resistance, as a single transporter (within this gene 
family) has the ability to efflux several diverse molecules. It has been shown that CSCs 
also share this feature (Dean, 2009, Gatti et al., 2009).   
 
As well as indirect mechanisms to reduce apoptotic events, CSCs also have perturbed 
apoptosis pathways, such as increased expression of anti-apoptotic proteins such as B-
cell lymphoma 2 (bcl-2) and survivin (Hambardzumyan et al., 2008, Altieri, 2013, An et al., 
2007). 
 
1.4.2. Prostate Stem cells and Cancer Stem Cells 
Early and compelling evidence of a SC population within the normal adult prostate came 
from observations of androgen cycling experiments (castration followed by androgen 
restoration in male rats) (Kyprianou and Isaacs, 1988, English et al., 1989, Evans and 
Chandler, 1987). Upon castration it was observed that the prostate undergoes rapid 
involution and, with the restoration of androgens, the gland regenerates both 
morphologically and functionally (English et al., 1989). The key findings of these 
experiments were: Firstly, the cycle of involution and regeneration can be performed 
many times and restoration of physiological levels of androgens even after long term 
castration (>3 years) resulted in full prostate regeneration (Isaacs et al., 1987). This 
implies the existence of a long lived prostate SC within the prostatic epithelium (Isaacs et 
al., 1987). Secondly, 90% of prostate epithelial are cells lost through apoptosis upon 
castration. This, alongside the loss of secretory activity of the prostate, indicates that the 
secretory luminal compartment is preferentially destroyed by castration (Bonkhoff and 
Remberger, 1996, Wang et al., 2015). Thus the prostate SCs are independent of 
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androgens for survival, but are capable of producing differentiated luminal progeny upon 
restoration of androgens (Bonkhoff and Remberger, 1996, Wang et al., 2015).  
 
The phenotype of the murine SC, i.e. basal or luminal is a topic of much debate and 
experimental endeavour. 5-bromo-2'-deoxyuridine (BRDU) incorporation assays showed 
that quiescent label retaining cells were present in both basal and luminal populations 
(Tsujimura et al., 2002). Fractionation experiments utilising the stem cells antigen-1 (Sca-
1) cell surface antigen led to the identification of rare (lineage markers (Lin)-, Sca-1+, 
cluster of differentiation (CD)133+, CD44+, CD117+) cells which have the capacity to 
recapitulate a complete prostate acinus in vivo (Leong et al., 2008). In support of a luminal 
phenotype, castration-resistant Nkx3.1-expressing cells (CARN cells), which express CK18, 
AR and are p63 negative, are capable of regenerating both luminal and basal cells after 
androgen cycling (Wang et al., 2009). CARN cells were also capable of reconstituting 
vestigial prostate structures in vivo, upon engraftment of a single cell (Wang et al., 2009). 
Both basal and luminal progenitor fractions are capable of tumourigenesis when 
manipulated in a physiologically relevant way i.e. after phosphatase and tensin homolog 
(PTEN) deletion (Lawson et al., 2010, Choi et al., 2012, Korsten et al., 2009). The likelihood 
is that several murine prostate-progenitor compartments could be the cell type of origin 
of CaP, but which one is dominant in nature is hard to establish as mice, unlike dogs and 
humans, do not spontaneously develop CaP without genetic manipulation. Furthermore 
due to the morphological and histological differences between the rodent and human 
prostate, both pre- and post- castration (Fig. 8.), it is debatable whether translation of 
paradigms from mouse to man is valid (Maitland, 2013). 
 
In contrast to rodent models, there is a large body of evidence that the normal human 
prostate epithelial SC resides in the basal compartment. For example, it was found that 
only p63 positive cells were present after the xenografting of benign human prostate 
glands into immunocompromised mice and subjecting the host to prolonged periods of 
castration (Huss et al., 2004).  Additionally, tumour-associated calcium signal transducer 
2 (Trop2)+, CD44+, CD49f-high, basal cells had sphere-forming ability in vitro and could 
regenerate prostate structures in vivo (Goldstein et al., 2010, Garraway et al., 2010). 
 
Perhaps the most compelling evidence of a common SC for all human prostate epithelial 
cells came from in situ lineage tracking, which utilises the unique accumulation of 
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mitochondrial mutations in SCs which leads to traceable respiratory chain defects e.g. 
cytochrome c oxidase activity (Blackwood et al., 2011). This natural ‘barcoding’ is retained 
in their progeny (Blackwood et al., 2011). These experiments performed in human tissue 
showed an entire acinus including basal, luminal, and even neuroendocrine cells were 
formed from the progeny of a single cell (Blackwood et al., 2011). 
 
Collins et al., (2001) utilised the combined knowledge of prostate SCs residing within the 
basal cell compartment and the composition of the BM (collagen type I and IV) to develop 
a method for enriching for cells with stem-like properties. This group used CD44 
expression to fractionate the basal cells followed by selection of cells which adhered 
rapidly (within 5 minutes) to collagen type I (high expression of α2β1 integrin). It was 
found that the enriched basal population had enhanced colony forming efficiency in vitro 
and when transplanted into immune compromised mice, formed prostatic-like acini 
which stained positively for basal and luminal cytokeratins, AR, PAP and PSA (Collins et 
al., 2001). There are similarities with other SC systems, such as the skin, where adhesion 
to the BM is important for spatial regulation of SCs within a niche (Jones and Watt, 1993). 
Work from the same laboratory showed that the α2β1hi population could be further 
enriched for colony forming efficiency and development of prostatic acini in vivo by 
including the SC marker CD133 in the selection protocol (Richardson et al., 2004). 
 
As with other cancers (Adhikari et al., 2011) it was found that CSCs resident within CaP 
tumours could be isolated based on the presence of the same cell surface markers as their 
non-malignant counterparts, namely: CD44, α2β1 and CD133 (Collins et al., 2005). These 
cells have extensive proliferation potential, increased invasiveness in Matrigel™ assays 
and the ability to differentiate into cells with a luminal phenotype (AR+, PAP+, CK18 
(Collins et al., 2005, Lang et al., 2009)).  Even more compelling evidence for the existence 
of a basal CSC in CaP comes from xenotransplantation studies in which fewer than 100 
cells expressing glycosylated CD133 were required to initiate tumour growth in 
immunodeficient mice harbouring homozygous deletion of recombination activating 
gene 2 (Rag2) and Interleukin (IL)-2 receptor γ-chain gene (γC) (leading to a complete 
block of both B and T cell development) bred on a BALB/c background (BALB/c/RAG2-/-
/γC-/-). This was in contrast to cells displaying a luminal phenotype (CD24) from the same 
tumours (Maitland et al., 2011).   
  37                                  Chapter 1. Introduction 
Further evidence in support of human CaP CSCs having a basal phenotype was provided 
by (Rajasekhar et al., 2011), who isolated in vivo tumour-initiating cells (TICs) that did not 
express luminal markers such as AR or PSA, but were positive for basal markers (CD44 and 
elevated integrin expression). These cells were capable of in vitro sphere-formation and 
in vivo tumour-initiation in which they recapitulated the heterogeneity of the original 
parent tumour (Rajasekhar et al., 2011). Conversely fractionated tumour prostate-specific 
membrane antigen (PSMA) positive cells were not tumourigenic in vivo (Rajasekhar et al., 
2011). Using a modified Hoechst 33342 dye efflux assay, Brown et al identified a stem cell 
enriched side population (SP) with high efflux capacity consistent with other SC and CSC 
systems (Brown et al., 2007). These cells could be induced to form spheroids with acinus 
like morphology in vitro by 3D culture in the presence of androgens (Brown et al., 2007). 
The SP population was immuno-phenotyped and was found to be enriched for cells 
expressing basal markers such as CK5 and CK14 (Brown et al., 2007). 
 
In conclusion, the available evidence suggests that the human prostate SC is resident 
within the basal compartment and has a cell surface expression and cytokeratin profile 
consistent with basal cells. Currently there is little evidence to suggest a luminal stem cell 
compartment as seen in rodents.  
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Fig. 8. Castration-Induced Prostate Gland Involution. 
 
Stem cells in the epithelial and stromal compartments are shown in green, basal cells 
in blue, and luminal cells in pink, with cells positive for AR-expression are depicted by 
red nuclei. Hormone-responsive stromal cells are also shown in pink. The effects of 
androgen withdrawal upon castration are distinct in human and rodent, prostates, 
reflecting the distinctive anatomies of the prostate tissue from these sources. 
 
From: (Maitland, 2013) 
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1.5. Introduction to Models 
1.5.1. Cell Lines 
There are several established cell lines representing normal, BPH, CaP and CRPC 
phenotypes (Berthon et al., 1995, Hayward et al., 1995, Maitland et al., 2001, Miki et al., 
2007, Attard et al., 2009, Marques et al., 2006, Horoszewicz et al., 1980, Korenchuk et al., 
2001, Stone et al., 1978, Kaighn et al., 1979). They represent the traditional modes for 
studying CaP, and are as such well-studied experimentally. Cell lines have several 
advantages as model systems, they can be maintained for extended passages,  are easily 
manipulated, can be adapted to culture under different conditions and are readily 
transfectable. 
Alongside these advantages there are also significant disadvantages in the predictive 
value of cell lines. Long-term culture of cells in serum-containing media can induce 
karyotype defects (Lee et al., 2006). Also there are gross changes in gene expression 
profiles due to genome-wide DNA hypermethylation (Meissner et al., 2008). Perhaps 
most importantly, due to their clonal nature, they do not represent the cellular 
heterogeneity observed in human disease. 
In summary, cell lines are an excellent model for optimising protocols, testing hypothesis 
and generating preliminary data. However, due to the limitations discussed above they 
are often not clinically predictive. As such a number of well characterised cell lines are 
used in this project representing benign, malignant and metastatic models of CaP, 
isolated from various tissues (Table. 2).  
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Table. 2. Prostate Cell Lines. 
From: (Oldridge, 2012)  
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1.5.2. Primary Cultures 
Primary prostate cells from normal, benign or malignant patient tissues can be cultured 
in vitro following enzymatic cellular-dissociation or explant outgrowth (Niranjan et al., 
2013, Frame et al., 2016, Peehl, 2005).  Epithelial cultures were derived from samples 
taken, with consent and ethical approval, from patients undergoing radical 
prostatectomy, TURP or cystectomy. Primary cultures offer several advantages over cell 
line models. Most importantly, primary cultures have not been immortalised by strong 
oncogenes such as simian vacuolating virus 40 (SV40) large T antigen. They also retain 
cellular heterogeneity in early passage cultures which is lost in cell lines after repeated 
passages. Additionally, there is less culture-related karyotype and methylome changes 
although these abnormalities increase with serial passaging (Liang and Zhang, 2013).    
There are also several disadvantages of primary in vitro prostate cultures as an 
experimental tool. Importantly, primary cultures have a limited life-span and are difficult 
to manipulate by traditional transfection. Also, primary cultures select for more 
proliferative cells with a predominantly basal phenotype. Prostate cancer is characterised 
by an accumulation of luminal cells which do not survive or proliferate in vitro (Peehl et 
al., 1994, Peehl, 2005, Frame et al., 2016). Another major disadvantage of primary 
cultures, is that there are currently no cell-surface markers that can distinguish normal 
from malignant cells. Consequently, normal cells overgrow malignant cells after extended 
passage (Chen et al., 2012, Peehl, 2005).   
Primary cultures represent the best in vitro strategy to investigate CaP having been shown 
to be a better predictive model than cell lines (Peehl, 2005, Niranjan et al., 2013, Miki et 
al., 2007).  However, it must be noted that several (typically three or more) patient 
samples must be investigated due to the inter-patient heterogeneity of disease. This can 
be in both a gross (Gleason grade) and subtle way e.g. presence of transmembrane 
protease, serine 2 (TMPRSS2) to ETS-related gene (ERG) gene fusion (TMPRSS2-ERG) 
and/or PTEN status. 
1.5.3. Mouse Models 
Transgenic mouse models, have traditionally utilised a potent oncogene, typically SV40 
large T antigen under the control of a prostate specific promoter such as the probasin 
promoter (e.g. Transgenic Adenocarcinoma Mouse Prostate (TRAMP) mice)) (Greenberg 
et al., 1995, Asamoto et al., 2001). SV40 large T antigen is a viral oncogene, known to 
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inactivate the critical cellular tumour-suppressor protein - tumour protein p53 (p53) and 
retinoblastoma protein (Rb) (Ahuja et al., 2005). The TRAMP model is characterized by 
spontaneous and rapid progression to prostatic neoplasia at 28 weeks, with 100% 
penetrance of lymph node metastasis (Greenberg et al., 1995). 
One major criticism of these early transgenic mouse models is that the frequency of p53 
mutations seems to be lower in CaP than in other cancers (Schlomm et al., 2008, Kubota 
et al., 1995), which is consistent with the observation that Li-Fraumeni patients carrying 
germline p53 mutation have a low incidence of CaP compared to other malignancies 
(Malkin, 2011). 
More recent transgenic mouse models have sought to more closely mimic the human 
disease by utilising deletion of PTEN to induce oncogenic transformation (Wang et al., 
2003, Parisotto and Metzger, 2013, Grabowska et al., 2014). PTEN deletion is the most 
common genetic abnormality in CaP, deletions occur in approximately 23% of HGPIN, 69% 
of localised CaP, and 86% of metastatic CRPC (Yoshimoto et al., 2006, Holcomb et al., 
2009, Grabowska et al., 2014). 
Due to neoplasia arising in multiple organs of the PTEN+/- mice and the embryonic 
lethality of PTEN knock-out  mice, subsequent models have used targeted PTEN deletion 
in an organ-specific manner using CRE-LOX recombination (Kwak et al., 2013). 
Unfortunately these models fail to recapitulate key features of the human disease. In 
animals aged 11-17 weeks with established CaP, castration did extend the survival time 
compared to control animals. Additionally, castrated animals maintained prostates 5-10 
fold larger than wild-type (WT) controls even after 11 weeks of castration (Grabowska et 
al., 2014, Wang et al., 2003). In these castrated animals, AR levels measured by 
immunohistochemistry were diminished, which is not the case in human CRPC (Wang et 
al., 2003, Grabowska et al., 2014, Holzbeierlein et al., 2004). Perhaps most importantly, 
castration or genetic ablation of the AR at any age in the PTEN flox/flox model does not 
prevent tumour formation, suggesting that these tumours are inherently androgen 
independent (Mulholland et al., 2011, Grabowska et al., 2014). 
In summary, transgenic models have major advantages in terms of amenability to genetic 
manipulation and lineage tracking experiments which are impossible to perform in man 
(for ethical reasons). However, they represent at best an approximation of the human 
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disease which is inherently deficient due to the morphological and histological differences 
between the human and mouse prostate. 
An alternative to transgenic systems is near-patient xenotransplantation, in which donor 
prostate biopsies are engrafted into immunocompromised mice such as NOD-SCID or 
BALB/c/RAG2-/-/γC-/- (Rea et al., 2016, Valkenburg and Williams, 2011, Nemeth et al., 
1999, Lawrence et al., 2013). The grafting can be either subcutaneous, to the renal 
capsule (advantage of increased blood supply) or orthotopic (have the advantage of 
growth within the prostate microenvironment). 
Subcutaneous grafts demonstrated the lowest ‘take rates’ and differentiation (Tentler et 
al., 2012). Renal subcapsular engraftment is most efficient (>90%), additionally this form 
of engraftment also demonstrated differentiation and expression of AR and PSA (Tentler 
et al., 2012). However, the orthotopic models exhibit the highest degree of differentiation 
e.g. AR and PSA expression (Wang et al., 2005, Tentler et al., 2012). 
Xenotransplantation has many advantages over transgenic models, as no transgenes are 
necessary for transformation, cells retain the same unique array of genetic abnormalities 
present in the original disease and cells can be manipulated ex-vivo. As with primary 
cultures, inter-patient disease-heterogeneity is a confounding factor that must be 
accounted for by experimentation on several grafts. The presence of both benign and 
malignant epithelial cells in grafts accurately reflects the original tumour, but it makes 
analyses more difficult. A further complication is incurred by the tendency of host 
(murine) fibroblasts to invade the graft (Hayward et al., 1992). In conclusion, near-patient 
xenograft models are the ‘gold standard’ in which human TICs can be studied in vivo 
(Siolas and Hannon, 2013, DeRose et al., 2011). In comparison, transgenic mouse models 
give rise to murine tumours which may have different properties to the corresponding 
human disease, and in vitro cultures of primary human cells fail to fully replicate 
epithelial-stroma interactions, angiogenesis and metastasis. 
 
1.6. Regulation of Gene Expression in the Prostate Epithelium  
For the prostate epithelium to function properly it is essential that tissue homeostasis is 
maintained i.e. there is an equilibrium between proliferation, differentiation and self-
renewal of a long-term progenitor pool. Ultimately it is the differing expression of genes 
at the protein level that bestows the unique properties upon each distinct cell type within 
the prostate epithelium. Gene expression can be modulated by controlling the 
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transcription of a gene and/or by controlling the translation of mRNA to protein. 
Transcriptional control involves regulation by specific transcription factors and co-factors 
within the cell which bind to their target sequences within the promoter and/or enhancer 
regions of the target gene. The transcriptional activity of a particular region of DNA can 
be silenced by reversible DNA methylation (Jones and Laird, 1999). Additionally, the 
accessibility of the gene to transcription factors, cofactors and the transcription 
machinery can be modulated at the epigenetic level by modification of histone proteins 
which dictate how condensed the DNA is at a particular region (Ducasse and Brown, 
2006). Post-transcriptional control of gene expression has many forms which influence 
the rate of translation by modulating the half-life of the target mRNA species. mRNA half-
life can be modulated by polyadenylation  of the 3’ end, capping of the 5’ end, and by 
targeted translation silencing and/or degradation by microRNAs (miRNAs) (Ghosh and 
Jacobson, 2010, Huntzinger and Izaurralde, 2011). 
It is accepted that androgens and therefore AR is a critical regulator of prostate epithelial 
cell differentiation during development (Kellokumpu-Lehtinen et al., 1981) (discussed in 
the next section). In addition AR signalling is essential for the survival of the exocrine 
luminal cells, in the adult prostate (English et al., 1987). 
Inactivation of PTEN facilitates activation of phosphoinositide 3-kinase (PI3K) (Majumder 
and Sellers, 2005). PI3K generates phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) from 
phosphatidylinositol 4,5-bisphosphate (PIP2) via phosphorylation at the inner leaflet of 
the plasma membrane. Important downstream targets of PI3K via PIP3 include 
serine/threonine Kinase 1 (Akt) (Majumder and Sellers, 2005). PIP3, once generated in 
the plasma membrane, recruits Akt and phosphoinositide-dependent kinase-1 (PDK1) to 
the plasma membrane through an interaction between the phosphoinositide and  Akt or 
PDK1 pleckstrin homology domains. Once recruited to the plasma membrane, Akt is 
phosphorylated and activated by PDK1. Thus, PTEN-null cells also harbour constitutively 
high-levels of Akt signalling, resulting in enhanced survival and proliferation (Majumder 
and Sellers, 2005). 
Several other pathways are important in the development and differentiation of the 
prostate epithelium. The regulation of prostate morphogenesis is mediated, in part, by 
androgens, but also involves numerous signalling  pathways, including Sonic hedgehog 
(SHH) (Sanchez et al., 2004), Fibroblast  Growth  Factor  10  (FGF10) (Prins and Putz, 2008) 
and Bone Morphogenetic Protein 4 and 7 (BMP4 and BMP7) (Pu et al., 2004). SHH and 
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FGF10 have been shown to promote prostate growth, while BMP4 and 7 suppress 
prostate branching (Prins and Putz, 2008, Pu et al., 2004, Grishina et al., 2005). A less 
studied signalling molecule is all-trans-retinoic acid (atRA). atRA has been shown to be a 
potent inducer of budding in the mouse prostate (Lohnes et al., 1995, Seo et al., 1997, 
Vezina et al., 2008), which involves SHH and BMP4 (increased SHH expression, and 
downregulation of BMP4) (Vezina et al., 2008, Lohnes et al., 1995, Seo et al., 1997).  
It is important to note that signalling pathways do not operate in isolation, there is 
considerable cross-talk and compensatory pathways with overlapping functions to fine 
tune cellular behaviour (Fig. 9.) (Sarker et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  46                                  Chapter 1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Pathway Cross-talk.  
The figure depicts the interaction of the PI3K/AKT pathway with AR signalling as an 
example of ‘pathway cross-talk. In the cytoplasm, AR is bound to heat-shock protein 
90 (HSP-90), this interact stabilises AR and prevents nuclear localisation. Upon 
androgen binding, AR undergoes a conformational change leading to dissociation 
from HSP-90 and subsequent phosphorylation of AR. The AR-androgen complex then 
able to enter the nucleus and  bind androgen response elements (AREs) present 
within the promoters of AR-responsive genes. Binding of AR to ARE sequences 
induces gene expression. Activation of the PI3K pathway induces  AKT 
phosphorylation and downstream signalling. Several downstream signalling events 
are likely to interact with AR transcriptional activity. These include interaction of the 
AR with FKHR and FKHRL1 transcription factors, cross-talk of AR and AKT with NF κβ; 
regulation of AR via coactivator Wnt/β- catenin, and activation of AR via the mTOR 
pathway.   
From: (Sarker et al., 2009) 
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1.6.1. Androgen Signalling  
The human AR gene is located on the X chromosome at Xq11-12 and encodes a 110 kDa 
nuclear transcription factor. The AR is composed of an amino (N)-terminal transactivation 
domain, a central DNA-binding domain, a short hinge region, and a carboxy (C)-terminal 
region containing a ligand-binding domain and a nuclear localization sequence 
(Nadiminty and Gao, 2012). The AR serves a fundamental role in prostate development, 
maturation and homeostasis as it mediates the stimulus produced by androgens, causing 
genome-wide alterations in gene expression of prostate cells, promoting proliferation, 
survival and differentiation (Nadiminty and Gao, 2012). DHT is the primary ligand of AR 
however, testosterone can bind AR directly, albeit with significantly lower affinity (Klokk 
et al., 2007).  
 
In the absence of ligand, AR exists in a functionally inactive state, residing in the cytoplasm 
as a monomeric protein complexed with chaperones, which include heat-shock proteins 
(HSPs) (Saraon et al., 2011). Ligand binding induces a conformational change in AR 
resulting in dissociation of chaperone proteins, dimerisation and transport to the nucleus 
(Saraon et al., 2011). In the nucleus, AR binds to specific DNA sequences termed androgen 
response elements (AREs), via the DNA-binding domain, promoting further association of 
transcription machinery, culminating in transcription. A schematic diagram of androgen 
signalling is shown in (Fig. 10.) (Saraon et al., 2011, Li and Al-Azzawi, 2009). 
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Fig. 10. Androgen Signalling. 
AR binding of testosterone (T) or the more potent dihydrotestosterone (DHT) leads 
to dissociation of molecular heat shock protein (HSP) chaperones. This allows 
dimerization of AR and subsequent translocation to the nucleus where AR binds to 
AREs, causing recruitment of DNA transcriptional machinery and subsequent gene 
transcription.  
From: (Li and Al-Azzawi, 2009) 
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1.6.2. Retinoic Acid 
Retinoic acid (RA) is known to play a crucial role in the development and homeostasis of 
a wide range of tissues including prostate, neuronal and liver, by its regulation of 
numerous genes involved in differentiation, proliferation and homeostasis (Seo et al., 
1997, Ito et al., 2011, Huang et al., 2009, Rhinn and Dollé, 2012). 
RAs are the ligands of a family of six nuclear ligand-activated receptors, termed retinoic 
acid receptors (RARα, β, and γ) and retinoid X receptors (RXRα, β, and γ) (Leid et al., 1992, 
Kastner et al., 1997). These heterodimeric transcription factors (RAR/RXR) bind retinoic 
acid response elements (RAREs) in target genes in the absence of RA where they act to 
inhibit expression (Bastien and Rochette-Egly, 2004, Rhinn and Dollé, 2012). Upon ligand 
binding, a conformational change is induced which leads to transcription via displacement 
of a co-repressor complex and subsequent recruitment of transcriptional co-activators, 
thereby stimulating transcription of target genes (Fig. 11.) (Leid et al., 1992, Rhinn and 
Dollé, 2012).  
RA has been shown to induce apoptosis through upregulation of caspase 7 and 9 in breast 
cancer (Donato and Noy, 2005). RA signalling promotes differentiation and also inhibits 
proliferation of SCs from many tissues including, mouse embryonic SC, human 
haematopoietic stem cells (HSCs), stem-like glioma cells and breast CSCs (Luo et al., 2007, 
Simandi et al., 2010, Campos et al., 2010, Ginestier et al., 2009). In agreement with these 
observations, inhibition of retinoid signalling induces the expansion of HSCs (Chute et al., 
2006). 
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Fig. 11. Retinoic Acid Signalling.  
RA is generated from circulating retinol or by diffusion from an adjacent cell (curved 
red arrow). RA enters the nucleus where it binds  RA receptors (RARs) and retinoid X 
receptors (RXRs) dimers (RAR/RXR). RAR/RXR are able to bind to RA-response 
elements (RAREs) in target genes promoters in the absence of ligand, where the act 
to inhibit transcription. RA binding induces a conformational change in RAR/RXR, 
thereby inducing the release of  co-repressors and subsequent recruitment of co-
activator complexes which facilitate transcription by recruitment of RNA polymerase 
II (Pol II), TATA-binding protein (TBP) and TBP-associated factors (TAFs). 
From: (Rhinn and Dollé, 2012) 
  51                                  Chapter 1. Introduction 
1.7. Epigenetic Regulation  
Epigenetics is the study of heritable changes in gene activity or function, in contrast to 
genetics, these changes are not associated with modification of the DNA sequence itself. 
 
1.7.1. Histone Modifications and Chromatin Remodelling 
The histone code (posttranslational modification(s) of histone tails) influences higher-
order chromatin structure by affecting contacts between different histones and between 
histones and DNA (Bowman and Poirier, 2015). DNA exists in the cell as compacted 
chromatin, this packaging is achieved through the formation of nucleosomes in which 
DNA is wound round an octamer of two subunits of each of the core histones: H2A, H2B, 
H3, H4 and linker H1 (Mariño-Ramírez et al., 2005). By controlling chromatin architecture, 
the histone code is fundamental to several key cellular processes such as transcription, 
replication and DNA repair (Bártová et al., 2008). Chromatin exists in two major states: 
 Highly condensed heterochromatin that is transcriptionally silent. 
 Relaxed euchromatin that is transcriptionally active. 
The core histone domain is flanked by protruding N- and C-terminal tails which are targets 
for several covalent modifications that determine histone-DNA interaction, including: 
methylation, acetylation, phosphorylation, poly-adenosine diphosphate (ADP) 
ribosylation, ubiquitination and glycosylation (Fig. 12.) (Bannister and Kouzarides, 2011, 
Kim, 2014). 
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Fig. 12. Chromatin Conformations. 
Schematic diagram illustrating euchromatin and heterochromatin. Heterochromatin 
on the left is characterized by DNA methylation and deacetylated histones, is 
condensed and inaccessible to transcription factors (closed chromatin 
conformation), which is repressive regulation of transcription. On the contrary, 
euchromatin on the right is in a loose form and transcriptionally active; DNA is 
unmethylated and histone tails acetylated (open chromatin conformation), which is 
active regulation of transcription  
From: (Kim, 2014) 
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The most well studied histone-phosphorylation event is the formation of gamma H2A 
histone family, member X (γH2AX) which is the product of phosphorylation of serine 139 
of the H2AX variant histone (Rossetto et al., 2012). This modification is one of the earliest 
events in response to DNA damage, and functions to direct diverse DNA repair 
mechanisms to the site of DNA damage. It is now recognised that histone phosphorylation 
also plays an important role in transcriptional regulation as well as chromatin 
organisation (Rossetto et al., 2012). 
Acetylation and methylation are two of the best-studied histone modifications, both can 
play a positive and negative role in gene activation (Bannister and Kouzarides, 2011). The 
outcome is dependent on the nature and position of the alteration, e.g. mono-, di- or tri- 
methylation of lysine 27 on histone 3 (H3K4), lysine 36 on histone 3 (H3K36) and lysine 79 
on histone 3 (H3K79) results in enhanced transcription but, methylation of lysine 9 on 
histone 3 (H3K9), lysine 27 on histone 3 (H3K27) and lysine 20 on histone 4 (H4K20) 
usually results in gene silencing (Vakoc et al., 2006). 
Histone acetyltransferases (HATs) catalyse the acetylation of lysine residues, removing 
the positive charge on the histone tail, resulting in reduced affinity between histones and 
DNA. As a result the DNA is more accessible to the transcription machinery (Gallinari et 
al., 2007, Bannister and Kouzarides, 2011).  
Histone deacetylases (HDACs) act in the opposite way to HATs. They deacetylate lysine 
residues resulting in condensed chromatin and repression of transcription in the majority 
of cases (Fig. 13.) (Bannister and Kouzarides, 2011, Kim, 2014). Acetylation of histones 
can be experimentally modified by treating cells with HDAC inhibitors (HDACI), which 
include trichostatin A, sodium butyrate and valproic acid (Biermann et al., 2011). 
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Fig. 13. Histone Tail Modifications. 
Illustration of histone code according to active and repressive markers. DNA is 
wrapped around histone octamer of the four core histones H2A, H2B, H3, and 
H4. Histone H1, the linker protein, is bound to DNA between nucleosomes. 
Different amino acids constituting histone tails are represented along with the 
different covalent modification specific of each residue. Active marks are 
represented in the upper part of the figure and repressive marks are represented 
in the lower part of the figure. Lysine (K), arginine (R), serine (S), and threonine 
(T)  
From: (Kim, 2014) 
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1.7.2. MicroRNAs 
miRNA are small non-coding RNAs (18-25 nucleotides long), which are first synthesised as 
primary (Pri)-miRNA species before being subsequently processed into precursor (Pre)-
miRNA (Macfarlane and Murphy, 2010). Pre-miRNAs are then exported from nucleus and 
cleaved in the cytoplasm to produce the mature miRNA. The mature miRNAs function by 
binding to complementary mRNA molecules. Modulation of mRNA expression is achieved 
through a RNA-induced silencing complex (RISC) which degrades target mRNAs 
(Macfarlane and Murphy, 2010). Cancer often displays an altered miRNA expression 
profile compared to normal cells, typically overexpressing oncogenic miRNAs and 
downregulating miRNAs that function as tumour suppressors (Sassen et al., 2008). 
1.7.3. Long Non-Coding RNAs 
The advent of next generation sequencing technology has facilitated the discovery of 
novel transcripts, a significant portion of which are not from known protein coding genes. 
Long non-coding RNAs (lncRNA) are >200 nucleotides in Length. lncRNAs can be antisense 
transcripts, pseudogenes, transcribed intronic regions, divergent transcripts (from either 
the sense or antisense strand of protein coding genes) or stand-alone i.e. the genomic 
location of these lncRNA does not overlap with protein coding genes (Kung et al., 2013).  
lncRNAs are involved in several aspects of biology including imprinting and 
developmental regulation. One well studied role is in the inactivation of one copy of the 
X chromosome in females providing dosage compensation. X chromosome inactivation 
mainly controlled by cluster of lncRNAs collectively called the X-inactivation centre (Kung 
et al., 2013). In CaP, the lncRNA – PCA3 is used as a diagnostic marker as its expression is 
restricted to prostate tissue and is overexpressed in CaP (Schroder, 2012). 
1.7.4. DNA Methylation  
The only known epigenetic modification of DNA itself is DNA methylation. Typically this is 
through methylation of cytosine, at position C5 in CpG dinucleotides (Jin et al., 2011). 
DNA methylation represses transcription directly, by inhibiting the binding of specific 
transcription factors, and indirectly, by recruiting methyl-CpG-binding proteins and their 
associated repressive chromatin remodelling activities (Curradi et al., 2002). DNA 
methylation patterns are critical regulators of development and are also required for 
correct functioning of differentiated tissues. They must therefore be established and 
maintained with high fidelity (Robertson, 2005). DNA methylation has been shown to 
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regulate transcription, embryonic development, genomic imprinting, genome stability 
and chromatin structure (Robertson, 2005, Jin et al., 2011). 
In normal cells, DNA methylation is most commonly associated with satellite DNA and 
parasitic elements e.g. endogenous retroviruses (Barros and Offenbacher, 2009). DNA 
methylation is controlled by DNA methyltransferases, methyl-CpG binding proteins and 
other chromatin-remodelling factors (Bogdanović and Veenstra, 2009). 
The link between cancer and DNA methylation can be demonstrated by comparing the 
genome-wide methylation status of cancer relative to normal cells. This analysis revealed 
that the genomes of cancer cells are hypomethylated (Robertson, 2005). The major cause 
of genome-wide hypomethylation in tumour cells is due to the loss of methylation from 
repetitive regions, while this may seem innocuous, it results in genomic instability (Yoder 
et al., 1997).  
 
1.8. Research Aims 
 
There is currently an ‘unmet need’ in the molecular profiling of CaP, as well as theranostic 
evaluation of CaP evolution due to ADT. This is of importance as healthcare organisations 
prioritise the use of ‘next-generation’ of ADT compounds in patients that are likely to 
respond i.e. GAAR. Traditionally, GAAR is detected by the labour intensive and semi-
quantitative fluorescent in situ hybridization (FISH) technique which is not compatible 
with high-throughput screening.  
 
A major hypothesis of the project is that a quantitative polymerase chain reaction (qPCR) 
assay could be established that is capable of detecting GAAR in a heterogeneous sample, 
and that this assay could be used to interrogate the GAAR status of primary prostate 
epithelial cultures, patient-derived tissue biopsies and near-patient xenograft models of 
CaP. 
 
The specific objectives to achieve the above hypothesis were as follows: 
 Develop and validate a qPCR based method for the identification and 
quantification of GAAR. 
 Determine the GAAR status of several near-patient xenograft models of CaP to 
investigate if the GAAR could be found in the progeny of in vivo TIC. 
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The investigation of Latexin (LXN) and Retinoic Acid Receptor Responder 1 (RARRES1) in 
CaP, was initiated by (Oldridge et al., 2013, Oldridge, 2012) through the analysis of the 
expression, regulation and function of these genes/proteins in the prostate epithelium. 
These studies determined that both LXN and RARRES1 are induced by atRA and that both 
genes have tumour-suppressive functions in vitro which were independent of 
carboxypeptidase A (CPA)-4. Additionally, it was shown that DNA methylation was the 
primary form of epigenetic regulation in prostate cell lines but not in primary cultures, 
patient tissue samples or near-patient xenograft models.  
 
The other major aim of this project was to further the study of the regulation of LXN and 
RARRES1 by testing the hypothesis that LXN and RARRES1 are epigenetically regulated by 
post-translational modification of histones. Additionally, a combined transcriptomic and 
proteomic analysis were used to elucidate the mechanism of action of LXN and RARRES1. 
 
Specific objectives were as follows: 
 Investigate the potential for epigenetic regulation of LXN and RARRES1 by post-
translational modification of histones in the putative promoter sequences of 
these genes.  
 Examine changes in gene expression upon LXN and RARRES1 overexpression 
using microarray technology. 
 Explore potential interacting partners of LXN and RARRES1 using mass 
spectrometry 
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2. Materials and Methods 
2.1. Mammalian Cell Culture 
2.1.1. Maintenance of Mammalian Cells 
Cell lines were maintained and passaged in T25, T75 or T175 flasks in a humidified 37°C 
incubator with 5% CO2. Medium constituents were supplied by Invitrogen, unless 
otherwise stated. As cultures reached 80-100% confluence they were sub-cultured using 
commercial grade 0.05% trypsin- ethylenediaminetetraacetic acid (EDTA) in phosphate-
buffered saline (PBS). The cells were passaged at a cell line dependent ratio, typically 1:3 
to 1:12. Specific culture conditions are shown in (Table. 3.). 
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Table. 3. Culture Conditions of Prostate Cell Lines. 
RPMI = Roswell Park Memorial Institute 1640 cell culture medium, FCS = 
foetal calf serum, KSFM = keratinocyte serum-free medium, BSA = Bovine 
serum albumin, SCM = stem cell medium, EGF = Epidermal growth factor, 
DMEM = Dulbecco's modified Eagle's medium, ATCC = American Type 
Culture Collection, ECACC = European Collection of Authenticated Cell 
Cultures 
From: (Oldridge, 2012) 
  60            Chapter 2. Materials and Methods 
2.1.2. Isolation and Maintenance of Primary Cultures 
Primary prostate tissue was obtained from patients undergoing radical prostatectomy or 
TURP procedures. Samples were taken with informed patient consent and approval from 
the York Research Ethics Committee. Diagnosis (BPH or CaP) was confirmed by 
histological examination. Sample details are provided in (Appendix 1.).  
 
A disposable scalpel was first used to remove a section of the tissue to be retained for 
histology. Then, the patient sample was chopped into small pieces. The pieces were 
enzymatically digested using 200 U/mg collagenase (Lorne Laboratories) which was 
dissolved in a 1:2 mixture of Keratinocyte Serum-Free Medium (KSFM) and  Roswell Park 
Memorial Institute-1640 medium (RPMI) to a total volume of 7.5 ml per gram of tissue. 
The KFSM medium was supplemented with human epidermal growth factor (EGF) (5 
ng/ml) and bovine pituitary extract (50 μg/ml). The RPMI was supplemented with  100 
U/ml antibiotic solution and 2 mM L-Glutamine. The digestion was allowed to proceed 
overnight at 37 °C with shaking at 80 revolutions per minute (RPM).  The digested tissue 
was then mechanically disrupted using trituration first by passing the digestion through a 
5 ml pipette and subsequently a blunt needle. After centrifugation at 500 x g for 10 min 
to sediment cells the collagenase was diluted out with PBS: the supernatant was 
aspirated, 10 ml PBS was added, the cell pellet was re-centrifuged at 500 x g for 10 min 
and the procedure repeated. The resulting cell pellet was further disrupted by incubation 
with 5 ml 0.05% trypsin-EDTA for 30 min at 37°C with shaking at 80 RPM.  Trypsin-EDTA 
was inactivated with R10 medium, and epithelial cells centrifuged at 300 x g for 3 min. 
Primary cells were co-cultured on type I Collagen-coated 100 mm plates (BD Biosciences) 
with STO fibroblast feeder cells (mouse origin) in stem cell media (SCM). SCM is composed 
of keratinocyte serum-free medium, 1 ng/ml granulocyte macrophage colony stimulating 
factor (Miltenyi Biotec), 5 ng/ml human EGF, 50μg/ml bovine pituitary extract, 2 ng/ml 
leukaemia inhibitory factor (Chemicon), 100 ng/ml cholera toxin (Sigma), 2 ng/ml stem 
cell factor (First Link UK Ltd) and 2 mM L-Glutamine. Sub-culturing of primary cultures 
was performed using 0.05% trypsin-EDTA. Typically, primary cultures were passaged 1:2-
1:6 and  maintained until passage 6. 
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2.1.3. Irradiation of Fibroblasts  
For inducing cell cycle arrest through irradiation of mouse STO fibroblast cells, cells were 
first grown to 80-90% confluency before being harvested by trypsinisation and 
centrifugation at 300 x g for 3 min. STO cells were then resuspended in 10 ml SCM per 
100 cm2 of culture surface and exposed to 60 Gy of radiation. Cells were routinely stored 
at 4°C for up to 3 days before use. This was routinely performed by all members of the 
lab as a rota system (although Paul Berry, Fiona Frame or John Packer performed the 
irradiation). 
2.1.4. Generation and Maintenance of Xenografts 
Xenograft models were generated by subcutaneously engrafting patient-derived tissue 
into the left flank of BALB/c/RAG2-/-/γC-/- mice. A 5α-DHT pellet (Innovative Research of 
America) was placed under the right flank (subcutaneously) to ensure the availability of 
androgens. Once the tumour volume had exceeded a width of 15 mm, it was removed 
and a small piece was passaged into a different mouse in the same manner as the primary 
engraftment. The remainder of the tissue was either fixed in formalin for histology or 
used experimentally. This was performed by Dr. Anne Collins or Paul Berry. 
2.1.5. Cryopreservation of Mammalian Cells  
For long term storage, mammalian cells were kept frozen in liquid nitrogen in the liquid 
phase. Cells to be frozen were then trypsinised and sedimented by centrifugation at 300 
x g for 3 min. The resulting cell pellet was then resuspended in freezing medium at a 
concentration of 1-2 x 106 cells per ml. The cell suspension was then divided into 1 ml 
aliquots which were frozen in cryovials. Upon thawing, cells were diluted into 15 ml of 
R10 culture medium, sedimented by centrifugation and plated in either T25 flasks (cell 
lines) or 100 mm collagen-I coated plates (primary cultures). 
 
2.1.6. Determination of Live Cell Number Using a Haemocytometer 
Total cell number live cell number was determined using Trypan Blue exclusion as a 
surrogate for viability. Live cells (non-stained cells) were then counted using a 
haemocytometer (Neubauer). To determine live cell counts 10 μl 0.4% Trypan Blue Stain 
(Sigma-Aldrich) was diluted 1:1 with 10 μl cell suspension.  
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2.2. Primary Culture Enrichment  
 
Primary prostate epithelial cultures were enriched into three major subpopulations 
representing different states of cellular differentiation. The enrichment exploits the 
differential expression of two cell surface markers namely: α2β1-integrin and CD133 as 
described previously (Collins et al., 2001; Richardson et al., 2004):  
 
 SCs have high cell surface levels of α2β1-integrin and CD133 (α2β1-
integrinhighCD133+).  
 Transit amplifying (TA) cells high levels of α2β1-integrin but negative for 
CD133 (α2β1-integrinhighCD133-).  
 Committed basal cells (CB) low levels of α2β1-integrin and negative for CD133 
(α2β1-integrinlowCD133-).  
 
2.2.1 Enrichment of α2β1-Integrin Expressing Cells  
 
At least 2-3 ~80% confluent 10 cm culture dishes of primary prostate cultures were used 
in the enrichment process. STO cells were removed by 5 min incubation with 0.05% 
trypsin-EDTA at room temperature. The trypsin was then removed and fresh 0.05% 
trypsin-EDTA was added to harvest the epithelial cells. Type I collagen-coated 100 mm 
plates were blocked with 0.3% (w/v) heat-denatured Bovine serum albumin (BSA) 
dissolved in PBS for 1 h at 37°C. 3 ml of cell suspension was plated out onto the blocked-
plates and incubated at 37°C for 20 min. Media was aspirated and the plates were washed 
5 times with 5 ml PBS which was also collected. The stored media and washes were spun 
at 300 x g  for 5 min to pellet the cells expressing low levels of α2β1-integrin (α2β1-
integrinlow; CB). The α2β1-integrinhigh adherent cells were then harvested by incubation 
with 0.05% trypsin-EDTA and used for CD133 cell isolation. 
 
2.2.2. Enrichment of CD133 Expressing Cells 
The Direct-CD133 Cell Isolation Kit (Miltenyi Biotec) was used to isolate CD133-expressing 
cells from primary prostate epithelial cultures. α2β1-integrinhigh cells were enriched (as 
described in Section 2.2.1). Up to 108 cells were resuspended in 300 μl magnetic-activated 
cell sorting (MACS) buffer (2 mM EDTA, 0.5% (v/v) foetal calf serum (FCS) in PBS), 100 μl 
FcR blocking reagent (Miltenyi Biotec) and 100 μl CD133 beads (Miltenyi Biotec) the 
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reaction was incubated at 4°C for 30 min. Cells were washed with 3 ml MACS buffer, 
centrifuged at 300 x g for 5 min and the cell pellet was suspended in 500 μl MACS buffer. 
Magnetic cell labelling and cell separation on MACS-MS columns were performed as 
directed by the manufacturer. Briefly, the MACS-MS column was first equilibrated with 
500 μl MACS buffer then cells bound to magnetic beads were allowed to pass through the 
column by gravity. Three wash steps each with 500 μl MACS buffer were utilised to collect 
the CD133- population. Finally, 1 ml MACS buffer was added to the column and the 
CD133+ cells were eluted from the beads with the ‘plunger’ provided. To increase the 
purity of the CD133+ fraction from 70-75% to 95%, the cells were passed through a 
second MACS-MS column. The CD133- and CD133+ cells were sedimented by 
centrifugation at 300 x g for 3 min, the supernatant was then carefully removed and the 
resulting cell pellets were frozen at -80°C to use in downstream applications. 
 
2.3. Transfection of Cell Lines with Plasmid DNA  
 
ViaFect transfection reagent (Promega) was used to transfect cell lines plasmid DNA. 
Typically, 0.1-2 x 105 cells per ml were plated 24 h before transfection to ensure that cells 
were at least 50% confluent at the time of transfection. The optimal ViaFect plasmid ratio 
was determined empirically for each cell line. Typically 1-3 µl of ViaFect per μg of plasmid 
was used. ViaFect reagent was first equilibrated to room temperature (RT) and was mixed 
by gentle vortexing before each use. Each transfection reaction consisted of  100-2500 ng 
plasmid DNA diluted in OptiMEM serum-free medium which was mixed by pipetting. 
ViaFect reagent was then added to the tube, and the solution was again gently mixed by 
pipetting. The DNA-ViaFect mixture was incubated at RT for 20 min to allow complex-
formation. The complexes were then introduced to cells in a drop-wise fashion. Cells were 
incubated in the presence of complexes overnight at 37°C. After incubation the DNA-
ViaFect complexes were aspirated and replaced with fresh culture medium. Cells were 
then incubated for a further 18-90 h before evaluation.  
 
2.4. Lentivirus Production 
 
Lentiviral donor, destination plasmids and packaging plasmids were a very kind gift from 
Prof Stephan Geley, Innsbruck Medical University. Details of the plasmids can be found in 
(Appendix 4.). 
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2.4.1. Bacterial Transformation  
 
Aliquots of chemically-competent bacteria, typically DH5α E. coli cells (Fisher Scientific 
Limited) were placed on ice for 30 min to gently thaw. Next, 1-5 ng of plasmid DNA was 
added to each aliquot and the resulting mixture was incubated for a further 30 min on 
ice. The bacteria were then heat-shocked for 30 s at 42°C, and immediately returned to 
ice for 2 min.  250 μl super optimal broth (SOC) medium was then added to the bacteria 
and incubated at 37°C for 1 h at 220 RPM in a shaking incubator. The bacteria were then 
plated onto lysogeny broth (LB) agar plates containing a selection antibiotic and 
incubated for 24 h at 37°C. After incubation colony screening was performed.  
 
2.4.2. Bacterial Cultures and Plasmid Purification 
 
A starter culture was initiated from a single colony from a freshly streaked selective plate. 
This was used to inoculate 5 ml of LB medium (tryptone (10 g/L), yeast (5 g/L) extract and 
NaCl (10 g/L)) containing an antibiotic for selection, before incubation for 8 h at 37°C  at 
220 RPM in a shaking incubator. The starter culture was then used to inoculate 250 ml 
selective LB media. The 250 ml cultures were allowed to grow by incubation at 37°C 
overnight with shaking (220 RPM). Bacteria were harvested by centrifugation at 1800 x g 
for 10 min using a Heraeus Megafuge 1.0R centrifuge (Thermo Fisher Scientific). The 
EndoFree Maxi kit (Qiagen) was used to generate endotoxin-free plasmid DNA according 
to manufacturer’s instruction. Bacterial cell pellets were resuspended in 10 ml Buffer p1 
(50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 μg/ml ribonuclease (RNase) A). 10 ml Buffer 
p2 (200 nM NaOH, 1% SDS (w/v)) was then added to the mixture which mixed thoroughly. 
Ice-cold Buffer P3 (3 M potassium acetate, pH 5.5) was added and the solution was 
immediately mixed. The lysate was then transferred to a QIAfilter cartridge and incubated 
at RT for 10 min. The lysate was then filtered by forcing it through the column using a 
plunger. After the lysate had been filtered, 2.5 ml Buffer ER was added to the lysate. The 
tube was then inverted several times to mix and was incubated on ice for 30 min. 
Meanwhile a Qiagen tip 500 was equilibrated with 10 ml Buffer QBT (750 mM NaCl, 5 mM 
3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.0, 15% isopropanol (v/v), 0.15% 
Triton X-100 (v/v)), the lysate was applied to the Qiagen tip and was allowed to pass 
through the Qiagen tip by gravity. The Qiagen tip was then washed twice using 30 ml of 
Buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v), 0.15% Triton X-100 
(v/v)). The plasmid was eluted by the addition of 15 ml QN buffer (1.6 M NaCl, 50 mM 
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MOPS pH 7.0, 15% isopropanol (v/v)). The plasmid DNA was then  precipitated by adding 
0.7 volumes (10.5 ml) of isopropanol and was centrifuged at 15000 x g for 30 min at 4°C 
using a Heraeus Multifuge X1R centrifuge (Thermo Fisher Scientific). The resulting plasmid 
DNA pellet was washed with 70% ethanol (v/v) at RT, re-sedimented, and air-dried for 10 
min. Finally, the plasmid DNA was then resuspended in PCR grade water (Sigma).  
 
2.4.3. Gateway™ Cloning  
 
The sequence specific recombination sites attB1.1 and attB2.1 were used to flank the 
gene of interest. These were added by 2 separate PCR reactions. The first PCR reaction 
used gene specific primers with overhangs to add the inner half of the attB sequences. 
This product was the run on a 1% agarose gel at 100 V for 1.5 h before the band was 
excised and the DNA purified from the agarose gel using Qiagen gel extraction kit (as 
described in 2.6.6.). This product was used as the template for the 2nd PCR reaction to add 
the outer half of the attB sites. The product was then separated by electrophoresis on a 
1% agarose gel at 100 V for 1.5 h before the band was excised and the DNA purified from 
the agarose gel using Qiagen gel extraction kit as described earlier. 
  
The attB flanked PCR product was then cloned into pDONR-221 which contains attP sites 
using the BP clonase. 25 fmol of attB flanked PCR product was combined with 75 NG of 
pDONR-221 and 1 μl of BP clonase. This was then made up to a volume of 5μl with PCR 
grade water. The reaction was allowed to proceed for 24 h at 25⁰C. 0.5 μl of proteinase K 
was added to the reaction which was then incubated at 37⁰C for 10 min. The entire 
content of the reaction was then used to transform bacteria as described in section 2.4.1. 
Four single colonies were isolated and cultured for plasmid purification as described in 
section 2.4.2. The four clones where then sent for sequencing to ensure that the sequence 
had not been mutated.  
 
A pDONR-221 clone containing the un-mutated gene of interest was used as the substrate 
for generating destination plasmids (pDEST) capable of producing lentiviral vectors in the 
presence of packaging plasmids. Briefly, 25 ng of pDONR-221 containing the gene of 
interest in a volume of 1 μl was mixed with 50 ng of the required pDEST (containing attR) 
sites in a volume of 1 μl. This reaction was made up to a total volume of 4 μl with PCR 
grade water (Sigma). 1 μl of 5X LR clonase II was added to the reaction the reaction was 
mixed by centrifugation. The reaction was left to proceed for 24 hours at 25⁰C. 0.5 μl of 
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Proteinase K solution was added and the reaction was incubated for 10 min at 37°C. The 
entire reaction was used to transform bacteria as described in section 2.4.1. Four single 
colonies were isolated and cultured for plasmid purification as described in section 2.4.2. 
These clones were then tested for presence of the gene of interest by PCR before further 
verification of expression of the gene of interest by western blot. 
 
2.4.4. Virus Packaging 
 
HEK293FT cells (Thermo Fisher Scientific) were used as the packaging cell line. The 293FT 
cell line is a fast-growing, highly transfectable clonal isolate derived from human 
embryonal kidney cells transformed with the SV40 large T antigen to enhance lentiviral 
production. 
 
HEK293FT cells were transfected with the pDEST of interest and the viral packaging 
plasmids psPAX2 and pVSV-G. In order to ensure consistent viral production at any scale 
and any size of transgene insert the number of molecules of each plasmid per cell used 
to transfect the HEK293FT cells was standardised. This was 1.62x105 molecules of psPAX2, 
9.25x104 molecules of pVSV-G and 3.30x105 molecules of pDEST per cell. The molecular 
ratio of the plasmids was 1.75 molecules of psPAX2: 1.00 molecules of pVSV-G: 3.57 
molecules of pDEST. 
 
ViaFect transfection reagent (Promega) was used to transfect HEK293FT cells with the 
plasmid cocktail at a ratio of 2 μl of ViaFect per μg of plasmid. This was performed in the 
same way as described in section 2.3.1 but with some minor differences. Firstly the 
HEK293FT cells were grown to 90% confluency before transfection. Secondly, the 
HEK293FT cells were plated on to tissue culture plastic coated with Poly-L-lysine (Sigma 
Aldrich) this was to prevent the confluent HEK293FT cells from sloughing off during 
harvesting of the virus-containing supernatant.  Finally the scale of virus production 
needed for large scale experimentation necessitated the transfection to be carried out on 
10 cm dishes. 
 
HEK293FT cells were transfected as described above. 12 h post transfection the culture 
media was replaced with fresh culture medium to remove transfection reagents which 
may be cytotoxic. 24 h after the medium change the culture medium containing viral 
particles was harvested, filtered  through a 0.44 μm syringe filter, aliquoted and stored at 
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-80⁰C. Culture medium was replaced and the virus producing HEK293FT cells cultured for 
a further 24 h before a second harvesting of viral particles which was performed in the 
same way. 
 
2.4.5. Determining Lentiviral Titres 
 
All titrations of virus containing solutions were performed on solutions that had 
previously been frozen. This was to accurately assess the viral titre of frozen aliquots over 
virus containing solutions. Most viruses used contained a visible marker (enhanced green 
fluorescent protein (eGFP)). Where a visible selectable marker was not present a virus 
was produced using the same backbone as experimental viruses but with eGFP as an 
insert. This was used to estimate the titre of experimental viruses. 
 
Serial dilutions of the virus containing solution were made, typically: neat, 1:5, 1:50, 1:500 
and 1:5000. 250 µl of each solution was mixed with 250 µl of 1.2x105 HEK293FT cells/ml 
suspension. The resulting cell virus mixture was plated on to a 48 well plate at a total 
volume of 500 µl per condition with each condition containing 3x104 HEK293FT cells. Final 
virus dilutions would therefore be 1:2, 1:10, 1:100, 1:1000 and 1:10000.  
 
48 h after plating the cells were harvested by trypsinisation and were interrogated using 
flow cytometry to determine the percentage of eGFP positive cells per condition. SYTOX 
(Thermo Fisher Scientific) was used to exclude dead cells from analysis. The lowest serial 
dilution that was >1 % but <10% eGFP positive cells was used to calculate the viral titre 
using the following calculation: 
 
𝑇𝑖𝑡𝑟𝑒 = (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐸𝐾 𝑐𝑒𝑙𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑 × 𝑣𝑖𝑟𝑎𝑙 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
× % 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠) ÷ 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑠𝑜𝑙𝑢𝑡𝑖𝑜 
 
2.5. Transduction of Mammalian Cells  
 
Mammalian cells were transduced with the lentivirus of choice depending on 
experimental demands. Typically cells were transduced with 1-10 virus particles per cell 
with 3 virus particles per cell being the most commonly used in this project. Cells were 
trypsinised and counted as described previously. They were then mixed with the pre-
titrated supernatant from the viral packaging cells. Cells were then plated on to a suitable 
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multi-well plate, flask or petri dish. After 16 h the cell culture medium was removed and 
replaced with fresh media. After 48 h from the initial transduction the percentage 
transduction was calculated and a small sample was taken to determine the number of 
viral integrations per cell (described below) and protein expression of the transgene by 
western blot. 
 
2.5.1. Determination of Viral Integration 
 
In order to avoid a situation where affects could be due to insertional mutagenesis it is 
important to determine the number of viral integrations per cell. By using a specific qPCR 
assay, primers were designed to be specific to the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE). This element is found on all destination 
vectors used in the project and is integrated along with the transgene. The assay also 
incorporated primers designed to be specific for the single copy RNase P gene.  
 
Briefly, genomic DNA (gDNA) was extracted as described in section 2.6.1, 10 ng of sample 
was interrogated with both the WPRE and RNase P primers along with a 5 point standard 
curve for each set of primers (normal human gDNA for RNase P and pDEST for WPRE). 
This allowed the copy number of each gene within the sample to be determined. With 
this information the average number of integrations per cell is calculated as follows: 
 
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 = 𝑊𝑃𝑅𝐸 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 ÷ (𝑅𝑁𝑎𝑠𝑒 𝑃 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 ÷ 2)    
 
2.5.2. Generation of Stable Lines 
 
Stably expressing cell lines were generated by transducing cells with lentivirus made using 
the pDEST-236 plasmid. These viruses also contain the selectable puromycin-resistance 
gene (PURO-R) which confers resistance to the antibiotic puromycin. The sensitivity of 
non-transduced cells to puromycin was determined empirically, typically this was 10 
ng/ml. After 48 h post transduction the cell culture medium was supplemented with a 
concentration of puromycin to which the non-transduced cells were sensitive. Cells were 
cultured in the culture medium containing puromycin, which was refreshed every 2 days, 
for a minimum of 2 weeks. 
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2.6. Isolation and Analysis of Mammalian Cell DNA 
 
2.6.1. DNA Extraction (Qiagen) 
 
gDNA was extracted from tissues and cultures using the DNeasy Blood and Tissue Kit 
(Qiagen) according to the manufactures’ instruction. Briefly, up to 5 x 106 cells were 
washed once in PBS and dissociated by trypsinisation (0.05% trypsin-EDTA at 37°C). R10 
was added to inactivate the trypsin, before the cell suspension was centrifuged at 300 x 
g for 3 min and the supernatant removed and discarded. The cell pellet was then 
resuspended in 200 μl PBS supplemented with 20 μl proteinase K and 4 μl RNase A (100 
mg/ml). Next, 200μl Buffer AL was added to the cell suspension, which were then 
thoroughly mixed by vortexing before incubation at 56°C for 10 min to lyse the cells. 200 
μl ethanol was added to the tube which was again vortexed to ensure thorough mixing. 
The cell lysate was introduced to a DNeasy mini spin column and was then centrifuged at 
6000 x g for 1 min. The flow-through and collection tube were discarded and the column 
was placed into a fresh collection tube, 500 μl Buffer AW1 was then added to the column 
which was then centrifuged at 6000 x g for 1 min. The flow-through and collection tube 
were discarded and the column placed into a new collection tube, 500 μl Buffer AW2 was 
added to the column before centrifugation at 15000 x g for 3 min. The flow through was 
discarded and the column was centrifuged at 15000 x g for 3 min without the addition of 
any buffer. This was to remove any remaining ethanol from the column prior to elution. 
Elution of gDNA was performed by the addition of 50 μl of PCR-grade water to the column, 
which was then a centrifuged at 6000 x g for 1 min.  
 
2.6.2. DNA Extraction (Phenol Chloroform) 
 
Modified from (Collas, 2011). 
 
Cell pellet, tissue (both fresh and frozen in optimal cutting temperature (OCT) compound 
or previously isolated DNA to be ‘cleaned up’ was treated the same way. 
 
The sample was re-suspended in 500 μl of complete elution buffer which consisted of: 20 
mM Tris–HCl (pH 7.5), 5 mM EDTA, 50 mM NaCl, 1% (wt/vol) sodium dodecyl sulphate 
(SDS) and 50 mg/ml proteinase K. The sample was then incubated at 68⁰C at 1300 rpm in 
a heated shaking cabinet (Hybade) for 2 hours. The resulting solution was briefly 
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centrifuged before 500 μl of phenol–chloroform–isoamylalcohol pH 8 (25:24:1) (Sigma) 
was added directly to the sample. The sample was then vortexed and centrifuged at 
15000 x g for 5 mins at 25⁰C to separate the aqueous and phenol phases. 480 µl of the 
aqueous phase was transferred to a new 1.5ml centrifuge tube. 480 μl of chloroform–
isoamylalcohol (24:1) was added to the aqueous phase. The sample was then vortexed 
before centrifugation at 15000 x g for 5 mins at 25⁰C to separate the aqueous and 
chloroform phases. 450 μl of the aqueous phase was transferred to a clean 2 ml tube. 
 
The DNA in the aqueous phase was precipitated by the addition of 44 µl of 3 M NaAc (pH 
5.2), 5 μl of linear acrylamide carrier (Ambion) and 1 ml of 96% ethanol at -20⁰C. The 
solution was mixed by inverting 10 times before being incubated overnight at -80⁰C. 
 
The sample was then thawed on ice before being centrifuged at 20000 x g for 15 min at 
4⁰C. At this point a clearly visible pellet consisting of DNA and carrier could be seen. The 
supernatant was removed 1 ml of 70% ethanol at -20⁰C was added. The sample was then 
centrifuged at 20000 x g for  15 min at 4⁰C. The supernatant was removed and the pellet 
was dried using an Eppendorf Concentrator 5301 at 30⁰C. The pellet was then re-
suspended in an appropriate volume of PCR grade water (Sigma), typically 30-100 μl. DNA 
concentration and quality checks were performed using a Nanodrop spectrophotometer 
and DNA samples were routinely stored at -20°C. 
 
2.6.3. DNA Extraction from Formalin Fixed Paraffin Embedded Tissue 
 
This method used the ReliaPrep™ FFPE gDNA Miniprep System (Promega) with minor 
modification.  
 
The Formalin Fixed Paraffin Embedded (FFPE) tissue was transferred to a 1.5 ml centrifuge 
tube. Deparaffinisation was performed using mineral oil.  For sections ≤ 50 microns, 300 
μl of mineral oil was added and for sections ≥ 50 microns, 500 μl of mineral oil. The sample 
was then incubated at 80⁰C for 1 min and was then vortexed. 200 μl of Lysis Buffer 
(supplied as part of the kit) was added to the sample which was then centrifuged at 10000 
x g for 15 seconds at 25⁰C. At this point an aqueous and a mineral oil phase became 
apparent. 20 μl of Proteinase K was then added directly to the lower phase which was 
then mixed by pipetting. The sample was then incubated for 1 h at 56⁰C and then for 1 h 
at 80⁰C. The sample was then allowed to cool to room temperature before a brief 
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centrifugation. 10 μl of RNase A was directly added to the lysed sample in the lower phase 
which was then mixed by pipetting. The sample was then incubated at 25⁰C for 5 mins. 
220 μl of BL Buffer (supplied as part of the kit) was added to the lysed sample along with 
240 μl of ethanol (95–100%) the sample was then vortexed. The sample was the 
centrifuged at 10000 x g 15 seconds at 25⁰C. At this point the aqueous and mineral oil 
phases were separated. The entire lower (aqueous) phase of the sample, including any 
precipitate that may have formed was transferred to the column. The remaining mineral 
oil was discarded. The assembly was centrifuged at 10000 x g for 30 secs at 25⁰C the flow 
through was discarded. 500 μl of 1X Wash Solution (supplied as part of the kit) was added 
to the column before centrifugation at 10000 G for 30 seconds at 25⁰C the flow through 
was discarded. The column was the then dried by centrifugation at 16000 g for 6 minutes 
at 25⁰C. The Binding Column was transferred to a clean 1.5 ml microcentrifuge tube. 30–
50 μl of PCR grade water was added to the column (to elute the DNA) which was then 
centrifuged at 16000 x g for 1 min at 25⁰C. DNA concentration and quality checks were 
performed using a Nanodrop spectrophotometer and DNA samples were routinely stored 
at -20°C. Often the DNA was cleaned up by a further phenol chloroform extraction as 
described in section 2.6.2. 
 
2.6.4. Agarose Gel Electrophoresis  
 
Agarose gel electrophoresis was used to assess the quality and purity as well as the 
specificity of the amplification reaction. Typically, each sample or PCR product was 
analysed on 1-2% (w/v) Tris-acetate-EDTA (TAE) agarose gel using GelRed nucleic acid 
stain (1:10,000 (v/v); Biotium) to visualise DNA. 20 μl PCR product, PCR grade water 
(Sigma) and 4 μl DNA loading dye (4 mg Ficoll 400, 0.1 M EDTA, 0.1% (w/v) SDS, 0.05% 
(w/v) bromophenol blue and 0.05% (w/v) xylene cyanol) were added, homogenised and 
loaded onto a gel which was submerged in TAE buffer. 100 bp or 12 kb plus molecular 
weight (MW) DNA ladders were run alongside samples to allow sizing. Gels were 
visualised using GeneSnap ID software (Syngene). 
 
2.6.5. PCR Amplification 
 
 A full list of primer sequences and corresponding PCR conditions can be found in 
(Appendix 2). PCR reactions were performed using Platinum™ Taq polymerase and 
associated reaction components (Thermo Fisher Scientific) or using Phusion polymerase 
  72            Chapter 2. Materials and Methods 
kit (Thermo Fisher Scientific). Typically reactions were between 20-50 μl and involved a 3 
step amplification protocol consisting of denaturation at 98⁰C, primer annealing (typically 
52-65⁰C) and extension at 72⁰C using a thermocycler. 
 
2.6.6. Gel Extraction 
 
Gel extraction of a PCR product was performed using the QIAquick® Gel Extraction Kit 
(Qiagen) according to the manufacturers’ protocol. Briefly, the gel was made using Syber-
safe DNA stain (Thermo Fisher Scientific) to allow visualisation of the band under blue 
light which is less energetic compared with ultraviolet (UV) light and should therefore 
minimise DNA modifications and hence mutation of the extracted product. The DNA band 
was excised from the gel using a clean, sharp scalpel. The gel piece was then weighed and 
3 volumes of Buffer QG (supplied as part of the kit) to 1 volume of gel (100 mg gel ~ 100 
μl). This was then incubated at 50°C for 10 min (or until the gel slice dissolved completely). 
The tube was vortexed every 2–3 min to help dissolve gel. One gel volume of isopropanol 
was added to the sample which was then mixed. The solution was then transferred to a 
QIAquick® spin column and centrifuged for 1 min and the flow-through was discarded.  
500 μl Buffer QG was added to the column which was then centrifuged for 1 min and the 
flow-through was discarded. 750 μl Buffer PE (supplied as part of the kit) was added to 
the column which was centrifuged for 1 min and the flow-through discarded. The column 
was transferred to a clean 1.5 ml microcentrifuge tube and DNA was eluted with 50 µl of 
PCR grade water. 
 
2.6.7. Quantitative PCR of Genomic DNA 
 
qPCR reactions were composed of 7.5 μl of SsoFast™ EvaGreen® Supermix 2 X master mix 
(Bio-Rad), 2 μl of DNA, 0.6μl Of 10 mM forward primer, 0.6 μl Of 10 mM reverse primer 
and PCR grade water (Sigma) up to a total volume of 15 μl. All reactions were performed 
on FrameStar white-tubed (4titude) 96 well plates in triplicate. Reactions were run on a 
CFX96 Real-Time PCR Detection System, and analysed using the Bio-Rad CFX Manager 2.0 
(Bio-Rad. Standard thermal-cycling conditions included or 2 min at 98°C followed by 40 
cycles of 98°C for 5 s and 60°C for 5 s (Bio-Rad CFX96). To ensure specificity of the 
reactions a melt curve step was added at the end of each cycle: 95°C for 15 s, 52-60°C for 
20 s and 95 °C for 15 s. 
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Melt curve analysis utilises the ability of an intercalating dye (used to detect the 
abundance of an amplicon) to fluoresce when bound to double-stranded DNA (dsDNA) 
(no fluorescence is detected in the presence of single-stranded DNA (ssDNA)). By 
gradually heating the DNA present at the end of a qPCR reaction and analysing the 
fluorescence it is possible to determine the point at which dsDNA denatures becoming 
single-stranded. As the denaturation is dependent on the length of the amplicon and its 
GC:AT nucleotide ratio it is possible to determine if a single product (one denaturation 
event) or multiple products (multiple denaturation events) are present. 
 
2.6.8. Analysis of AR Genomic Copy Number Alterations 
 
Samples were interrogated using specific primers for AR, dystrophin (DMD) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by qPCR as described in section 
2.6.7. A standard curve using normal female DNA was generated to allow absolute 
quantification of these genomic regions. The copy number of AR and DMD was expressed 
relative to the copy number of GAPDH. Also included was a reference sample of normal 
male DNA to which the copy number of samples could be normalised.  Additionally a 
sample of VCaP DNA was included which is well documented to have a specific 
amplification of the AR gene and therefore serves as a positive control. 
 
2.7. Isolation and Analysis of Mammalian Cell RNA  
 
2.7.1. RNA Extraction  
 
RNA was extracted using the RNeasy Mini Kit (Qiagen). Typically, 5 x 106 cells were first 
washed using PBS before being tripsinised (0.05% trypsin-EDTA at 37°C). R10 was then 
added to inactivate the trypsin, before centrifugation at 300 x g for 3 min and the 
supernatant removed. The resulting cell pellet(s) were resuspended in 350 μl Buffer RLT 
buffer (supplied as part of the kit) supplemented with 2-mercaptoethanol and vortexed 
to mix. The cell lysate was then introduced into a QIAshredder homogeniser column 
(Qiagen) and centrifuged at 15000 x g for 2 min. 350 μl 70% ethanol diluted in diethyl 
pyrocarbonate (DEPC)-treated water was added to the homogenised lysate which was 
then thoroughly mixed by pipetting. The homogenised sample was then transferred to an 
RNeasy spin column to allow RNA binding and centrifuged at 15000 x g for 15 s. The 
column was then washed with 700 μl Buffer RW1 (supplied as part of the kit), spun at 
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15000 x g for 15 s, followed by further washing with 500 μl Buffer RPE (supplied as part 
of the kit). At each wash step the ‘flow-through’ was discarded. Elution of RNA was 
performed with 30 μl RNase-free water by centrifugation at 15000 x g for 1 min. 
Determination of RNA quality and concentration was performed using a NanoDrop ND-
1000 spectrophotometer (Thermo Fisher Scientific) or using Bioanalyser (Agilent). RNA 
samples were routinely stored at -80°C. 
 
2.7.2. Complementary DNA Synthesis  
 
Total RNA was reversed transcribed in 14.25 μl, mixed with 0.75 μl PCR grade water 
(Sigma) and 0.75 μl Random primers and heated to 70°C for 10 min. The 14.25 μl reaction 
mix included 6 μl of 5x First strand buffer, 3 μl 0.1 M dithiothreitol (DTT), 0.75 μl PCR 
grade water (Sigma), 3 ΜL 10 mM Deoxynucleotide (dNTP)s. 1.5 μl Superscript III enzyme  
was added and the mixture was incubated at 45°C for 2 h. Ethanol-precipitation was used 
to purify the cDNA this was performed with the addition of 15 μl 3 M NaCl and 120 μl 
100% ethanol and samples placed at -80°C for 30 min. The complementary DNA (cDNA) 
was pelleted by centrifugation at 15000 x g for 10 min and the supernatant was aspirated. 
The pelleted cDNA was then washed by the addition 100 μl of 70% and centrifugation at 
15000 x g for 5 min. The supernatant was then aspirated and the cDNA pellet was dried 
using an Eppendorf Concentrator 5301 (Eppendorf), before resuspension in PCR grade 
water (Sigma). 
 
2.7.3. Reverse Transcription PCR 
 
Reverse transcription polymerase chain reaction (RT-PCR) was performed in 10 μl 
reactions which consisted of 5 μl TaqMan Gene Expression Master Mix (Applied 
Biosystems) or SsoFast Probes Supermix (Bio-Rad), 0.5 μl TaqMan gene expression assays 
(Applied Biosystems) and 4.5 µl cDNA (30 ng) diluted in PCR grade water (Sigma). 
Reactions were performed on FrameStar white-tubed (4titude) 96 well plates in triplicate. 
Reactions were run on a CFX96 Real-Time PCR Detection System, and the resulting data 
was analysed using the Bio-Rad CFX Manager 2.0 software (Bio-Rad). Standard thermal 
cycling conditions were 2 min at 95°C (initial denaturation), 40 cycles of 95°C for 5 s and 
60°C for 5 s (Bio-Rad CFX96). The delta-delta Ct method (Schmittgen and Livak, 2008) was 
used to analyse the results of RT-PCR.  Where relative quantification was appropriate, the 
target gene expression was normalised to the expression of a control gene(s). Typical 
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control genes include GAPDH, 60S acidic ribosomal protein P0 (RPLPO) or 18S ribosomal 
RNA (18S). 
 
2.8. Chromatin Immunoprecipitation 
 
2.8.1. Chromatin Preparation  
 
107 – 108 cells were harvested by trypsinisation (0.05% trypsin-EDTA at 37°C). R10 was 
added to inactivate the trypsin, before the cell suspension was centrifuged at 300 x g for 
3 min and the supernatant removed and discarded. The resulting cell pellet was then 
resuspended in 5 ml of the same culture medium in which the cell were grown.  Cell-
fixation was performed by the addition of  formaldehyde to achieve a concentration of 
1% (w/v). The formaldehyde-fixation was allowed to proceed for 10 min at RT. The 
fixation was then stopped by the addition of  0.125 M glycine and subsequent incubation 
at RT for 5 min. The cells were then pelleted by centrifuged at 300 x g for 5 min at 4°C. 
The cell pellet was then washed twice using 20 ml of ice-cold PBS and centrifugation at 
300 x g for 5 min at 4°C. Cell pellets were then resuspended in ice-cold swelling buffer (5 
mM Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) pH 8, 85 mM KCl), supplemented 
with Tergitol-type NP-40 (NP-40) (0.2% (v/v)) and complete EDTA-free protease inhibitors 
(Roche). The reaction was allowed to proceed for 20 min on ice with gentle rocking before  
centrifugation at 300 x g for 10 min at 4°C. The resulting pellet was then  resuspended in 
TSE 150 (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, 150 
mM NaCl) supplemented with complete EDTA-free protease inhibitors. The sample was 
sonicated using a Biorupter sonicator (Diagenode), for 20 cycles of 30 s on / 30 s off at 
maximum power. Chromatin was centrifuged at 15000 x g for 30 min at 4°C and the 
supernatant was aliquoted and stored at -80°C. 
 
2.8.2. Sonication Control DNA Extraction  
 
DNA form a sample (20 μl) of the sonicated chromatin was isolated using phenol 
chloroform extraction (described in section 2.6.2.). The extracted sonicated chromatin 
was analysed on a 0.75% (w/v) TAE agarose gel using GelRed nucleic acid stain (1:10000 
dilution) to visualise. 5 μl sonicated chromatin, 7.5 μl PCR grade water (Sigma) and 2.5 μl 
DNA loading dye were mixed and loaded onto the gel run in TAE buffer for a minimum of 
  76            Chapter 2. Materials and Methods 
1 h at 80 V. 100 bp and 1 Kb+ MW DNA ladders were run in alongside the sonicated DNA. 
Gels were visualised using the GeneSnap ID software. 
 
2.8.3. Immunoprecipitation  
 
Protein A or Protein G-sepharose beads (Sigma) were first blocked by incubation in buffer 
TSE 150 (20 mM Tris‐HCl (pH8),150 mM NaCl, 2 mM EDTA, 0.1% SDS,1% Triton X‐100) 
supplemented with 1 μg/ml yeast transfer ribonucleic acid (tRNA) (Sigma) pre-denatured 
at 95°C for 5 min) and 250 μg/ml BSA (Sigma). The blocking reaction was performed with 
rotation at 4°C for 4 h. The blocked beads were then washed three times using buffer TSE 
150 and centrifugation at 800 x g for 1 min, before storage at 4°C.  
 
Chromatin pre-cleared by incubating the sample (20 μg per immunoprecipitation (IP)) 
with 50 μl of 50% pre-blocked protein A or protein G-sepharose beads in 1 ml IP buffer 
TSE 150, supplemented with complete EDTA-free protease inhibitors for 1.5 h at 4°C while 
rotating. The beads were removed by centrifugation at 800 x g for 1 min. The supernatant 
(pre-cleared chromatin) was transferred into a new tube. 20 μl pre-cleared chromatin was 
used as input control. The remaining pre-cleared chromatin was used for the IP reactions 
by incubation with the relevant primary antibody (Appendix 3.) at 4°C overnight with end 
over end mixing. 
 
Antibody-protein-DNA complexes were recovered by incubation with 50 μl of 50% pre-
blocked protein A or protein G sepharose beads for 1.5 h at 4°C with end over end mixing. 
Beads were pelleted by centrifugation at 800 x g for 1 min at RT and were swashed once 
with 1 ml of IP buffer TSE 150. The beads were then pelleted by centrifugation at 800 x g 
for 1 min at RT and washed with 1 ml of IP buffer TSE 500 (0.1% SDS, 1% Triton, 2 mM 
EDTA, 20 mM Tris-HCl pH 8 and 500 mM NaCl). A third was performed using 1 ml of 
washing buffer (10 mM Tris-HCl pH 8, 0.25 M LiCl, 0.5% (v/v) NP-40). The final two wash 
steps were performed using 1 ml Tris-EDTA (TE) buffer (1 mM EDTA, 10 mM Tris-HCl pH 
8).  After the washes, DNA was eluted from the beads by the addition of 100 μl of elution 
buffer (1% (w/v) SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8), the bead-elution buffer mixture 
was first mixed by vortexing before incubation at 65°C for 15 min with shaking. The beads 
were then pelleted by centrifugation at 15000 x g for 1 min. The supernatant containing 
the eluted DNA was transferred to a new tube. A second elution was performed by 
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resuspending the beads in 150 μl TE/1% SDS buffer, mixing using a vortex and 
centrifugation at 15000 x g. The supernatant from the second elution was then combined 
with that of the first elution. Immuno-precipitated was extracted using the phenol 
chloroform extraction method described in section 2.6.2. 
 
2.8.4. Quantitative PCR Analysis  
 
Quantitative PCR (qPCR) was performed using 7.5 μl of SsoFast™ EvaGreen® Supermix 2 
X master mix (Bio-Rad), 2 μl of DNA, 0.6 μL of 10 mM forward primer, 0.6 μL of 10 mM 
reverse primer and PCR grade water (Sigma) up to a total volume of 15 μl. All reactions 
were run in at least triplicate wells on FrameStar white-tubed (4titude) 96 well plates. 
Reactions were run on a CFX96 Real-Time PCR Detection System. The data was analysed 
using Bio-Rad CFX Manager 2.0 (Bio-Rad) software. Typical cycling conditions were 2 min 
at 98°C  (initial denaturation) followed by 40 cycles of 95°C for 5 s and 60°C for 5 s. 
Reaction specificity was determined using melt curve analysis. The level of enrichment 
was interrogated using 5 specific primers spanning each of the RARRES1 and LXN 
promoter sequences. The enrichment of the sequences by IP was calculated relative to 
INPUT (chromatin with no IP) by the following equation. 
 
% 𝑖𝑛𝑝𝑢𝑡 = ((2−𝐶𝑇 𝑜𝑓 𝐼𝑃) × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 1 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 3 ÷ (2−𝐶𝑇 𝑜𝑓 𝐼𝑁𝑃𝑈𝑇)
× 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 2 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 3)  × 100 
 
 Dilution factor 1 – the number of IPs that the chromatin is split between i.e. if the 
chromatin is split between 3 IPs the value of dilution factor 1 would be 3. 
 Dilution factor 2 – the relative size of the input sample taken from the chromatin 
i.e. if a 20 μl sample is taken for the input from 1 ml of chromatin then dilution 
factor 2 would be 50. 
 Dilution factor 3 – the dilution of the extracted DNA that enters the qPCR reaction 
i.e. if eluted DNA is resuspended in 50 µl of PCR grade water and 2 μl is used per 
reaction then dilution factor 3 would be 25. 
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2.8.5. Micro-Chromatin Immunoprecipitation 
 
103 – 105 cells were trypsinised, sedimented and resuspended in 500 µl PBS. Cell-fixation  
was performed by the addition of 1% formaldehyde to a concentration of 1% (w/v). The 
fixation was allowed to proceed for 10 min at RT. The fixation was then stopped by the 
addition glycine to a final concentration of 0.125 M and incubation for 5 min at RT. The 
fixed cells were then pelleted by centrifugation at 470 x g for 10 min at 4°C. The cells were 
then washed twice with 500 μl ice-cold PBS and centrifuged at 470 x g for 10 min at 4°C. 
The supernatant was then aspirated so that only 20 μl remained before addition of 120 
µl of lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% (wt/vol) SDS, and protease 
inhibitors) followed by vortexing, a 5 min incubation on ice and a further vortexing. The 
sample was sonicated using a Biorupter (Diagenode), for 20 cycles of 30 s on / 30 s off at 
maximum power. 400 μl of Radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-
HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid (EGTA), 1% (vol/vol) Triton X-100, 0.1% (wt/vol) SDS, 0.1% 
(wt/vol) Na-deoxycholate and protease inhibitors) was added and the sample was 
centrifuged at 12000 x g for 10 min at 4⁰C. The supernatant (chromatin) was removed, 
aliquoted and stored at -80°C. 
 
Due to the very low levels of DNA isolated from small samples, the adequacy of sonication 
could not be determined by gel electrophoresis. However, by employing A qPCR method 
established by (Dahl and Collas, 2008) it is possible to estimate the level of fragmentation. 
Briefly, the DNA was amplified In a qPCR reaction using two sets of primers, one set 
amplifies a product of 100 bp while the second amplifies a product of 300 bp. The qPCR 
ratio of the 100 bp to a 300 bp products increases as a function of sonication cycles, 
indicating that the mean chromatin fragment size is reducing with the number of cycles. 
This is because 300 bp template is broken at a greater rate than the 100 bp template, due 
to its size. 
 
IP was performed as described in section 2.8.3. however, magnetic protein A or protein 
G dynabeads were used instead of sepharose beads as it was found empirically that 
dynabeads have less non-specific binding of chromatin and hence provide a better signal 
to noise ratio. 
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qPCR analysis was performed as described in section 2.8.4. 
 
2.9. Analysis of Protein Expression  
 
2.9.1. Cell Lysis  
 
Cells were first washed once in PBS before cell-lysis using either CytoBuster protein 
extraction reagent (Novagen) or RIPA. Complete EDTA-free protease inhibitor cocktail 
was routinely included and the resulting mixture was incubated with the cells, on ice for 
5 min. The culture surface was then scraped and the lysate centrifuged at 4°C at 16000 x 
g for 5 min using a Hettich Mikro 220R Centrifuge (SLS). The lysates were routinely stored 
at -80°C. 
 
2.9.2. Bicinchoninic Acid Assay  
 
The protein concentration of samples was determined using the bicinchoninic acid (BCA) 
assay  protein assay kit (Thermo Fisher Scientific). 25 μl of BSA standards or samples were 
added to (an individual well each) a 96 well plate. 200 μl working reagent was added to 
each well and the reaction was allowed to proceed at 37°C for 30 min. Absorbance of 
samples and standards were measured at 562 nm on a POLARstar OPTIMA microplate 
reader (BMG Labtech). The protein concentration of unknown samples was determined 
by interpolation from the standard curve. 
 
2.9.3. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
 
Cell-lysate equivalent to 20 μg of protein was mixed in a 3:1 ratio with 4 x SDS loading 
buffer (10% (v/v) glycerol, 62.5 mM Tris-HCl pH 6.8, 1% (w/v) SDs, 65 mM DTT and 
bromophenol blue). Mixing was performed using a vortex for 10 s and was then incubated 
at 100°C for 15 min using a Grant QBD2 heating block (Grant). Samples were then 
vortexed to mix before loading onto a 8-12% Tris-SDS acrylamide gel, cast using the Bio-
Rad Protean II system. The gel was then and run at 100 V in 1 x SDS running buffer (25 
mM Tris-HCl, 0.19 M glycine and 3.5 mM SDS). Biotinylated (Cell Signalling Technology) 
and Kaleidoscope (Bio-Rad) molecular weight ladders were run alongside samples to 
allow  sizing.  
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2.9.4. Western Blot  
 
Methanol was used to activate Immobilon-P membrane which was then washed with 
distilled H2O and equilibrated in transfer buffer (48 mM Tris-HCl, 39 mM glycine and 10% 
(v/v) methanol). Proteins were transferred from the gel to the membrane at 100 V for 2 
h.  After transfer, the membranes were blocked by incubation with 5% (w/v) non-fat 
skimmed milk (Marvel) solution for 1 h at RT. The blocking solution was then removed 
and primary antibody in a 1% Marvel solution was added. The binding of primary antibody 
was performed RT for 1 h. The primary antibody solution was then removed and the 
membrane was washed three times using TBST (150 mM NaCl, 50 mM Tris-HCl and 0.1% 
(v/v) Tween-20 at pH 7.4). Next, Peroxidase-labelled secondary antibodies at a dilution 
factor of 1:10,000 (Cell Signalling Technologies/Boehringer) in 5% marvel were added and 
allowed to bid by incubation at RT for 1 h. The secondary antibody solution was then 
removed before the membrane was washed four times using TBST. Peroxidase substrate 
(Roche) was then added to the membrane. Luminescence was detected using 
GeneGnome XRQ Chemiluminescence imager (Syngene). 
 
2.9.5. Protein Immunoprecipitation 
 
2x106 cells were lysed with RIPA and precleared with anti-keratin conjugated sepharose 
beads. All IPs were performed using pre-conjugated anti-HA conjugated sepharose beads 
(Sigma). The resulting precipitation was washed 5x with high salt RIPA (300 mM NaCl) to 
remove non-specific binding proteins. Interacting proteins were eluted with Laemmli 
buffer with the addition of 2-Mercaptoethanol. The resulting eluate was either analysed 
by western blot as previously described or by mass spectrometry which was performed 
by the technology facility at the University of York. 
 
2.10. Protein Localisation Assays  
 
2.10.1. Immunofluorescence  
 
The culture surface for immunofluorescence was BD-Biocoat collagen-I-coated for 
primary cells. When cell lines were to be analysed BD-Falcon uncoated 8-well chamber 
slides (BD Bioscience) were used. 300 μl cell suspensions were plated into chamber slides 
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at 2-5 x 104 cells per well and incubated at 37°C. Culture medium was then removed 
before the cells were washed twice with PBS. Cells were then fixed with 200 μl 4% (w/v) 
paraformaldehyde pH 7.4 for 20 min. Three washes were performed after fixation, each 
with 500 μl of PBS for 5 min. The cells were then permeabilised with 300 μl 0.5% (v/v) 
Triton X-100 for 25 min. After permeablisation, cells were washed 3 times with PBS. 
Blocking was done using with 200 μl 10% (v/v) goat serum diluted 1% (w/v) BSA in PBS for 
30 min. The sample was then incubated in the presence of primary antibody diluted in 1% 
BSA in PBS for 1 h. Before incubation with secondary antibody the cells were then washed 
three times with 500 μl PBS for 5 min. 200 μl of secondary antibody diluted in 1% BSA in 
PBS was then added and allowed to incubate for 45 min at RT. Next, the cells were washed 
three times using 500 μl PBS with 5 min incubation per wash. The chambers were then 
removed from the slide and Vectashield mounting medium with 4’,6-diamidino-2-
phenylindole (DAPI) (Vector laboratories) was added to the cells. A coverslip (SLS) was 
then placed on top of the sample, which was sealed with nail varnish. Analysis was 
performed using a Nikon Eclipse TE300 fluorescent microscope (Nikon) or a LSM 720 meta 
confocal microscope (Zeiss). Primary antibody dilutions used for immunofluorescence are 
listed in (Appendix 2.). Secondary Alexafluor 488 or 568 goat anti-rabbit or goat anti-
mouse IgG antibodies (Invitrogen) were typically used at a dilution factor of 1:200. 
 
2.10.2. Subcellular Fractionation 
 
Nucleocytoplasmic fractionation of PC3, PC3M, 293 cell lines and primary cells was 
performed using NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Fisher Scientific) 
and according to the manufactures’ protocol. Cells were harvested by trypsinisation, 
washed once with culture medium and then once with PBS 1X at 300 x g for 5 min at 4⁰C. 
The pellet was resuspended in 1 ml PBS and transferred to a 1.5 ml microcentrifuge tube 
and washed once more in PBS. The supernatant was then removed and the cells were re-
suspended in ice-cold CER I buffer (supplied as part of the kit) with protease inhibitors.  
The sample was then vortexed vigorously on the highest setting for 15 s before being 
incubated on ice for 10 min. Ice-cold CER II buffer (supplied as part of the kit) was then 
added to the sample which was then vortexed for 5 s. The sample was then incubated on 
ice for 1 min and was then vortexed for 5 s before being centrifuged at 16000 x g for 5 
min at 4⁰C. The top 90% of the supernatant (cytoplasmic extract) to a clean pre-chilled 
microcentrifuge tube this is the cytoplasmic fraction. The final 10% of the supernatant 
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was then removed and discarded and the pellet was re-suspended in 1 ml of ice-cold PBS 
and centrifuged at 16000 x g for 10 min at 4⁰C the supernatant was discarded and the 
pellet was suspended in ice-cold NER buffer (supplied as part of the kit) with protease 
inhibitors. The sample was then vortexed for 15 s and incubated on ice for 40 min with 
vortexing every 10 min. The sample was the centrifuged at 16000 x g for 10 min at 4⁰C. 
The top 90% of the supernatant (nuclear extract) was then transferred to a clean pre-
chilled tube. Both nuclear and cytoplasmic fractions were stored at -8. 
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3. Development and Validation of a qPCR Test for Simultaneous Detection of AR 
Amplification and X Chromosome Aneuploidy 
 
3.1. Introduction   
 
As discussed in section 1.3.6. GAAR has been detected in up to 80% of CRPCs, of which 
30% of these have a high level amplification (≥3.8 copies per cell) (Visakorpi et al., 1995, 
Waltering et al., 2012). In contrast, the prevailing consensus is that AR amplification 
represents a very rare event in ADT-naïve  CaP e.g. in only 2 out of 205 cases in a study by 
(Bubendorf et al., 1999) were positive for GAAR. This view has recently been challenged 
by (Merson et al., 2014) who showed, through extensive FISH experiments, that very 
small foci of cells with X chromosome aneuploidy (XCA) and/or locus specific GAAR (≤ 
600 nm, ≤1% of tumour volume) (Fig. 14B.) were present in patients (33 out of 261 cases 
examined (12.6%) of Gleason 6 cancers) with low grade disease, who had not undergone 
hormone deprivation therapy (Fig. 14.) (Merson et al., 2014). Therefore, GAAR could be 
the result of evolution of CaP in direct response to the selection pressure of ADT leading 
to the specific clonal expansion of very these rare clones (Saraon et al., 2011, Merson et 
al., 2014).  
 
GAAR and/or XCA is associated with reduced survival, demonstrated by (Merson et al., 
2014), this study showed that patients with small foci of tumour cells with four or more 
copies of the X chromosome (Cat 4) had a hazard ratio of 7.92 (95% confidence interval 
(CI)= 2.50–25.13) and patients with small focal tumours cells containing specific AR gene 
amplification (Cat 5) had a hazard ratio of 5.08 (95% CI=1.85–13.95) compared to patients 
with a single X chromosome and no amplification of the AR gene (Cat 1). This dramatic 
effect on survival can be seen in (Fig. 14C.). However, GAAR has been shown to predict 
the patients who will respond to ‘second-line’ combined androgen blockade i.e. 
combination of androgen antagonist and androgen synthesis inhibitors (Palmberg et al., 
1997). The androgen signalling axis is presumed to be intact, but with a lower threshold 
of activation, in these patients.  
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Fig. 14. AR Amplification and X Chromosome Aneuploidy can be Detected in 
Small Foci of Hormone Naïve CaP Tumours and is Associated with Poor 
Prognosis. 
 
A. Definition of the five categories (Cat1–5) of AR and X chromosome copy 
number alterations. Cat1–4 represents of increasing level of X chromosome 
aneuploidy. Cat5 is defined by locus-specific amplification of AR with or 
without X chromosome aneuploidy. Tumours were scored  by counting the 
Green (probe is specific to a region 1.15 Mb upstream of AR), Blue (probe 
specific to the AR gene), Red (probe specific to a region 0.1 Mb downstream of 
AR) and signals. Cat1 contain a single X chromosome and AR gene. This is 
visualised as single and overlapping Green, Blue and Red signals which 
correlated with an X chromosome centromere probe (not shown). This normal 
pattern was counted as 1:1:1:1. X chromosome aneuploidy was inferred when 
multiples of this pattern were seen (Cat2–4) e.g. 2:2:2:2 represents two copies 
of the X chromosome. A Cat5 amplification (locus-specific gain of AR) was 
defined as an unequal accumulation of the probes e.g. a 1:2:2:1 pattern 
represents a single X chromosome with a duplication of the AR gene. It was 
found that amplifications could involve all three probes or just multiples of 
adjacent probes. Exclusive amplification of the Blue probe was detected I this 
study. 
 
B. Whole TURP-block sections analysed by FISH for AR and X chromosome 
accumulations. Yellow regions are positive for a Cat2 X chromosome 
amplification, Orange regions are positive for a Cat3 X chromosome 
amplification, Blue regions are positive for Cat4 X chromosome amplification 
and Red regions are positive for a Cat5 locus-specific amplification of the AR 
gene. Grey regions are not positive for CaP (determined by histological 
analysis) and were not scored. Yellow and green circles indicate positions of 
the 600 μm diameter cores taken from areas of tumour and normal, 
respectively, for TMA construction. Blue and red arrows highlight the small 
foci of Cat4 and Cat5 tumour, respectively. In all patients analysed, CaP foci 
that were designated as Cat5 were less than 1% of the whole-block tumour 
area. 
 
C. = Kaplan–Meier plot of CaP-specific mortality for the five categories.  
 
From: (Merson et al., 2014) 
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The ability of clinicians to stratify patients, according to their likelihood of responding to 
2nd line androgen blockade, is likely to have several clinical and economic benefits. One 
major benefit in terms of patient outcome would be in the timing of optimal therapy i.e. 
if a patient is unlikely to respond to 2nd line androgen blockade, then a chemotherapeutic 
regimen can be implemented immediately rather than waiting for 2nd line androgen 
blockade to fail.  
 
Since the formation of the National Institute for Health and Care Excellence (NICE), to 
govern the use of therapeutics in the UK National Health Service (NHS) and the healthcare 
reforms due to occur in the USA, the economics of cancer therapy must now be 
considered, e.g. the incremental cost-effectiveness ratio (Cerri et al., 2013). An affordable 
assay that predicts patient response to 2nd line androgen blockade would enable clinicians 
to justify the use of high-cost therapies, such as Abiraterone and Enzulutamide in a 
particular group of patients that are likely to respond i.e. those with GAAR.  
 
Detection of GAAR is most commonly performed using FISH. This technique has 
limitations however, as it is semi-quantitative and subjective. A report highlighted these 
inadequacies when determining genomic amplification (Albertson, 2012). In which it was  
shown that the differing results between groups were clearly the result of FISH-artefacts 
specifically the detection of Oestrogen receptor alpha (ESR1) transcripts, confirmed by 
RNase treatment eliminating these signals (Albertson, 2012).   
 
An alternative method to identify GAAR is genomic sequencing. While this approach is 
likely to reveal a lot of additional information, which may aid patient care and guide 
treatment options, it is at present prohibitively expensive. Even though the cost of 
genomic sequencing is falling year on year, a 10 times coverage of the human genome, 
(which is required to accurately sequence both alleles in 90% of human genes, from 25 
base pair reads, using shotgun sequencing) would cost in the region of $5,000 per patient 
(Cho et al., 2012).  A lower-cost sequencing strategy would be to use targeted-sequencing 
of AR alleles. However this approach would not provide the additional information 
generated by whole-genome sequencing. 
 
The most appropriate platform for accurate and cost-effective detection of genomic copy 
number variations is qPCR. As such several assays for the detection of AR copy number 
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variations are commercially available, such as TaqMan® Copy Number Assays (Life 
Technologies™) and qBiomarker Copy Number Assays (Qiagen). However, these ‘off the 
shelf’ assays are not without their limitations. For example, it is important to note that 
these assays do not include a non-CaP associated X-chromosome normalising gene as 
standard, and are thus unable to discriminate between specific GAAR and  amplification 
due to XCA, which is common in prostate cancer (Brothman et al., 1994). 
In this chapter a qPCR method has been developed for the detection of locus-specific 
GAAR as well as XCA, furthermore, it is capable of discriminating between these gross 
genetic changes. It is specific, sensitive, amenable to high-throughput screening and less 
time-consuming than FISH, whilst retaining the ability to resolve minor cell populations in 
a heterogeneous biopsy. It could provide an affordable and effective means for 
identifying patients with ‘high-risk disease’. It also has the potential to aid triaging of CaP 
patients (through theranostic evaluation) as disease progresses from a hormone 
responsive and non-metastatic phenotype to castration-resistant, metastatic disease. 
Aiding the selection of the most appropriate treatment from the many options available 
(Fig. 15.), in a timely manner, to improve patient outcomes (Heidenreich et al., 2013). 
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Fig. 15. Current, Ongoing, and Future Landscape in the Management of Castration-
Resistant Prostate Cancer.  
Depiction of the various treatment choices as CaP progresses from a hormone-naïve, 
non-metastatic, asymptomatic disease to a metastatic CRPC phenotype. 
Drug colour key: green = US Food and Drug Administration/European Medicines 
Agency (FDA/EMA) approved; light green = positive  trial results in high-risk patients 
but the compound is not approved; orange = completion of phase 3 clinical trial with 
positive results; blue = prospective, randomized, phase 3 clinical trial completed, 
results awaited; purple = promising agent.  
From: (Heidenreich et al., 2013) 
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3.2. Premise of the Assay  
The assay is composed of three qPCR reactions using primers specific to AR, DMD and 
GAPDH genes. The locations of these genes on their respective chromosome are shown 
in (Fig. 16.). The GAPDH gene is used as a somatic chromosome control to which AR and 
DMD copy numbers can be normalised to. Additionally the copy number of  AR  can be 
normalised to both GAPDH and DMD genes, this allows distinction between locus-specific 
GAAR and AR gain due to XCA.  
The DMD gene was chosen as a good control gene to analyse XCA as after an exhaustive 
literature search (not shown) it was found to be not implicated in CaP initiation, 
susceptibility, maintenance, expansion or metastasis. Also it is located far from the AR 
gene so is highly unlikely to be included in a specific AR amplification. It could be argued 
that several genes on the X chromosome should be utilised as X chromosome control 
genes however, this would lead to an increase in assay preparation, sample usage and 
analysis time, without providing any more information.  
When AR copy number is normalised to GAPDH copy number, female DNA shows twice 
the compliment AR relative to male DNA i.e. male DNA = 1 copy of AR divided by 2 copies 
of GAPDH = 0.5 relative ratio. Female DNA = 2 copies of AR divided by 2 copies of GAPDH 
= 1 relative ratio. When samples are normalised to both GAPDH and DMD copy numbers, 
both male and female DNA have equal relative ratios of AR i.e. male DNA = (1 copy AR 
divided by 2 copies of GAPDH) divided by (1 copy of DMD divided by 2 copies of GAPDH) 
= 0.5/0.5 = 1. Female DNA = (2 copies of AR divided by 2 copies of GAPDH) divided by (2 
copies of DMD divided by 2 copies of GAPDH) = 1/1 =1. This has the effect of eliminating 
any AR copy number gains which are due to XCA. 
All primers are located within either an intronic region or exon-intron junction within their 
respective genes (sequences in Appendix 2.). This precludes any unintended amplification 
of mRNA species. In the case of the AR primers they were designed to amplify the junction 
between intron two and exon two as well as the majority of the short exon two (Fig. 17.). 
This is of importance because exon two encodes part of the DNA-binding domain allowing 
detection of WT and mutant AR genes which are most commonly corrupted in the ligand 
binding domain.  
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Fig. 16. Location of AR, DMD and GAPDH Genes. 
 
X chromosome and chromosome12 gene-maps, with the approximate regions 
(highlighted in red) where the AR, DMD and GAPDH genes are located. 
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Fig. 17. Location of AR Primers.  
Modular structure of the AR gene and protein. The approximate locations of the 
forward and reverse primers used in the assay are shown in red. 
AF = activation function, AR = androgen receptor, DBD = DNA-binding domain, LBD = 
ligand-binding domain and NTD = amino-terminal domain. 
Adapted from: (Lorente et al., 2015) 
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3.3. Assay Work-Flow 
This section describes in brief how genetic material from a sample is prepared and 
analysed. 
Any human gDNA is compatible with the assay. gDNA from cell lines, primary cultures and 
lymphocytes can be extracted using Qiagen kits or phenol-chloroform extraction. When 
analysing tissue samples either frozen in OCT or FFPE, it is necessary to ensure that a 
cancerous lesion is present in the tissue section from which DNA is extracted. This is 
achieved by serially sectioning the tissue and performing haematoxylin and eosin (H&E) 
staining on flanking tissue slices (Fig. 18.). 
Once the DNA was extracted it was amplified using primers specific to AR, DMD and 
GAPDH genes according to the cycling protocols in (Table. 4.). 
Certain control samples were analysed on every run of the assay to ensure the assay was 
performing consistently these were normal male DNA, normal female DNA and VCaP 
DNA. Comparison of male and female DNA ensured that the assay was sensitive enough 
to detect the extra copy of both the AR and DMD genes whilst the VCaP DNA was utilised 
as a positive control for GAAR. Wherever possible, patient lymphocytes were analysed 
alongside the primary tissue, culture or xenograft tissue. The assay also incorporated a 
standard curve of normal female DNA to enable absolute quantification. 
 
 
 
 
Table. 4. qPCR Cycling Conditions for AR, DMD and GAPDH Primers 
 
Target Gene
Melting 
Temperature 
(°C)
Annealing and 
Extension 
Temperature 
(°C)
Number 
of Cycles
AR 98 58 38
DMD 98 58 38
GAPDH 98 58 38
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Fig. 18. Preparation of Genetic Material for Analysis of AR, DMD and GAPDH 
Copy Numbers from Tissue Samples. 
 
A sample of the patient or xenograft tissue is taken either through biopsy or 
direct excision from whole tumour. The sample is then prepared for histological 
sectioning by either preservation by freezing in OCT or by formalin fixing and 
paraffin embedding. Once the sample has been mounted it can then be serially 
sectioned. Flanking tissue slices are used to identify a cancerous lesion by H&E 
staining. Once an area of cancer has been located it can then be further 
processed to extract the genomic DNA (gDNA) by either Qiagen kits or phenol-
chloroform extraction. Once the gDNA has been extracted the copy number of 
AR, DMD and GAPDH genes is elucidated by qPCR using gene specific primers. 
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3.4. Results 
3.4.1. Semi-Quantitative Analysis of AR Copy Number in Male and Female Genomic 
DNA by PCR  
A pilot study was performed using standard PCR on male and female genomic DNA (10 
ng) using primers specific for AR and GAPDH (Fig. 19.). Both 25 and 30 cycles were 
investigated to increase the chance of seeing an unsaturated reaction. 25 cycles did not 
yield any visible DNA bands (Fig. 19A. lanes 9-14). 30 cycles yielded no bands in the non-
template control (-ve) lanes, faint bands of in the AR lanes (an expanded view is shown in 
(Fig. 19C.) for clarity) which correspond to the expected AR PCR product and relatively 
bright bands in the GAPDH lanes which correspond to the expected GAPDH PCR product 
(Fig. 19A.).  
The gel image was analysed using ImageJ software  results of this are tabulated in (Fig. 
19D.). The area under the curve was used to compare the copy number of AR between 
male and female DNA once normalised to GAPDH (Fig. 19E.). This analysis gave a 1.44 fold 
difference in AR copy number in female DNA compared to male DNA. An expected value 
for this analysis is a fold difference of two, representing the two X chromosomes present 
in females versus the single X copy in males. A potential explanation for this discrepancy 
is that the increased products in the female DNA reaction may have inhibited said reaction 
causing a plateau (particularly in the GAPDH reactions). Additionally, measuring band 
intensity by densitometry has inherent inaccuracies i.e. drawing around the band and 
unequal brightness across the band, which also contribute to this method being semi-
quantitative. However, this pilot study confirmed the feasibility of the project and allowed 
the progression to qPCR. 
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Fig. 19. Semi-Quantitative Analysis of AR Copy Number in Male and Female 
Genomic DNA by PCR. 
A. Agarose gel following gel electrophoresis loaded as described in the lane legend 
depicted in B. C. Expanded image of the area of the gel encircled in red. D. 
Tabulated data acquired using ImageJ software to analyse the size and intensity of 
the bands in lanes 3, 4, 6 and 7. E. Table of the AR bands normalised to the 
corresponding GAPDH bands along with the fold difference between the male and 
female DNA analysed.                                                      
A 
B 
C
 
D
 
E
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3.4.2. Primer Efficiency and Species Specificity of AR, GAPDH and DMD Primers in 
qPCR 
Primers were designed using the National Center for Biotechnology Information (NCBI) 
primer designing online tool. The following parameters of the qPCR assay for each primer 
pair were validated: efficiency, R2 (a statistical measure of how close the data are to the 
fitted regression line), presence of non-specific amplifications and species specificity. 
Human female DNA was used to generate a standard curve using AR (Fig. 20A.), GAPDH 
(Fig. 20C.) and DMD (Fig. 20E.) primers. The starting quantities analysed were 10 ng, 3 ng, 
1 ng, 0.3 ng, 0.1 ng, 0.03 ng and 0.0 1ng. Melt curves for all primers were also generated 
to ensure only a single specific product was amplified (Fig. 20B, D and F). Mouse DNA was 
also tested using the same primers to determine species specificity at a starting quantity 
of 10 ng. Each condition was measured in triplicate. 
The AR primer pair had an efficiency of 97.1% an R2 value of 0.997 and a species specificity 
of 5093-fold (Fig. 20G.). The DMD primer pair had an efficiency of 101.4% an R2 value of 
0.990 and a species specificity of 1343-fold.  The GAPDH primer pair had an efficiency of 
101.5% an R2 value of 0.991 and a species specificity of 2042-fold. The efficiency and R2 
values and species specificity of all the primers tested were deemed acceptable such that 
it was possible to proceed to the validation of the assay. 
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Fig. 20. Primer Evaluation - Standard Curve Analysis and Species Specificity. 
The suitability of each primer pair for investigating genomic copy number variation 
was determined by generating a 7-point standard curve from female DNA covering 4 
log units ranging from a starting DNA quantity of 10ng to 0.01ng of normal female 
DNA.   A. AR, C. DMD and E. GAPDH.  Specific amplification of the target sequence 
was assessed by generating a melt peak for each primer pair B. AR, D. DMD and F. 
GAPDH. The species specificity was also determined by comparing the 10 ng of 
Mouse Liver DNA to 10 ng of normal male DNA. G. Summary of the standard curve 
analysis and species specificity for AR, DMD and GAPDH primer pairs. All samples 
were measured in triplicate. Analysis was performed using Bio-Rad CFX software. 
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3.4.3. Genomic Copy Number of AR and DMD in Human Prostate Cancer Cell Lines  
To validate the assay, genomic copy number of AR, DMD and GAPDH were elucidated in 
a number of prostate cancer cell lines. Human female DNA was used to generate standard 
curves, and acted as a control together with normal male DNA. AR copy number is 
expressed relative to GAPDH (Fig. 21A.) or normalised to GAPDH and DMD (Fig. 21B.). 
As expected, female DNA had a copy number of 2, for AR and DMD, whilst normal male 
DNA had a copy number of 1 for both genes (Fig. 21A.). Both PNT1A and PNT2C2 
(immortalised normal prostate cell lines) had a single copy of AR and DMD. The only cell 
line tested that showed specific amplification of the AR gene was the CaP cell line, VCaP, 
which showed dramatic amplification of approximately 28 fold. In contrast, DU145, PC3, 
PC346C (which is not derived from PC3) and RWPE1 had increased copy numbers of AR 
and DMD.  However, when the AR:DMD ratio was examined it revealed that these cells 
had not specifically amplified the AR gene but had increased X chromosome copy number 
(Fig. 21B.). These results highlight the importance of controlling for XCA.  A similar level 
of AR amplification in the VCaP cell line was reported by Li et al (2012) who also showed 
that LNCaP cells have a single copy of AR (Li et al., 2012).  
One deficiency of this experiment was that any potential GAPDH amplification was not 
taken into account. The major goal of this experiment was to obtain a positive control of 
specific GAAR to interrogate the sensitivity and accuracy of the assay. This was found to 
be the VCaP cell line.  
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Fig. 21. AR Copy Number Variation in CaP Cell Lines. 
The AR copy number of several CaP cell lines was analysed by normalising the AR 
starting-quantity (SQ) to the SQ of GAPDH A. or AR to GAPDH and DMD B. All 
samples are expressed relative to normal male DNA. A four-point standard curve 
(ranging from 10 ng to 0.3 ng) was generated from female DNA for AR, DMD and 
GAPDH. Analysis was performed using Bio-Rad CFX software. The total starting 
quantity for all conditions (excluding the standard curve) was 3 ng and all samples 
were measured in quadruplicate.  
Error bars = one standard error of the mean. 
Each sample represents at least 3 experimental replicates each comprising 3 
technical replicates. 
* = p≤ 0.05   ** = p≤ 0.01     *** = p≤ 0.001  ns = non-significant 
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3.4.4. Assay Validation – Sensitivity and Accuracy 
Biopsy samples display cellular heterogeneity and contain areas of normal tissue. This 
could lead to false negative results, potentially masking GAAR in a sample. The sensitivity 
and accuracy of the assay was determined using differing amounts of VCaP and normal 
male DNA mixed together to simulate a heterogeneous population. The total starting 
quantity for all conditions (excluding the standard curve) was 3 ng and all samples were 
measured in quadruplicate. Human female DNA was used to generate standard curves 
for AR, GAPDH and DMD primer pairs as previously described. The conditions analysed 
were as follows: 10% VCaP - 90% normal male, 5% VCaP - 95% normal male, 2% VCaP - 
98% normal male and 1% VCaP - 99% normal male. The expected AR copy number for 
VCaP – normal male DNA mixtures were calculated and used to investigate the sensitivity 
and accuracy of the assay. 
The assay succeeded in detecting an AR amplification above normal male DNA in all of 
the conditions tested including 1% VCaP - 99% normal (Fig. 22A.). The achieved AR copy 
numbers of all the VCaP - normal male mixtures did not deviate significantly from 
predicted values (Fig. 22B.). 
Similar to the cut-off threshold in PSA testing a threshold for GAAR detection was 
established using three standard deviations above the average normal AR value of 23 
normal samples (data not shown). This was done to account for variability of the assay. 
Using this threshold it was possible to generate an equation to determine the minimum 
percentage of abnormal DNA required for detection of GAAR (Fig. 22C.). This equation 
was used to calculate the minimum percentage of abnormal DNA required to detect GAAR 
in a heterogeneous sample containing cells with a normal AR gene copy number (Fig. 
22D.). The analysis revealed that an AR amplification of 2-fold can be detected in a 
heterogeneous sample if only 20% of cells are positive for the amplification.   
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Fig. 22. Assay Sensitivity, Accuracy and Heterogeneity Limitations. 
A. Assay sensitivity: the overall AR copy number was measured in various mixtures 
of VCaP and normal male DNA, mimicking the dilution of CaP DNA which is likely to 
occur in a heterogeneous biopsy containing normal DNA from origins such as 
infiltrating leukocytes, stroma and non-malignant epithelial cells. 
B. Assay Accuracy: using the known AR copy numbers of VCaP and normal male 
DNA (as determined experimentally) theoretical overall AR copy numbers for VCaP 
and normal male DNA mixtures were calculated and compared to experimental 
values.  
C. Heterogeneity Limitations: Three standard deviations above the mean AR copy 
number (relative to GAPDH and DMD) of 23 normal samples was used to determine 
a threshold of significance GAAR detection. This value was used to generate a 
formula C. which would calculate the minimum amount of CaP DNA within a sample 
necessary to detect a genomic AR amplification, this is relative to the level of 
genomic AR amplification within CaP cells shown in Table D. 
All conditions were measured in quadruplicate at a starting quantity of 3ng. 
Analysis was performed using Bio-Rad CFX software.  
Error bars = one standard error of the mean. 
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
 
* = p≤ 0.05   ** = p≤ 0.01      ns = non-significant 
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3.4.5. Genomic Copy Number of AR and DMD in Several Primary Cultures of Human CaP 
and BPH 
Human female DNA was used to generate standard curves as previously described, 
against which several human prostate cancer primary cultures, BPH derived primary 
cultures, patient lymphocytes and normal male gDNA were tested. Both normal male and 
normal female DNA are appropriate controls to which test samples can be normalised to. 
The total starting quantity for all conditions (excluding the standard curve) was 3 ng and 
all samples were measured in quadruplicate (data shown in Fig. 23A. and B.). 
As expected, female DNA had a copy number of 2 for AR and DMD with normal male DNA 
having a copy number of 1 for these genes. The BPH derived cell cultures (H226/12 and 
H227/12) and lymphocyte DNA preparations displayed normal values for AR and DMD 
copy number. None of the primary human prostate cancer derived cultures tested 
positively for GAAR.  
The importance of controlling for XCA was further highlighted in the samples: H229/12 L, 
H229/12 P, H217/12 Rb L, H217/12 Rb P, H110/11 Lb L, H110/11 Lb P, H135/11 L, H135/11 
P, H224/12 L and H224/12 P. These samples all had a value above 1 for AR copy number 
when normalised to GAPDH. However when these values were further normalised by 
generating an AR:DMD ratio, it was revealed that these cells had not specifically amplified 
the AR gene but had instead have XCA.  
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Fig. 23. Genomic Copy Number of AR and DMD in Several Primary Cultures of 
Human CaP and BPH.  
A. Graphical representation (generated using Bio-Rad CFX software gene expression 
analysis feature) of the genomic copy number of AR and DMD in all conditions 
tested. Data shown has been normalised to the control gene GAPDH with values 
being expressed relative to female genomic DNA (Error bars = one standard error of 
the mean.) 
B. Tabulated version of data shown in (Fig. 23A.) with a further column depicting the 
AR:DMD ratio. Values depicted are mean averages with +/-1 standard error of the 
mean in brackets. 
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
 
A 
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3.4.6. Genomic Copy Number of AR and DMD in Several Tissue Samples of Human 
Prostate Cancer 
Human female DNA was used to generate standard curves as previously described, 
against which several human prostate cancer tissues, patient lymphocytes and normal 
male genomic DNA were tested. The total starting quantity for all conditions (excluding 
the standard curve) was 3 ng and all samples were measured in quadruplicate (data 
shown in Fig. 24A. and B.). 
As expected, female DNA had a copy number of two for AR and DMD. However the 
normal male DNA showed reduced copy number compared to the predicted value of 1 
and previous results, as such the data for this experiment was expressed relative to 
female DNA.  Also as expected none of the lymphocyte DNA preparations significantly 
deviated from the expected value of one for AR copy number.  
The importance of controlling for XCA was even further demonstrated in the  HO24/10 L, 
H027/10 T and HACaP T samples. These samples all had a value above one for AR copy 
number when normalised to GAPDH however when these values were further normalised 
by generating an AR:DMD ratio it was revealed that these cells had not specifically 
amplified the AR gene. 
 
  
B 
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Fig. 24. Genomic Copy Number of AR and DMD in Several Tissue Samples of 
Human CaP.  
A. Graphical representation (generated using Bio-Rad CFX software gene expression 
analysis feature) of the genomic copy number of AR and DMD in all conditions 
tested. Data shown has been normalised to the control gene GAPDH with values 
being expressed relative to female genomic DNA (Error bars = one standard error of 
the mean.) 
B. Tabulated version of data shown in A. with a further column depicting the 
AR:DMD ratio. Values depicted are means +/-1 standard error of the mean in 
brackets). 
Each sample represents 3 experimental replicates each comprising 3 technical 
replicates. 
 
A 
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3.4.7. Analysis of 10 Blinded Samples - Independently Assessed for AR Amplification 
Using FISH 
To test the ability of the assay to detect samples known to be positive for GAAR, 10 
samples, which had been independently screened for GAAR using FISH, were assessed.  
The total starting quantity for all conditions (excluding the standard curve) was 3 ng and 
all samples were measured in quadruplicate. Human female DNA was used to generate 
standard curves for AR, GAPDH and DMD primer pairs as previously described. Copy 
number was expressed relative to GAPDH. 
Specific AR amplification (indicated by an AR:DMD ratio greater than 1) was detected in 
all samples that tested positive using FISH: B, C, LuCaP 35, H, and I (Fig. 25A., 25B. and 
25C.). LuCaP 41, D and E showed elevated AR copy number (Fig. 25A. and 25B.) however 
in these cases there was a concurrent and equal elevation in the DMD copy number. As 
previously described, this phenomenon indicates that XCA is the mechanism of increased 
AR gene in these samples. 
(Linja et al., 2001) previously demonstrated XCA In the LuCaP 35 xenograft indicated by 
multiple green signals (label for X centromeres). This is consistent with the increase in 
DMD copy number detected by THE qPCR method. Personal communication with 
Professor Visakorpi confirmed that the level of AR amplification seen in these samples 
was consistent with their FISH analysis. However, it was also communicated that focal 
amplifications of AR that exceed 10 copies are difficult to enumerate by FISH as the 
fluorescent signals from the AR copies (in close proximity to one-another) merge. 
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Fig. 25. Genomic Copy Number of AR and DMD in Clinical Samples and Cell Line 
Xenografts.  
A. Graphical representation of the genomic copy number of AR and DMD in all 
samples tested. Data shown has been normalised to the control gene GAPDH with 
values expressed relative to male genomic DNA. Error bars = 1 standard error of the 
mean. Insert is dual-colour FISH analysis of prostate cancer xenograft LuCaP 35 
showing two chromosome X centromeres (green signals) and AR clusters (red signals) 
Insert adapted from (Linja et al., 2001). 
B. Tabulated version of data shown in figure 25A. Including AR:DMD ratio. Values 
depicted are means (+/-1 standard error of the mean in brackets).  
C. Table showing the results of independent analysis of the amplification status of the 
samples tested, assessed using FISH. 
* = p≤ 0.05   ** = p≤ 0.01     *** = p≤ 0.001  ns = non-significant 
Each sample represents 3 experimental replicates each comprising 3 technical 
replicates. 
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3.4.8. Analysis of X Chromosome Aneuploidy and AR Amplification in Near-Patient 
Xenografts 
Recently our lab has derived several near-patient xenograft (PDX) models derived from 
different stages of CaP including hormone naïve, hormone responsive and CRPC (Fig. 
26B.) This sample set was investigated for the frequency and nature of GAAR and XCA in 
comparison with patient-specific lymphocyte DNA (Fig. 26A.). 
The total starting quantity for all conditions (excluding the standard curve) was 3 ng and 
all samples were measured in quadruplicate. Human female DNA was used to generate 
standard curves for AR, DMD and GAPDH primer pairs as previously described. Copy 
number is expressed relative to GAPDH.  
GAAR was detected in two samples namely; H427X and H455X. However, upon closer 
analysis it can be seen that the nature of these amplification events is different between 
the two samples (Fig. 27.). H427X has an equal amplification of AR and DMD sequences. 
In contrast, H455X has elevated AR over and above the increase in DMD which itself is 
significantly different compared to normal male DNA.  
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Fig. 26. Genomic Copy Number of AR and DMD in Near-Patient Xenograft 
Models.  
A. Genomic copy number of AR and DMD in patient-derived xenografts of 
prostate cancer. Data has been normalised to the control gene GAPDH with 
values being expressed relative to male genomic DNA. Error bars = 1 standard 
error of the mean.   
B. Pathology data for the near-patient xenograft models at engraftment. 
HR = hormone responsive, CRPC = castration resistant prostate cancer, G = 
Gleason score, N1 = metastasis to lymph nodes, T3 = locally-advanced prostate 
cancer, b1 = metastasis to bones 
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
 
 
 
 
* = p≤ 0.05   ** = p≤ 0.01     *** = p≤ 0.001  ns = non-significant 
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Fig. 27. Genomic Copy Number of AR and DMD in Near-Patient Xenograft Models 
Relative to Patient Lymphocyte DNA.  
Genomic copy number of AR and DMD in xenografts H427 and H455 and 
corresponding lymphocytes. Data shown has been normalised to the control gene 
GAPDH with values expressed relative to patient lymphocyte DNA. Error bars = 1 
standard error of the mean. A. = H427X B. = H455X. 
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
 *** = p≤ 0.001   
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3.4.9. Assay Compatibility with Formalin-Fixed Paraffin-Embedded Tissue  
FFPE samples represent the most common form of patient tissue preparations within the 
clinic. Additionally, there are a tremendous number of FFPE samples in hospital archives. 
In order for this assay to have maximum applicability, it is necessary for the assay to 
function properly using DNA extracted from FFPE tissue as template. This represents a 
challenge as DNA extracted from FFPE tissue is often of poor quality compared with DNA 
extracted from fresh or fresh-frozen samples. 
Initial validation was performed using the cell line VCaP, as the assay was established 
using this cell line and it has a large-magnitude GAAR. VCaP cells were clotted in cell-free 
human blood plasma and then either formalin-fixed and paraffin-embedded or frozen in 
OCT. DNA was subsequently extracted from FFPE VCaP, OCT VCaP and fresh VCaP cell-
pellet. When DNA from all three preparations was interrogated, no statistical significant 
difference was observed with respect to AR and DMD genomic copy number (Fig. 28A.). 
The ability of the assay to function in FFPE tissue was also investigated in two near-patient 
xenograft models (H427X and H455X), and again no significant differences between DNA 
extracted from fresh cell pellet and FFPE tissue (with respect to AR and DMD copy 
number) was seen  (Fig. 28B. and C.). 
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Fig. 28. Assay Compatibility with Formalin-Fixed Paraffin-Embedded Tissue 
Samples. 
A. Genomic copy number of AR and DMD in the VCaP cell line in freshly isolated cells, 
those embedded in OCT, and FFPE  
B. Genomic copy number of AR and DMD in PDX sample H427X. 
C. Genomic copy number of AR and DMD in PDX sample H455X. 
Data shown has been normalised to the control gene GAPDH with values being 
expressed relative to male genomic DNA (VCaP) or patient derived lymphocyte DNA 
(H427X and H455X). Error bars = 1 standard error of the mean.  
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
 ns = non-significant 
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3.5. Discussion  
CaP is often a clinically irrelevant disease with many patients dying with CaP rather than 
as a result of CaP (Swanson and Basler, 2010). This has led to unacceptably high 
overtreatment in which patients undergo surgery (with all associated risks) and ‘life 
altering’ side-effects. In an effort to curb over-treatment of CaP by radical prostectomy, 
an approach often termed ‘watchful waiting’ is employed by urologists. This involves 
repeated PSA screening and biopsies to ensure that a patient is only operated on when 
the disease is likely to progress into a potential life-threatening form i.e. grade 4 cancer 
or escape from the capsule (Swanson and Basler, 2010).  
The rationale for an GAAR test is that by providing a molecular interrogation of one of the 
most fundamental genes for CaP progression, urologists’ (which mostly rely on 
morphological changes in the CaP to determine the likelihood of disease progression) 
could use this assay to identify patients at risk of disease progression and stratify them 
accordingly. Also the assay can be used to monitor disease evolution in response to 
therapy i.e. progression to incurable CRPC. This is of particular relevance as (Linja et al., 
2001) demonstrated that GAAR correlated with AR expression. 
Evolution of cancer to acquire a treatment-resistant phenotype through the mechanism 
of gene amplification is a well-established phenomenon. For instance methotrexate 
(MTX) is an important chemotherapeutic for the treatment of acute lymphoblastic 
leukaemia (ALL) (Göker et al., 1995). While complete remission is seen in the vast majority 
of patients (upwards of 90%) this is often followed by relapse, with the recurrent cells 
possessing a MTX resistance phenotype (Göker et al., 1995). This situation has several 
parallels with that of CRPC emergence following ADT treatment of CaP. Not least of these 
parallels is the most common mechanism by which resistance is acquired – gene 
amplification. In ALL the gene in question is dihydrofolate reductase (DHFR) (Göker et al., 
1995, Srimatkandada et al., 1983). The protein encoded by this gene is the therapeutic 
target of MTX in ALL. The amount of MTX required to achieve inhibition of the DHFR 
enzyme is directly proportional to the level of DHFR expression in target cells. Several 
MTX-resistant cell lines have increased levels DHFR activity, due to gene amplification and 
it has also been shown that even low-level genomic amplification (2-4 copies/cell) is 
sufficient for cells to show MTX resistance in ALL (Göker et al., 1995, Srimatkandada et 
al., 1983). It should be noted that the MTX resistance by DHFR amplification is not exactly 
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equivalent to AR amplification in response to ADT as the former is based competitive 
inhibition of DHFR whilst the latter is based on a reduction of AR ligand(s). 
 
3.5.1. A qPCR Assay Capable of Detecting AR Amplification in a Variety of 
Heterogeneous Biological Samples has been Successfully Established 
The rationale behind using qPCR to identify genomic amplification of the AR gene has 
been verified. This was most rigorously demonstrated by the repeated ability to achieve 
the predicted AR genomic copy number difference, of two, between male and female 
DNA. Further demonstration of the technique’s ability to detect genomic amplification of 
the AR gene comes from the ability to determine the high numbers of AR copies in the 
VCaP cell line  26.17 (+/- 1.797) (p≤ 0.001) which is known to be GAAR positive (Waltering 
et al., 2012). This is in contrast to the LNCaP cell line which has acquired castration 
resistance through a mutation in the AR gene to produce a constitutively active variant 
(Waltering et al., 2012).  
The qPCR based assay is sensitive, accurate and comparable to FISH when using primary 
tumours and xenograft samples. Coupled with a reduced ‘turnaround time’, this 
amenability to high through-put screening and objectivity implies that this assay could 
prove useful in a clinical setting to ascertain GAAR and XCA status of a patient and thus 
help patient triaging in CRPC.  
The inclusion of a further control gene in the form of DMD has proven essential in order 
to discriminate between GAAR and XCA. This was shown in the following samples: RWPE1, 
DU145, PC3, PC346c, H229/12 L, H229/12 P, H217/12 Rb L, H217/12 Rb P, H110/11 Lb L, 
H110/11 Lb P, H135/11 L, H135/11 P, H224/12 L, H224/12 P, HO24/10 L, H027/10 T, 
HACaP LuCaP 41, D, E, H427X and H455X.  
None of the primary cell cultures derived from human CaP showed a specific amplification 
of the AR gene. This result may be attributed to the culture conditions used in the 
generation and maintenance of these cells, which are devoid of androgens. As such, 
current cell culture conditions may be selecting against the survival of cells positive for 
AR amplification. Additionally, many of the samples were from early CaP or from those 
that had not been on long-term ADT. It is possible that there are some rare cells in the 
cultures which have GAAR but are below the level of detection.  
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The data accrued from the primary tissue samples only yielded one sample that tested 
positive for a very modest increase in AR copy number namely YO19/09 T. This sample 
was from a tumour biopsy that was taken from a patient that had relapsed post ADT thus 
is CRPC. In order to ascertain the significance of this result, a total of 23 normal sample 
data sets, each of which being a mean of at least three replicates was used to determine 
a threshold for significance. A threshold of three standard deviations above the mean of 
these normal samples was determined (data not shown) this equalled 1.20. The corrected 
AR copy number for YO19/09 T was 1.38(+/-0.186). Subtracting the standard error of this 
sample from the mean value results in a value of 1.194, this is just below the threshold 
for the existence of GAAR. It is most noteworthy that the DNA preparation of this sample 
(and the other tissue samples tested) was performed without any targeted cancer cell 
enrichment. Within a CaP tumour there are still normal glands and non-malignant stromal 
cells, furthermore there are often infiltrating leukocytes present within a tumour. These 
normal cells may have diluted out the cancer cells and as a result could have masked the 
presence of GAAR within these samples. 
In terms of sensitivity, the assay was also able to detect the presence of a GAAR from a 
mixture of normal and abnormal DNA e.g. 1% VCaP – 99% normal male DNA mixture (Fig. 
22.). Using the threshold of detection a formula was generated to predict the maximum 
amount of normal DNA within a sample that would not mask a given AR copy number 
gain (Fig. 22C.). This revealed that an AR duplication could still be detected if 80% of the 
DNA within a sample was normal. This is particularly important when considering the 
heterogeneity of prostate cancer biopsies. 
Due to the lack of samples that tested positive for GAAR, the accuracy of the assay in 
comparison to FISH was investigated by assaying ten samples which had been 
independently analysed for AR amplification by FISH and subsequently blinded. The assay 
successfully detected the presence of specific GAAR gene all samples that were scored 
positive by FISH (five samples) but not in samples that were scored as negative by FISH 
(five samples). It must be stated that a much larger sample size would be necessary to 
obtain a reliable estimation of false positive and negative rates.  
The last batch of samples interrogated by the assay included samples of the latest round 
of PDXs generated in our laboratory (funded by Movember with an emphasis on 
generating xenografts from CRPC patients) as well as the xenograft generated from the 
Y019/09 T sample. This resulted in the identification of two samples that both had GAAR 
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and XCA, namely H427X and H455X. However, upon closer analysis it can be seen that the 
nature of these amplification events is different between the two samples. H427X has an 
equal accumulation of AR and DMD sequences which is indicative of XCA. H455X on the 
other hand, has elevated AR over and above the increase in DMD which itself is significant. 
This could represent an initial XCA event with subsequent locus-specific GAAR. It is of 
great importance to the biology of CaP initiation, in regards to the cell type of origin of 
the disease, that GAAR and XCA have been detected in passage zero PDXs, indicating that 
these genetic abnormalities are present in cells capable of tumour reconstitution in vivo. 
An interesting future direction to increase the likelihood of detecting GAAR in xenograft 
models would be to assess xenograft samples under castration conditions. The xenograft 
samples analysed in this project were grown within a male mouse, as such androgen 
supply is not a limiting factor for tumour growth. In this scenario, cells that have GAAR 
would not have a selectable advantage over cells that are negative for AR gene 
amplification. It would be interesting to see if samples previously negative for GAAR could 
form GAAR-positive tumours which would indicate that rare GAAR-positive cells were 
present in the original patient-tumour biopsy. 
The Y019X (xenograft) sample was negative for both GAAR and XCA. However, very recent 
data generated by our laboratory has thrown the provenance of this xenograft into 
disrepute as it tested positive for both Epstein–Barr virus (EBV) presence and 
immunoglobulin heavy locus (IGH) rearrangement (Appendix 5.) indicating that graft out-
growth was the result of a contaminating transformed B cell and not CaP epithelia. 
Further experiments were designed to investigate the compatibility of the assay with FFPE 
tissue, as this represents the most common form of sample preparation and archived 
tissue in the clinic. The results show that the assay produces copy number values for AR 
and DMD (from FFPE sources) that are not statistically significant from those derived from 
OCT. However, the standard error of copy number values was greater in FFPE samples, 
indicating that fresh or OCT preserved tissue is preferable. 
 
3.5.2. The Assay also Gives Information Regarding X Chromosome Aneuploidy – a 
Relatively Common Event in CaP Associated with Poor Prognosis 
As demonstrated by DMD copy number of the cell lines, xenografts and primary samples 
tested it appears that XCA is common in CaP. Being present in DU145, PC3, PC346c and 
VCaP, LuCaP 41, LuCaP 35, LuCaP 73, H427X, H455X, B, C, D, E, H samples.  
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A relationship between XCA chromosome and poor prognosis is not unique to CaP. Loss 
of X chromosome inactivation is a marker of aggressiveness in breast and ovarian cancers 
(Kang et al., 2015). It was also found that all male breast cancer cases harboured a XCA 
(100%) (Di Oto et al., 2015). This shows that XCA plays a role in the neoplastic 
transformation of male breast epithelial cells. In chronic neutrophilic leukaemia (CNL) 
which is an uncommon myeloproliferative disorder characterised by neutrophilia and 
myeloid hyperplasia in the absence of BCR/ABL gene fusion events (Elliott et al., 2001). A 
study has found that whilst most patients with CNL have normal karyotypes, those with 
46,XY,+X  (15 cases studied) had disease progression to myeloid crises accompanied by 
poor prognoses (Yamamoto et al., 2002). The authors concluded that XCA may play a role 
in the transition of CNL from a chronic to crisis phase of the disease (Yamamoto et al., 
2002). 
In CaP it is now established that there is a significant frequency of XCA, even in ‘treatment 
naïve’ patients. In a FISH study by (Merson et al., 2014) 152 out of 596 (25.5%) 
demonstrating gain of at least one copy of the X chromosome. A correlation between XCA 
and reduced survival is shown in (Fig. 14.) (Merson et al., 2014). This data corroborates a 
much earlier study by (Röpke et al., 2004) in which 9 out of 80 prostate cancers (11.25%) 
tested positive for XCA by FISH. The same group also found that XCA correlates with 
pathological classification and tumour volume (Röpke et al., 2004). 
The exact mechanism by which XCA contributes to poor prognosis in CaP is currently 
unresolved. However, there are two hypotheses which need not be mutually exclusive. 
One explanation shared by both (Röpke et al., 2004, Merson et al., 2014) is that XCA 
results in CRPC by driving AR expression (Fig. 29.). An alternative view which can also 
explain the poor prognosis of non-endocrine cancers (when additional copies of X 
chromosome are present) is that XCA is the product and therefore a marker and driver of 
genomic instability, a hallmark of cancer (Fig. 30.) (Giam and Rancati, 2015). 
Whichever mechanism is correct, the fact that this assay can simultaneously detect two 
genetic aberrations associated with poor prognosis and therapeutic resistance in CaP 
greatly enhances its applicability in a clinical setting. Also as XCA is not unique to CaP the 
assay described here may also be useful as a tool to stratify patients according to risk in 
several oncology fields. 
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Fig. 29. Selection of Cells with AR Gain by ADT. 
Small foci of CaP cells that are positive for genomic amplification of the AR gene 
could expand to form a CRPC tumour by positive selection by (1) androgen 
deprivation therapy or (2) natural androgen insufficiency within the tumour. 
From: (Merson et al., 2014) 
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Fig. 30. XCA Contributes to Genomic Instability. 
The combination of aneuploidy, chromosomal instability (CIN) and genomic 
instability (GIN) can have additive or even synergistic effects on tumourigenesis. 
Aneuploidy leads to increased gene expression of the genes located on the 
aneuploid chromosome, potentially leading to deregulation oncogenes (OG) and 
tumour suppressor genes (TSG) – directly effecting oncogenic transformation. CIN 
can result in aneuploidy by increasing chromosome missegregation events. 
Additionally, aneuploidy could result in CIN through changing the stoichiometry of 
protein-complexes responsible for genome maintenance. Chromosomal-
missegregation could also lead to DNA damage and GIN. CIN and GIN are thought 
to promote tumourigenesis by increasing the chance of accumulating oncogenic 
mutations. The ‘by-products’ of CIN and GIN namely: aneuploidy and DNA damage 
result in increased intra-tumour diversity potentially increasing the potential of the 
bulk tumour to adapt to changes in the microenviroment due to metastasis or 
therapeutic intervention.   
From: (Giam and Rancati, 2015) 
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4. Epigenetic Regulation and Investigation of the Mechanism of Action of LXN and 
RARRES1 in Prostate Epithelial Cells 
 
4.1. RARRES1  
RARRES1 was originally isolated from the skin epithelial cells, as the gene with greatest 
increase of expression in response to the synthetic retinoid – tazarotene (Nagpal et al., 
1996), which is  effective in the treatment of psoriasis (characterised by aberrant 
proliferation) (Weinstein et al., 2003). RARRES1 is a type III membrane protein (Sahab et 
al., 2011), and is located adjacent to the LXN gene on the long arm of chromosome 3. Two 
isoforms of RARRES1 are produced through alternative splicing: RARRES1 TS1 is a 294 
amino acid protein and RARRES1 TS2 is 228 amino acids in length. The two encoded 
proteins have very high amino acid sequence homology. The major distinction is a 
putative CPA binding site (present in RARRES TS1 and is highly conserved with LXN) which 
is absent in RARRES1 TS2 (Aagaard et al., 2005). The CPA binding site was found to be an 
inhibitory loop that protrudes into the CPA4 active site, including five critical amino acids 
(QEIIP) (Oldridge, 2012, Pallarès et al., 2005). 
RARRES1 expression is tightly linked to the differentiation status of cells and is most 
abundantly expressed in terminally differentiated cells from normal tissues (Wu et al., 
2006). This expression pattern is retained in malignant conditions where it was found that 
RARRES1 was generally down-regulated in metastatic lymph nodes compared to those in 
the primary tumours in breast cancer (Peng et al., 2012). Among 122 colorectal 
adenocarcinomas, the poorly differentiated adenocarcinomas and Dukes’ stage D 
tumours showed a significant decrease in RARRES1 expression i.e. expression of RARRES1 
is closely associated with the differentiation of colorectal adenocarcinoma (Wu et al., 
2006, Peng et al., 2012). 
In the prostate, reduction of RARRES1 expression is specifically associated with cancer 
progression. In one study, RARRES1 mRNA was detected in ten normal human prostate 
tissues and 51 BPH tissues, but was only present in fewer than 8% of the CaP tissues 
analysed (Jing et al., 2002). The silencing of RARRES1 expression seems to be an early 
event in CaP: 73% of very low grade CaP (Gleason scores of 2–3) do not express of 
RARRES1 (Jing et al., 2002). However, it is debateable whether such low Gleason scores 
are truly CaP. 
There is substantial evidence that RARRES1 acts as a tumour suppressor in multiple 
cancers. Re-introduction of RARRES1 expression in the highly aggressive CaP cell line: PC-
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3M, resulted in a dramatic reduction of the in vitro invasiveness and a 2.4-fold reduction 
in tumour burden in the PC-3M xenograft model (Jing et al., 2002, Youssef et al., 2004). 
In the leukaemic cell line K562, restoration of RARRES1 expression promoted apoptosis 
after treatment with all-trans retinoic acid (Wang et al., 2008). Also, RARRES1 was shown 
to retard cell proliferation and invasive features of nasopharyngeal carcinoma cells 
mediated by Epstein-Barr virus transformation (Kwok et al., 2009). In breast cancer, re-
expression of RARRES1 reduced cell invasion and augmented cell death induced by 
cytotoxic agents (Wang et al., 2008). Additionally, both RARRES1 isoforms inhibited the 
growth of SW620 colon cancer cells (Wu et al., 2011a).  
In concordance with the above studies, our laboratory has shown that RARRES1 
negatively regulates colony forming efficiency and invasion in malignant and benign 
prostate tissue (Oldridge, 2012, Oldridge et al., 2013). It has also been demonstrated that 
there is reduced (barely detectable) expression of RARRES1 in prostate SCs compared to 
their more differentiated progeny, implicating a role of RARRES1 in regulating 
differentiation within the prostatic epithelium (Oldridge, 2012, Oldridge et al., 2013). In 
cells derived from CaP, RARRES1 is barely detectable in CSCs and transit amplifying 
populations and is expressed at very low levels in committed basal cells. This is in stark 
contrast to normal tissues (Oldridge, 2012, Oldridge et al., 2013).  
There have been several reported mechanisms of RARRES1 mediated inhibition of 
proliferation and survival. Both RARRES1 isoforms inhibited prostaglandin E2 (PGE2)-
stimulated colon cancer cell proliferation (Wu et al., 2011a, Tsai et al., 2011). This was 
shown to be the result of suppressing subsequent β-catenin nuclear localization, β-
catenin/T cell factor (TCF) transactivation, and cyclic adenosine monophosphate 
(cAMP)/cAMP response element-binding protein (CREB) signalling in response to PGE2 
(Tsai et al., 2011). It was further reported that these actions were at least in part mediated 
through the up regulation of G-protein-coupled receptor kinase 5 (GRK5) expression (Wu 
et al., 2011a). GRK5 is a serine/threonine kinase, which suppresses the activation of 
ligand-activated G-protein-coupled receptors (GPCRs) by inducing internalisation (Harris 
et al., 2008, Wang et al., 2008). The importance of GRK5-mediated phosphorylation is 
further highlighted by its ability to increases histone deacetylase activity and promote 
p53 degradation (Chen et al., 2010, Liu et al., 2010a).  
RARRES1 knock-down  has been shown to down-regulate the serine/threonine-protein 
phosphatase 2A (PP2A) and  its catalytic subunit - β isoform encoded by PPP2CB (Sahab 
  125                                          Chapter 4. Results 
et al., 2010). PP2A has broad substrate specificity, targeting proteins of oncogenic 
signalling cascades including proto-oncogene serine/threonine-protein kinase (Raf), 
mitogen-activated kinase (Mek), and Akt (29) (Ory et al., 2003). PP2A is also a negative 
regulator of the growth factor stimulated signalling pathways. Furthermore, mutation of 
this enzyme has been identified in lung and breast cancer (Wang et al., 1999, Esplin et al., 
2006).  
RARRES1 has also been implicated in the regulation of cell cycle dynamics through 
mediation of End-binding protein-1 (EB1) (Sahab et al., 2010). The major function 
attributed to EB1 is the regulation of spindle dynamics and chromosome alignment during 
mitosis. As such downregulation of RARRES1 may have a role in enhancing genomic 
plasticity by increasing abnormal division events leading to aneuploidy (Green et al., 
2005). 
 
4.2. LXN  
LXN is a 29kDa protein composed of 222 amino acids. The gene encoding LXN is located 
on the long arm of chromosome 3. LXN is the sole carboxypeptidase inhibitor (CPI) in 
mammals. Experimentally it has been shown to act as a potent competitive inhibitor of 
CPA4 in humans (Liang and Van Zant, 2008). CPAs are first synthesised as inactive 
zymogens which are activated by proteolytic cleavage. They function as  exopeptidases 
i.e. mediate cleavage of C-terminal amino acids. The LXN primary sequence does not 
share significant homology with other known CPIs (Reverter et al., 2000). However, it 
does share 30% sequence homology with a cysteine protease inhibitor, cystatin C (Liang 
and Van Zant, 2008). It also shares structural homology with RARRES1 (Liu et al., 2012) 
which is encoded by an adjacent gene. The location of RARRES1 and its homology to LXN 
suggests that the two genes are the product of duplication and subsequent divergence 
(Fig. 31.) (Aagaard et al., 2005). Indeed evolutionary analysis of both genes shows that 
RARRES1 and LXN are paralogues, with RARRES1 implicated as the ancestral gene (Sahab 
et al., 2011).  
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CPA4 expression has been detected in hormone-regulated tissues including the prostate, 
where it has been shown to be involved in CaP and is specifically implicated in CaP 
aggressiveness (Huang et al., 1999, Kayashima et al., 2003).  CPA4 serum activity has also 
been suggested as a potential biomarker for pancreatic cancer. These two examples have 
implicated LXN as a tumour suppressor by proxy (Matsugi et al., 2007). However, 
evidence that LXN does not function through inhibition of CPA4 comes from a study on 
rat peritoneal mast cells where it was found that the two proteins are not localized in the 
same granular compartment in the cytoplasm (Uratani et al., 2000). Further evidence 
comes from work conducted in our laboratory which showed that CPA4 was secreted and 
LXN was localised to the nucleus in CaP cells (Oldridge, 2012). In conclusion, LXN is highly 
unlikely to perform its tumour suppressive and SC regulatory functions through an 
interaction with CPA4. 
Forward genetics has implicated LXN as a regulator of normal HSC number in mice, 
through decreasing self-renewal and increasing apoptosis (Bolger et al., 2012). This work 
was further extrapolated into leukaemia with the working hypothesis that LXN was down-
regulated in malignant disease (Liu et al., 2012). In this study several leukaemia and 
lymphoma cell lines were analysed, along with primary cells, showing that LXN expression 
at both the mRNA and protein level was decreased compared to normal controls (Liu et 
al., 2012). Moreover, re-initiation of LXN expression in two lymphoma cell lines reduced 
their growth in vitro and in vivo (Liu et al., 2012). Mechanistically it was found that LXN-
mediated suppression was achieved by down-regulation of anti-apoptotic genes, 
including bcl-2, leading to an increase in apoptosis (Liu et al., 2012). These actions could 
not be replicated by the treatment of cells with a CPI derived from potato, which is further 
evidence for an alternative function of LXN (Liu et al., 2012). 
Fig. 31. Adjacent Location of the RARRES1 and LXN Genes. 
The genes are located adjacent to one another on the long arm of chromosome 3 at 
the region 3q25.32-q25.33.  
 From: (Oldridge, 2012) 
 
EXAMINER COMMENT. Legend states adjacent genes so why not expect to have 
sistinct promoters? 
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Further evidence of a role for LXN in cancer comes from the study of gastric carcinoma. 
Initial evidence for an involvement in the disease came from the comparison between the 
‘normal’ immortalised gastric epithelial cell line GES-1, and its malignant derivative the 
MC cell line. Comparison between the two showed that high levels of LXN were found in 
GES-1 compared to the MC cells (Ke Y, 1996). Further evidence was gained through the 
analysis of primary samples and in vivo models where it was shown that LXN was 
significantly down-regulated in areas of disease compared to paired samples of adjacent 
normal tissue, and that over expression of LXN in MGC803 cells inhibited colony 
formation and tumour growth in nude mice (Li et al., 2011). Microarray analysis of 
changes in expression following knock-in of LXN, revealed several genes implicated in 
cancer progression that were differentially expressed in response to LXN namely, Maspin, 
WAP Four-Disulfide Core Domain 1 (WFDC1), secretory leukocyte protease inhibitor 
(SLPI), S100 calcium-binding protein P (S100P), and platelet derived growth factor 
receptor beta PDGFRB (Li et al., 2011). 
 
4.3. Low Expression of RARRES1 or LXN has a Negative Impact on Recurrence-Free 
Survival in CaP 
As discussed in sections 4.1 and 4.2, both RARRES1 and LXN have tumour suppressive 
functions in a variety of cancers. Furthermore, both genes have been shown to be 
downregulated in primary malignant samples compared to adjacent normal control 
tissues.  
(Taylor et al., 2010) assessed DNA copy number, exon expression and miRNA expression 
in 218 prostate cancers. This data is open access and through the betastasis initiative, it 
is possible to construct Kaplan-Meier plots for LXN and RARRES1 (Fig. 32.). From this data 
it can be seen that low expression of LXN or RARRES1 within CaP tumours correlates with 
a statistically significant reduction in recurrence-free survival (LXN p=0.000122 and 
RARRES1 p=0.00576) (Taylor et al., 2010). This data is consistent with the proposed 
tumour suppressive functions of these genes. However, the data presented in (Taylor et 
al., 2010) is the product of all the cells within the prostate tumour biopsy, and as such the 
data may be skewed by the presence of stroma and immune-cell infiltrates.  
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Fig. 32. High Expression of LXN or RARRES1 Correlates with Poor Prognosis in CaP. 
Kaplan-Meier plots of LXN and RARRES1), generated from 218 prostate cancer 
samples (Taylor et al., 2010). In both cases the median expression was used as a 
threshold to categorise high and low expressers.  Statistics were generated using a 
logrank test. Data was accessed through the Betastasis initiative.  
From: (Taylor et al., 2010) 
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4.4. Co-expression of RARRES1 and LXN in Primary Prostate Cultures 
Microarray expression profiling of primary prostate epithelial cultures of benign or 
malignant origin, either enriched for progenitor cells or more differentiated committed 
basal cells, was previously performed in our laboratory (Birnie et al., 2008). These 
cultured samples eliminate any non-epithelial contaminants that may artificially alter LXN 
and RARRES1 expression profiles. A caveat to this analysis is that due to the in vitro culture 
system employed the data may not be completely representative of the CaP in vivo i.e. 
culture conditions select for a proliferating phenotype and luminal cells do not survive in 
culture. This analysis, which was confirmed by RT-PCR, showed that LXN and RARRES1 are 
downregulated in SC fractions compared to CB cells (Oldridge, 2012, Oldridge et al., 
2013). Moreover, there was a non-significant trend of malignant CB samples towards 
lower LXN and RARRES1 expression, compared to benign CB samples. 
A re-analysis of these data showed a strong positive correlation exists between LXN and 
RARRES1 expression (R2=0.92) (Fig. 33.) suggesting that these two genes could be co-
regulated in both the benign and malignant prostate epithelium. This is likely, due to the 
close proximity of the two genes in the genome and the likelihood of regulation through 
common transcription factors and/or epigenetic control mechanisms.  
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Fig. 33. Co-Expression of LXN and RARRES1 in Prostate Epithelial Cells of 
Benign and Malignant Origin. 
Correlation analysis of Microarray gene expression data of a LXN probe vs a 
RARRES1 probe.  Data was analysed using Pearson’s correlation.  R2 values for 
correlation in prostate epithelial cells of benign and malignant origin 
Re-analysis of data from: (Birnie et al., 2008) performed by Davide Pellacani 
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4.5. Regulation of LXN and RARRES1 
Both RARRES1 and LXN have been shown to be targets of atRA mediated transcriptional 
control (Oldridge, 2012, Oldridge et al., 2013, Kamal et al., 2014). Studies of epigenetic 
regulation of LXN and RARRES1 have focused on CpG islands within the promoter regions 
of the two genes. Hypermethylation of CpG islands is an established mechanism of 
silencing tumour suppressor genes (Esteller, 2002, Liu et al., 2010b). Methylation of the 
LXN and RARRES1 promoters correlates with reduced LXN and RARRES1 expression (Liu 
et al., 2012, Peng et al., 2012, Youssef et al., 2004, Wu et al., 2011a). It has previously 
been shown that LXN and RARRES1 are regulated by promoter hypermethylation in CaP 
cell lines, but this is not observed in primary tissue or cultures (Oldridge et al., 2013). It is 
proposed, that in primary prostate epithelium, the major contributing factor in the 
epigenetic regulation of LXN and RARRES1 is through altered chromatin status by post-
translational modification of histone proteins in the region of the LXN and RARRES1 
genes. This form of epigenetic regulation is controlled by the post-translational 
modification of histone proteins. 
The identification of structural homology (Liu et al., 2012, Aagaard et al., 2005) and co-
regulation of LXN and RARRES1, coupled with their downregulation in undifferentiated 
cells and several cancers, resulting in enhanced invasion, colony formation and 
tumourigenic potential in vivo, highlights the importance of these genes (Oldridge et al., 
2013, Liu et al., 2012, Bolger et al., 2012, Wu et al., 2006). The nearly ubiquitous silencing 
of RARRES1 in CaP, indicates that reactivation of RARRES1 and/or LXN or their 
downstream signalling targets represents a logical strategy to reduce tumour 
aggressiveness and dissemination, as well as induction of differentiation, thereby 
augmenting current treatment regimens (Jing et al., 2002, Oldridge et al., 2013). 
 
4.6. Localisation of LXN in the Prostate Epithelium 
Our laboratory has previously shown using confocal microscopy that LXN is localised to 
the nucleus in primary prostate epithelial cells and the prostate cell line LNCaP (Oldridge 
et al., 2013). Initial evidence for this came from immunofluorescence performed on 
fractionated primary epithelial cultures. In order to verify that this wasn’t a result of non-
specific binding of the anti-LXN antibody, LNCaP cells were transfected with a plasmid 
containing LXN fused to the HA epitope tag. This allowed the use of a second, well 
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characterised, antibody (anti-HA) to confirm the localisation of LXN. LNCaP cells were 
utilised for this purpose as they have very low expression of endogenous LXN. Using 
confocal microscopy it was shown that DAPI (nuclear stain), anti-LXN and anti-HA co-
localised. The potential for controversy in this result is that LXN has no known nuclear 
localisation signal and as of 2016, this result remains the only study to show any 
localisation data for LXN. This nuclear localisation also opens the possibility for LXN to in-
part exert its effects on colony formation, migration and invasion by directly affecting 
gene expression at the level of transcription.  
 
4.7. Overview of Experimental Techniques Used in this Chapter 
4.7.1. Chromatin Immunoprecipitation  
Chromatin Immunoprecipitation (ChIP) is the ‘gold standard’ for precise localisation of 
the protein-DNA interactions which can control epigenetic regulation through histone 
modifications, and for confirmation of transcriptional regulation. Briefly, protein-DNA 
interactions are cross-linked in situ using formaldehyde. The cells are lysed and the 
chromatin is sheared by sonication to produce 200-500 bp fragments (Teytelman et al., 
2013). The fragmented chromatin is then incubated with an antibody-bead complex 
specific for a particular protein bound to the DNA. The DNA-bound protein is known as a 
protein ‘mark’. After the IP, the DNA is eluted from the antibody-bead complex and the 
cross-links are reversed. The resulting DNA (now free of protein interactions) is finally 
purified before analysis by qPCR using target specific primers. 
The resulting data is often expressed as a percentage of the input chromatin (chromatin 
that has not been immunoprecipitated) e.g. a value of 10% of input indicates that 10% of 
the target loci exist in association with the protein mark to which the precipitating 
antibody was raised.  
Recent advances in ChIP methodology have centred on reducing the amount of chromatin 
needed for successful immunoprecipitation (Schnerch et al., 2013, Collas, 2011). The 
result of this downscaling is micro- (μChIP) assays capable of measuring protein-DNA 
interactions from <1,000 cells which is equivalent to ~6 ng of DNA (Fig. 34.). In contrast, 
traditional ChIP protocols require 106-107 cells (6-60 μg of DNA) and are unsuitable for 
use in rare cell populations.  
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A functioning µChIP method was essential to study protein-DNA interactions in rare 
subpopulations of CaP cells, such as CSCs which account for <0.1% of tumour cells, and 
cannot be represented by established cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 34. Overview of μChIP Assay. 
The main differences between this µChIP protocol and traditional large-scale ChIP, 
are the lower volumes used and magnetic capture beads (instead of sepharose 
capture beads) used in µChIP. 
From: (Collas et al., 2011) 
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The chromatin status of the LXN and RARRES1 genes in primary epithelial cultures from 
benign and cancerous origin were investigated using ChIP. Capture molecules are 
antibodies that are specific for different histone modifications and markers of 
transcription. Downstream analysis, by PCR, assesses the enrichment of the target gene 
by each capture molecule. A list of targets for ChIP and control genes is provided in (Table.  
5. and Table. 6.) respectively.  
 
 
 
 
 
 
 
 
 
 
 
Table. 5. Primary and Alternative Targets for ChIP Capture Molecules. 
Tabulated list of histone marks and associated proteins with information regarding 
the implication of theses marks to chromatin status. The table also contains the 
validation status of each mark capture molecule (antibody) within our laboratory. 
Table. 6. ChIP Control Genes. 
The identity, expression details and expected ChIP analysis in prostate epithelium of 
the positive control gene (GAPDH) and negative control gene (PDYN). Of note is that 
both control genes have been validated in our laboratory.   
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4.7.2. Lentiviral Vectors as Gene Delivery Systems 
In order to determine the effect of LXN and RARRES1 on gene expression when 
overexpressed in a physiologically relevant model of primary prostate cancer (Collins et 
al., 2005).  A lentiviral gene delivery system was established. 
Lentivirus (LV) vectors, stably integrate into the genome of a transduced cell, forcing 
continued expression of the delivered gene. A major advantage of LV over γ-retroviral 
vectors is that they can transduce quiescent and senescent cells. The lentiviral vectors 
used in this project are based on human immunodeficiency virus (HIV), which has been 
modified to render the virus incapable of replication within the host. The modification in 
question (termed the self-inactivating (SIN) configuration) specifically targets the long 
terminal repeat (LTR) sequence through deletion of the U3 region of the 3’ LTR, which is 
transferred to the 5’ LTR during reverse transcription (Sanber et al., 2015). This deletion 
destroys the transcriptional activity of the LTR sequences, in turn abolishing the 
production of full-length vector RNA (Sanber et al., 2015). The use of the SIN configuration 
and heterologous envelopes has dramatically improved the overall safety of LV to the 
point that the later generation of LV vectors have the lowest hazard rating at the 
University of York.  
Another safety feature of LV production is pseudotyping: the process of producing viral 
vectors in combination with foreign viral envelope proteins i.e. not encoded by the 
original virus (Mátrai et al., 2010). Pseudotyping of HIV vectors removes the safety 
concerns associated with native HIV envelope (gp120). The heterologous vesicular 
stomatitis Indiana virus protein G (VSV-G) envelope protein is the most  commonly  used  
viral  envelope  for LV pseudotyping (due to its broad spectrum of susceptible cells) 
although, choice of envelope used to pseudotype the LV is at least partly determined by 
the target cell or tissue that needs to be transduced. 
The most widely employed method for the production of LV is by co-transfection of cell 
lines (packaging cells) with vector plasmid and the gag-pol, rev, and env packaging 
constructs resulting in LV production by the packaging cells, which are present in the 
supernatant (Fig. 35.) (Mátrai et al., 2010). The resulting supernatant is then filtered to 
remove any packaging cells that have sloughed off into the viral supernatant. 
The normal human embryonic kidney cell line HEK-293 is commonly used for this purpose, 
and as such several modified HEK-293 lines have been produced to enhance LV 
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production. These include but are not limited to 293T cells and 293FT cells (Mátrai et al., 
2010). These HEK-293 derivatives commonly contain the SV40 Large T-antigen, which 
mediates episomal replication of transfected plasmids containing the SV40 origin of 
replication (Durocher et al., 2002). Once the titre is known the multiplicity of infection 
(MOI) which  indicates  the  number  of  vector  particles  per  cell  used  in  a  transduction 
can be calculated and standardised across experiments e.g. a MOI of 1 means the addition 
105 viral particles to 105 cells (Zhang et al., 2004). 
 
 
Fig. 35. Lentiviral Vector Production by Trans-Complementation.  
Packaging cells are transfected with a combination of lentiviral vector plasmid 
and packaging plasmids which contain  Gag, Pol, Rev, and VSV-G sequences. Only 
the vector contains the packaging sequence Ψ. The lentiviral sequence is flanked 
by  5′ and 3′ LTR sequences. The LTR sequences through their enhancer/promoter 
function are necessary for proper expression of the full-length vector transcript. 
Additionally, the LTR sequences also involved in reverse transcription and 
integration of the vector into the genome.  
Viral particles are harvested from the medium the packaging cells are grown and 
used directly or further concentrated by purification methods. By changing the 
envelope genes encoded by the helper plasmids it is possible to pseudotype the 
lentivirus which directly effects the tropism of the resulting lentivirus.  
Abbreviations: SIN = self-inactivating  LTR sequences that contain Δ = LTR 
sequences that contain a partial deletion, WPRE = Woodchuck hepatitis virus 
post-transcriptional regulatory element, cPPT = central polypurine tract,  RRE = 
Rev responsive element and LV =  lentiviral vector. 
From: (Mátrai et al., 2010) 
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4.7.3. Gateway™ Cloning  
Invitrogen™ Gateway™ recombination cloning differs from traditional cloning techniques 
through the use of a reversible recombination reaction, as opposed to restriction 
enzymes and ligase reactions. This techniques offer several advantages: 
 Certain restriction enzymes cannot be used in conventional cloning because they 
might cut within the gene of interest, truncating the insert and making the gene 
useless for downstream expression. 
 Due to the removal of a death gene (ccb) from the vector upon recombination to 
insert the gene of interest, the amount of colony screening is reduced. 
The basic protocol for cloning a gene of interest into a LV plasmid vector is as follows. 
Addition of flanking attB recombination sites to the gene of interest using primers that 
are specific for the gene of interest, but with overhangs which contain the attB sites. This 
typically involves two PCR steps as the attB sequences are quite long, using a high fidelity 
polymerase such as phusion. The first PCR reaction adds the first half of the attB sequence 
to the gene of interest. The PCR product is then separated on an agarose gel and from 
which extraction of the product is then performed.  
The purified product from the gel extraction is then used as a substrate for a second PCR 
reaction which adds the 2nd half of the attB recombination site, before a second gel 
extraction is performed to yield the purified product which is the gene of interest flanked 
by the full attB sequence. This fully flanked sequence can now be added to an Entry vector 
through recombination using the Invitrogen BP clonase which, through recombination 
between the attB sites on the gene of interest and the attL sites which flank ccb, 
eliminates the ccb death gene from the Entry vector and replaces it with the gene of 
interest.  
The Entry vector is a shuttle vector which can be used in subsequent steps to deliver the 
gene of interest into several commercially available LV vectors which have specific 
properties depending on experimental needs such as co-expression of eGFP to allow 
transduction efficiency to be visualised. Once the Entry vector has been quality controlled 
through PCR and/or restriction digestion to ensure the presence of the gene of interest it 
is typically sequenced to guarantee that no mutations have been introduced through the 
PCR and gel extraction steps.   
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Once the Entry vector containing the gene of interest has been validated it is used as to 
generate the LV destination vector containing the gene of interest. The gene of interest 
is now flanked by the attL sequences and through the use of LR clonase which performs 
recombination between attL sequences and attR sequences the gene of interest can be 
transferred to the LV destination at the expense of another copy of ccb present in the LV 
destination vector flanked by attR sequences. Colonies are then picked and screened for 
presence of the gene of interest. An overview of the main steps of vector generation and 
virus production used in this report are shown in (Fig. 36.). 
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Fig. 36. Overview of Vector Production, Virus Production and Transduction Used in 
this Report. 
The gene of interest is first flanked with attB recombination sequences, 
recombination with the BP clonase results in an Entry vector containing the gene of 
interest. A second recombination reaction with the LR clonase results in a 
destination vector that contains the gene of interest. Co-transfection of HEK 293FT 
packaging cells with the destination vector, envelope and packaging plasmids allows 
lentivirus production through trans-complementation. Supernatant (containing the 
lentiviral particles) is then harvested which can be directly used to transduce cells 
including primary prostate epithelial cells.  
  140                                          Chapter 4. Results 
4.7.4. Microarray 
DNA microarray technology is now a wide-spread method for analysing expression 
profiles of biological samples. The technology is based on DNA hybridisation of cDNA 
molecules to complementary probes which are attached in ‘spots’ on the surface of the 
microarray chip at known locations. Commonly a single gene is covered by several probes 
to increase accuracy of detection above background. The hybridisation reaction between 
the sample cDNA library and the microarray is performed under high-stringency 
conditions so that only highly specific interactions between cDNA molecules and their 
corresponding probes can occur (Wildsmith and Elcock, 2001). Microarrays use relative 
quantitation in which the intensity of a probe is compared to the intensity of the same 
probe under a different condition, and the identity of the probe is known by its position. 
A typical protocol for expression profiling is as follows:  
1. RNA is extracted from the biological sample and is quality controlled for quality 
and quantity. This is typically performed using an Agilent Bioanalyzer (utilises 
capillary electrophoresis) which as well as giving a yield also provides an RNA 
integrity (RIN) number which ranges from 1 (highly degraded) to 10 (not 
degraded). 
2. The labelled cDNA library is generated via reverse transcription (an optional PCR 
amplification can be performed at this step if yield is too low). RNA is reverse 
transcribed with either polyT primers (which amplify only mRNA) or random 
primers (which amplify all RNA, most of which is ribosomal ribonucleic acid 
(rRNA)). The label (typically fluorescent) is added either during the reverse 
transcription step, or following amplification if it is performed.  
3. The labelled samples are then mixed with a propriety hybridization solution 
which includes blocking agents to limit non-specific binding thereby reducing 
background and enhancing signal to noise. 
4. The mixture is denatured and added to the pinholes of the microarray. The holes 
are sealed and the microarray hybridised. 
5. After hybridisation washing steps are performed to remove nonspecific binding 
events. 
6. The microarray is dried and scanned by using a laser to excite the fluorophore 
and emission levels which are proportional to the level of hybridisation and hence 
relative abundance of the cDNA species is measured by a detector. 
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7. As the location of each probe ‘spot’ is known the emission intensity can be 
mapped to specific genes.  
8. The raw data is normalised through subtraction of background intensity. 
9. Data is then analysed using bioinformatics software. The TAC console V3.0 was 
used in this report. 
 
4.7.5. Mass Spectrometry 
In addition to genomic approaches, the aim was also to characterise the function of LXN 
and RARRES1, using a proteomics based approach to investigate potential interacting 
partners. To this end affinity purification coupled to downstream mass spectrometry (MS) 
was used. 
MS is regarded as the analytical technique of choice for identifying proteins within 
complex biological samples, particularly when coupled to high pressure liquid 
chromatography (HPLC) (Dunham et al., 2012). MS measures the mass to charge ratio of 
ionised molecules by measuring their time of flight with the mass spectrometer. This 
allows the determination of their molecular mass after charge state resolution. In order 
to apply this technique to proteins it is first necessary to digest the proteins within a 
sample to yield peptides fragments which are more amenable to MS than intact proteins. 
Fragmentation of the intact (or parental peptide) results in ‘diagnostic fragments’ which 
can be used with the assistance of complex software tools and databases to elucidate the 
amino acid sequence of the parent peptide (Dunham et al., 2012, ten Have et al., 2011). 
The identified peptides are then used through the use of sophisticated software to assign 
a likely protein to the peptides. 
Affinity purification up-stream of MS is commonly employed to reduce the complexity of 
biological samples, particularly when one is trying to identify binding partners. Typically, 
affinity purification is performed using antibodies specific to the protein of interest 
(commonly called the bait). The bait is immunoprecipitated in a buffer that maintains the 
baits interaction with interacting proteins. Unfortunately it is often difficult to obtain an 
antibody with the required affinity and specificity for the bait. If one can’t be found, it is 
common for a tagged version of the protein to be constructed and introduced into the 
cell through transfection. This allows the use of highly validated anti-tag antibodies to 
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perform the IP. Typical epitope tags include but are not limited to: HA, GST, FLAG, HIS, c-
Myc, and V5 (Dunham et al., 2012). 
Once a suitable IP-grade antibody has been identified and validated, it is immobilised onto 
a matrix, usually a resin or micro-beads. Coupling is often performed through binding of 
the antibody to protein A or protein G which is pre-coupled to the matrix (Dunham et al., 
2012, ten Have et al., 2011). Alternatively the antibody can be covalently linked to the 
matrix. The resulting antibody-linked matrix is exposed to the biological sample and 
incubated to allow capture of the bait in complex with its interactome. After several wash 
steps, the bait and its interacting partners are eluted from the matrix. An efficient but 
non-specific elution solution is Laemmli buffer with the addition of 2-Mercaptoethanol 
(Dunham et al., 2012).  
Reduction of non-specific interactions is essential for enhancement of the signal to noise 
ratio and to allow the identification of low abundance interactions. Typically this is 
achieved through a pre-clear step in which ‘naked’ matrix (i.e. matrix without antibody) 
is incubated with the sample prior to affinity purification (Dunham et al., 2012). 
Alternatively or concomitantly stringent washing steps are included (ten Have et al., 
2011). Stringent washing has a downside which is the increased potential for false 
negative results, whereby true weaker interactions are lost. Quantitative proteomics is 
used to identify true interactors as opposed to non-specific interactions post MS by 
comparison to a control sample. This post MS screening is made more efficient and robust 
through the use of proper controls which are as closely linked as possible to the biological 
samples they are associated with. The control should be harvested, affinity purified and 
analysed in parallel to the experimental sample. 
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4.8. Results 
4.8.1. ChIP Primer Validation 
qPCR was used to interrogate precipitated chromatin for the enrichment of target gene 
sequences by each mark (listed in Table. 6.). The primers pairs in (Appendix 2.) were used 
to determine the chromatin status of LXN and RARRES1 genes and promoter regions. The 
location of the genomic sequences covered by these primers is depicted in (Fig. 37.) As 
such the following parameters of the qPCR assays must be validated: efficiency, R2 and 
presence of non-specific amplifications (multiple products). In order to expand the future 
applications of the assays two further parameters were investigated. Firstly, the cycle in 
which fluorescence rises above the threshold for detection, termed quantitation cycle 
(Cq) at 30 pg of genomic DNA (equivalent to 10 copies of template). This parameter was 
used to estimate the sensitivity of the primer pairs, with a view to measuring low 
chromatin yields obtained from low cell numbers i.e. μChIP. The second additional 
parameter is the species specificity of the primer pairs, which is important when 
downstream applications of the assays are considered e.g. analysis of samples derived 
from xenograft models. Xenograft samples contain a variable proportion of 
contaminating host (mouse) DNA, due to vascularisation and infiltration of engrafted 
tumours. Additionally, primary cultures of prostate epithelium are grown using a feeder 
layer of STO cells which are of mouse origin. If the primer pairs do not have a suitable 
human:mouse specificity ratio, the resulting data would be prone to artefacts and valid 
conclusions could not be able to be drawn. 
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Fig. 37. Genomic Location of the Chromosome Region Covered by RARRES1 and 
LXN ChIP Primers. 
The online annotated ensemble genome browser tool was used to construct a 
detailed diagram of the genomic regions around the transcription start site of 
RARRES1 A. and LXN B. The diagram shows the genes encoded in this region along 
with transcription factor binding sites, putative promoter regions and areas of open 
chromatin. The approximate region covered by the RARRES1 and LXN ChIP primers 
for each gene is depicted by the rainbow coloured box. 
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Table. 7. details the validation of all ChIP primer pairs analysed. The primers have been 
divided into two groups based on annealing temperature. The division allows streamlining 
of assays as multiple assays can be performed on a single plate and a single run.  
All primer pairs have an efficiency (defined as the increase in amplicon per cycle) value 
which falls within well-established guide lines (90-110%). The R2 value of all primers also 
meets the requirement of being greater than 0.98. qPCR reactions using all primers 
resulted in the amplification of a single product, as assessed using melt curve analysis. All 
assays are of high sensitivity, as the Cq values at 30 pg of genomic DNA are sufficiently 
low (<38), thus enabling quantitative analysis of small quantities of DNA. The 
human:mouse specificity ratio (determined by measuring the Cq observed in a reaction 
with 10 ng of human DNA template to the Cq observed in a reaction with 10 ng of mouse 
DNA) of all primer pairs is sufficiently large to avoid artefacts due to non-specific 
amplification of contaminating mouse DNA (Table. 7.).  
 
 
 
Table. 7. Performance and Parameters of ChIP Primer Pairs. 
Tabulated list of assay parameters and details of the performance of each assay.  
Primer pairs have been divided into two groups based on annealing temperature. An 
extra row has been included to detail the characteristics of an ideal primer pair. 
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4.8.2. ChIP Validation 
Before investigating the chromatin status of primary prostate epithelium, the ChIP assay, 
capture antibodies and reference genes were validated using chromatin derived from cell 
lines. Cell lines have several advantages as a validation tool. Their ease of culture and lack 
of feeder cells means that large quantities of target cell-derived chromatin can be 
prepared and repeat assayed. To cover the broad-spectrum of prostate epithelial cells, 
PNT2C2 (basal phenotype from normal origin) and LNCaP (luminal phenotype from cancer 
origin) were used to investigate reference gene and technique compatibility. 
The data shown in (Fig. 38.) shows the expected pattern (Table. 6.) i.e. the active gene 
(GAPDH) being enriched by the euchromatin (H3K4me3) and transcription (RNA Pol II) 
marks but not the heterochromatin (H3K27me3) mark (Fig. 38A. and Fig. 38C. for PNT2C2 
and LNCaP respectively). The silenced gene (PDYN) shows the converse pattern being 
enriched by H3K27me3 antibody but not anti- H3K4me3 or RNA Pol II (Fig. 38B. and Fig. 
38D.) for PNT2C2 and LNCaP respectively).  
Both cell lines showed the same pattern although the enrichment by all marks was higher 
in PNT2C2 cells when compared to LNCaP cells. It can be concluded that these antibodies 
and reference genes are compatible with cells representing the diversity of the human 
prostate epithelium. 
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Fig. 38. Validation of H3K27me3, H3K4me3 and RNA Pol II Antibodies and +ve 
(GAPDH) and –ve (PDYN) Control Genes. 
Graphical representation of enrichment of GAPDH and PDYN sequences by anti- 
H3K27me3 (K27me3), H3K4me3 (K4me3) and RNA Pol II antibodies in PNT2C2        
A. and B. and LNCaP cells C. and D. Error bars = 1 standard error of the mean.   
E. Agarose gel following gel electrophoresis loaded as described in the lane 
legend depicted in F. (minutes refer to length of sonication). 
G. Background binding levels of IgG control antibody. 
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates. 
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4.8.3. Chromatin Status of RARRES1 and LXN Promoter Sequences in PNT2C2 and 
LNCaP Cells 
In PNT2C2 cells RARRES1 showed a substantial enrichment by anti- H3K4me3 especially 
near the transcription start site, compared to the enrichment by anti- H3K27me3 (Fig. 
39A and 39C.). This indicates that the chromatin in this region exists as transcriptionally 
active euchromatin, in agreement With qPCR data which shows that PNT2C2 cells express 
a significant amount of RARRES1 mRNA. LNCaP cells showed a similar pattern to PNT2C2 
cells at the RARRES1 promoter with these sequences showing a net-enrichment for the 
euchromatin mark, although with much lower values than PNT2C2 cells. The positive 
transcription mark (RNA pol II) was absent from the RARRES1 promoter sequence in 
LNCaP cells, in agreement With qPCR data from our lab which shows that RARRES1 mRNA 
is undetectable in LNCaP cells. Taken together these data suggest that histone 
modifications play a role in modulating RARRES1 expression in PNT2C2 to a much greater 
extent than in LNCaP cells. 
The LXN promoter, in both cell lines, is not enriched for either histone mark, indicating 
that the chromatin in this region exists in an ambiguous intermediate state (Fig. 39B and 
39D.). The transcription mark (RNA pol II) was positive at this region in both cell lines. In 
PNT2C2 cells, RNA pol ll is equally abundant at the RARRES1 and LXN promoters even 
though RARRES1 is expressed to a greater extent in these cells. The presence of a single 
marker of transcription (in this case RNA pol II) does not necessarily reflect the level of 
transcription as multiple cis and trans-regulatory elements contribute.  Also the 
difference in mRNA levels between the two genes may be a result of differential mRNA 
stability. In LNCaP cells, enrichment of the LXN promoter sequence shows evidence of 
weak transcriptional activity compared to absence of the transcription mark at the 
RARRES1 promoter. This is again in agreement With qPCR quantification of mRNA 
expression, which shows that LXN is very weakly expressed in LNCaP cells compared with 
undetectable levels of RARRES1 mRNA.  
It has previously been shown that these genes are regulated by DNA methylation at CpG 
islands in prostate cell lines. As such, histone modifications were not expected to play a 
dominant role in the regulation of these genes in cell lines. It was encouraging that the 
ChIP data presented here correlated with mRNA expression profiles and that there is 
evidence of a role for histone modifications in the regulation of RARRES1, particularly in 
PNT2C2 cells. 
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Fig. 39. ChIP of LXN and RARRES1 Promoters in PNT2C2 and LNCaP Cells. 
A.-H. Graphical representation of enrichment of RARRES1 A., C., E. and G.) and LXN 
(B, D, F and H) sequences by anti- H3K27me3 (A and B), H3K4me3 (C and D), RNA Pol 
II (E., and F.), IgG (G and H) antibodies in PNT2C2 (red bars) and LNCaP (blue bars) 
cells. Error bars = 1 standard error of the mean.  
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates.  
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4.8.4. ChIP Scale Down 
It became evident that the novelty and value of future experiments could be increased 
by expanding the application of ChIP to the analysis of very rare tumour sub-populations, 
such as CSCs which comprise <0.1% of tumour cells. For this aim to be achieved, a µChIP 
method, capable of interrogating low amounts of chromatin (~2 ng/IP, compared to 20 
μg/IP in the standard ChIP) was established. To this end the µChIP method developed and 
published by (Collas, 2011) was adopted. The scale-down was performed using previously 
validated chromatin that was diluted in a stepwise manner from 20 µg to 2 ng with an 
intermediate step of 200 ng. 
The Collas protocol advocated the use of magnetic capture particles as opposed to 
sepharose capture particles used thus far (Collas, 2011). Magnetic capture particles 
yielded a lower level of nonspecific binding to chromatin compared with sepharose (Fig. 
40A.). It is important to note that 200 ng of chromatin had a greater background signal 
compared with 20 µg. This can be explained by the background binding following a non-
linear binding curve, and the reduction in the input due to dilution following linear 
kinetics i.e. all nonspecific binding sites were saturated at 200 ng of chromatin/IP. For 
example if the 200 ng had an arbitrary background binding level of 1 and input was 10 
then background would be one tenth of input. If the 20 µg sample also had an arbitrary 
background binding of 1 due to saturation of non-specific binding sites already being 
achieved at 200 ng and an input value of 1000 (due to 100-fold more chromatin) then 
background would be one thousandth of input.   
The two histone marks (H3K27me3 and H3K4me3) exhibited a dramatic increase in signal 
when the starting chromatin was reduced (Fig. 40C. and 40D.). The signal for RNA pol II 
did not dramatically increase when chromatin levels were reduced, indicating that the 
capture antibody was not being saturated at 20 µg conditions (Fig. 40B.). However, an 
increase in signal was observed when changing from sepharose to magnetic capture 
particles. 
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Fig. 40. ChIP Scale-Down Using Previously Validated  LNCaP Chromatin. 
A. Non-specific enrichment of GAPDH and PDYN sequences using either sepharose or 
magnetic capture-particles (labelled with anti-IgG)  
B.-D. Enrichment of GAPDH and PDYN sequences using either sepharose or magnetic 
capture-particles (labelled with anti- RNA Pol II B., H3K27me3 C. or, H3K4me3 D. 
antibodies in LNCaP cells.  
In all graphs: BLUE bars equal GAPDH and RED equal PDYN.  Shading is intended to 
represent initial chromatin levels with darker shades representing larger amounts of 
starting chromatin/IP. 
Error bars = 1 standard error of the mean  
Each sample represents 3 experimental replicates each comprising 4 technical 
replicates 
 *  = P ≤ 0.05    **  = P ≤ 0.01  
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4.8.5. Establishing a qPCR Protocol for the Estimation of Chromatin Fragmentation After 
Sonication of Small Quantities of DNA with a View to Micro-ChIP 
In order for any ChIP to be successful, the optimal sonication time must be determined 
empirically for each sample. This is because over-sonication reduces sensitivity and 
under-sonication increases false positives; the optimum size of chromatin fragments is 
200-500 bp.  
In µChIP the amount of DNA is too low to yield a visible band on a gel. However, the size 
of the DNA fragments can be estimated using the ratio of a 100 bp to a 300 bp qPCR 
product and thus optimal sonication time can be determined (Dahl and Collas, 2008).  
22Rv1 chromatin was sonicated and the resulting fragment size as a function of sonication 
cycles was assessed using both gel-based and qPCR-based methods (Fig. 41.). From these 
assays it can be seen that the chromatin fragments reduce in size as the number of 
sonication cycles increases. The qPCR ratio of the 100 bp to a 300 bp products increases 
as a function of sonication cycles, indicating that the mean chromatin fragment size is 
reducing with the number of cycles. The 300 bp template is broken at a greater rate than 
the 100 bp template, due to its size. The optimum sonication was 60 cycles. After this 
point there was an accumulation of chromatin fragments shorter than 200 bp (loss of 
sensitivity) and a consequent reduction in the 100 bp : 300 bp ratio (as for the first time 
in the time-course the 100 bp template is being broken).  
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Fig. 41. Sonication Titration of 22RV1 Chromatin.  
22Rv1 cells were cross-linked with formaldehyde prior to cell lysis. The resulting 
cross-linked chromatin was sonicated on ice. A chromatin sample was taken every 10 
cycles. The chromatin was extracted and the degree of fragmentation was assessed 
by qPCR using two primer pairs, one generating 100bp product and the other a 
300bp product. This was used to calculate the 100bp:300bp ratio at each sample 
point A.. In parallel 400ng of extracted chromatin was loaded on to a 2% agarose gel 
allowing the fragment size to be assessed by DNA staining following electrophoresis 
B.. 
The desired fragment size of between 200 and 500bp and optimal sonication time is 
indicated by the green arrow. 
Error bars = 1 standard error of the mean. 
Data presented is a single representative experiment each data point was measured 
in quadruplicate.   
 
 
A 
B 
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4.8.6. μChIP of Fractionated Primary CaP Samples Interrogated for Relative Enrichment 
of RARRES1 and LXN Promoter Sequences Using anti- H3K27me3, H3K4me3 and RNApol 
II Antibodies. 
In order to assess the contribution of histone modifications (and therefore chromatin 
status) to the epigenetic regulation of LXN and RARRES1, three primary epithelial cultures 
of malignant origin were fractionated in to CB, TA and SC populations (total nine cellular 
samples from three patients) and µChIP performed. The subfractionation of primary 
samples was chosen for this experiment as LXN and RARRES1 were previously shown to 
be upregulated upon differentiation from SC to TA and CB cells (Oldridge et al., 2013).  
All samples analysed had enrichment (above the immunoglobulin G (IgG) control) of 
RARRES1 and LXN promoter sequences when immuno-precipitated with the anti-
H3K27me3 antibody (Fig. 42A. and B. respectively). This was significantly elevated (5.66% 
(RARRES1) and 8.89% (LXN) average for all samples across all primer pairs analysed) over 
the negative control gene for this mark (GAPDH) (2.16% average for all samples) but to a 
much lesser extent than the positive control gene for this mark (PDYN) (26.52% average 
for all samples). Control gene enrichment by anti-H3K27me3 is shown in (Fig. 42C.). 
Similarly, all samples analysed had enrichment of RARRES1 and LXN promoter sequences 
when immuno-precipitated with the anti-H3K4me3 antibody (Fig. 42D. and E. 
respectively). Again the enrichment of these sequences was intermediate between that 
of the positive control GAPDH and the negative control PDYN (2.35% RARRES1, 2.71% 
LXN, 11.71% GAPDH and 0.81% for PDYN. Control gene enrichment by anti-H3K4me3 is 
shown in (Fig. 44F.) The enrichment of RARRES1 promoter sequences by anti-RNApol II 
(0.63% (average across all primer pairs and samples Fig. 42G.) was not significantly 
different from that of the negative control gene PDYN (0.52%) (Fig. 42I.). Conversely, the 
enrichment of LXN promoter sequences by anti-RNApol II (2.19% (average across all 
primer pairs and samples; Fig. 42H.) was significantly different from that of the negative 
control gene PDYN, but was not enriched to the same level as that of the positive control 
gene GAPDH (4.07%) (Fig. 42I.) 
For ease of analysis and interpretation, a single representative patient sample (H530) is 
shown in (Fig. 42M-R.). The pattern of results is the same as the entire cohort: enrichment 
of RARRES and LXN promoter sequences to an intermediate level between positive and 
negative controls by anti H3K27me3 (Fig. 42M. RARRES1 and N. for LXN) and anti-
H3K4me3 (Fig. 42O. RARRES1 and P. for LXN). Finally, the differential enrichment of 
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RARRES1 and LXN promoter sequences by anti RNApol II is shown in (Fig. 42Q. and R.), 
respectively. Here, RARRES1 was not enriched over the negative control PDYN and LXN 
was greatly enriched relative to PDYN, but to a lesser extent than that of the positive 
control gene GAPDH after subtraction of IgG-background binding.  
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Fig. 42. μChIP of Fractionated Primary CaP Basal Cells. 
Three primary CaP samples were grown to confluence in a 10cm dish in the presence 
of STO feeder cells. STO cells were removed with a 1 min trypsin-EDTA incubation at 
37⁰C. Epithelial cells were then harvested and allowed to adhere to a collagen I 
coated 10cm dish for 20 mins. Non adherent cells are the CB fraction. Adherent cells 
were trypsinised once more before MACS selection using anti-CD133 for SC 
enrichment. Cells that were not selected as CD133+ but rapidly adhered to collagen I 
are the TA fraction.  After selection the cells were cross-linked with formaldehyde 
prior to cell lysis. The resulting cross-linked chromatin was sonicated on ice and the 
chromatin fragments were quality checked using qPCR before being immuno-
precipitated with either anti- H3K27me3, H3K4me3, RNApol II or anti IgG (isotype 
control). After immunoprecipitation the captured DNA was eluted from the beads, 
extracted using phenol-chloroform and interrogated (in triplicate) using the LXN and 
RARRES1 ChIP primers as well as control GAPDH and PDYN primers. 
A. Enrichment of RARESS1 promoter sequences by anti H3K27me3 antibody. 
B. Enrichment of LXN promoter sequences by anti H3K27me3 antibody. 
C. Enrichment of GAPDH and PDYN promoter sequences by anti H3K27me3 antibody. 
D. Enrichment of RARESS1 promoter sequences by anti H3K4me3 antibody. 
E. Enrichment of LXN promoter sequences by anti H3K4me3 antibody. 
F. Enrichment of GAPDH and PDYN promoter sequences by anti H3K4me3 antibody. 
G. Enrichment of RARESS1 promoter sequences by anti RNA pol II antibody. 
H. Enrichment of LXN promoter sequences by anti RNA pol II antibody. 
I. Enrichment of GAPDH and PDYN promoter sequences by anti RNA pol II antibody. 
J. Background binding at RARRES1 promoter sequences 
K. Background binding at LXN promoter sequences 
L. Background binding at GAPDH and PDYN promoter sequences 
M. Enrichment of RARESS1 promoter sequences by anti H3K27me3 antibody. Sample 
H530 
N. Enrichment of LXN promoter sequences by anti H3K27me3 antibody.  Sample 
H530 
O. Enrichment of RARESS1 promoter sequences by anti H3K4me3 antibody.  Sample 
H530 
P. Enrichment of LXN promoter sequences by anti H3K4me3 antibody Sample H530 
Q. Enrichment of RARESS1 promoter sequences by anti RNA pol II antibody Sample 
H530 
R. Enrichment of LXN promoter sequences by anti RNA pol II antibody Sample H530 
 
Error bars = 1 standard error of the mean. 
The data presented is a 3 technical replicates of a single experiment. 
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4.8.7. Transient Transfection of Primary Prostate Epithelial Cells with Plasmid Vectors 
is Inefficient and Precludes Their Use 
Transfection of primary samples with plasmid vectors proved inefficient (Fig. 43.) which 
has precluded analysis of the function of LXN and RARRES1 sequences in primary samples. 
Also due to the relatively quiescent phenotype of stem cells (SCs) and cancer stem cells 
(CSCs) plasmid vectors are not ideal for transfection of these cells, as they only transfect 
dividing cells. Furthermore transient transfection is not the ideal system for looking at 
long term effects such as a reduction in colony-forming efficiency as these assays (~2 
weeks in duration) last longer than the transfection. 
To overcome the deficits mentioned above LV vectors were considered the logical choice 
as they have previously been shown to infect prostate CSCs (Frame et al., 2010). 
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Fig. 43. Transfection of Primary Prostate Epithelial Cells.   
Epithelial cultures derived from normal and malignant regions of two primary 
prostate biopsies were transfected with an eGFP plasmid using ViaFect transfection 
reagent at a ratio of 4 μl per μg of DNA. The optimal dose of ViaFect had been 
previously determined (data not shown). eGFP expression was determined using 
fluorescence microscopy 48 h post-transfection at this time all cultures were fully 
confluent. Representative images of forward transfection for the two samples (cells 
seeded overnight prior to transfection) are shown in A. and B. Representative images 
of reverse transfection for the two samples (seeding and transfection occur 
simultaneously) are shown in C. and D.. 
Images were captured using a 10x objective lens.  Scale bars = 62μm 
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4.8.8. Lentiviral Cloning and Virus Production 
A detailed example of the cloning strategy for the creation of all viral vectors is described 
in (Fig. 44.). Several lentiviral destination plasmids have been acquired by our group each 
with specific properties enabling different experiments to be performed:- 
 pDest-236 (PuroR co-expression vector) – for the generation of stable cell line 
through puromycin selection. To this end stable cell lines derived from LNCaP, 
P4E6, PNT1A, DU145, BPH1 and PC3 parental lines for LXNwt, LXNcpa (corruption 
of CPA binding site), RARRES1wt, RARRES1cpa (corruption of CPA binding site) 
and RARRES1-TmDel (deletion of transmembrane domain) (total of 30 stable 
lines) were derived and validated (data not shown). 
 pDeST-298 (eGFP co-expression vector) – for visualisation of transduction 
efficiency and potential Fluorescence-activated cell sorting of transduced primary 
cells. 
 pDest-159 (mVenus (modified yellow fluorescent protein fusion generator) – for 
localisation experiments. 
 FU-tetO-Gateway (Doxycycline inducible) could be used to investigate dose 
dependent and temporal effects of target proteins. 
 
Alongside generation of lentiviral plasmid vectors, lentivirus particle generation and titre 
analysis was investigated using a control eGFP only lentiviral plasmid called p35. The 
investigation of plasmid generation also utilised cell line (LNCaP) and primary prostate 
epithelial cells to examine the variation of transduction efficiency in different cell types 
in our system, with a view to perform titrating experiments on LNCaP cells and then apply 
a correction factor to allow an accurate MOI in primary cells. The results of this analysis 
show that LNCaP cells (Fig. 45.) are more readily transduced than primary prostate 
epithelial cells (Fig. 46.) from the same p35 lentivirus batch (1.45x108 IU/ml in LNCaP cells 
vs 2.02x107 IU/ml in primary prostate epithelial cells). Also the importance of performing 
a titration to determine lentivirus titre was also confirmed i.e. a 1:1 ratio of viral 
supernatant and culture media yielded a titre of 4.9x105 IU/ml whilst a 1:10000 ratio of 
viral supernatant and culture media yielded a titre of 1.45x108 IU/ml in LNCaP cells. This 
discrepancy is due to multiple viral vectors entering a single cell in the less-dilute viral 
supernatant. When the viral supernatant is more diluted a single viral vector enters a 
single cell and an accurate titre can be determined.  
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Fig. 44. Detailed Example of Cloning Strategy used to Generate LXNwt Destination 
Vectors. 
Detailed steps of cloning strategy including generation of attb flanked target 
sequence (LXN), Gateway™ cloning to produce the Donor (shuttle) plasmid which is 
then sequenced and used to generate the lentiviral plasmids which are then 
validated for presence of the insert by PCR and expression of the target gene by RT-
PCR and western blot analysis. 
PlasmaDNA software was used to produce this cloning strategy. 
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Fig. 45. Assessment of Lentiviral Titre.   
HEK-293 cells were co-transfected with 3 μg of psPAX2, 1 μg of pVSV-G and 4μg of an 
eGFP-lentivirus plasmid. The ratio of 3:1:4 was previously identified as optimal for 
virus yield (data not shown). The viruses were harvested 48h post-transfection, 
filtered through a 0.45micron syringe filter and frozen at -80⁰C. 5x104 LNCaP cells 
were seeded in 500 μl of media or media containing virus solution at various 
concentrations, in a 24 well plate. The cells were allowed to adhere overnight before 
the media was replaced. eGFP expression was determined by flow-cytometry 48 h 
post-transduction. A. sample colour key is shown in B. The gating strategy is show in 
C. and the calculated virus tire is shown in D. 
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Fig. 46. Transduction of CD44+ Primary Prostate Epithelial Cells.   
HEK-293 cells were co-transfected with 3μg of psPAX2, 1μg of pVSV-G and 4μg of an 
eGFP lentivirus plasmid. The ratio of 3:1:4 was previously identified as optimal for 
virus yield (data not shown). The viruses were harvested 48h post-transfection, 
filtered through a 0.45micron syringe filter and frozen at -80⁰C. 6x104Primary 
Prostate Epithelial Cells were seeded in 500μl of media or media containing virus 
solution at various concentrations, in a 48 well plate. The cells were allowed to 
adhere overnight before the media was replaced. eGFP expression was determined 
by flow-cytometry 48h post-transduction prior to labelling (in the APC channel) the 
cells with anti-CD44+. A. sample colour key is shown in B. The gating strategy is 
shown in C. and the calculated virus tire for CD44+ cells is shown in D. 
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4.8.9. Optimisation of Lentivirus Titres 
Unfortunately the pDEST-298 (eGFP co-expressing vector) produced much lower viral 
titres than the control p35 plasmid (rarely exceeding 1x106 IU/ml in LNCaP cells (data not 
shown). As such further optimisation of lentivirus production was needed. In order to 
optimise lentivirus production an investigation of several parameters was conducted. The 
parameters investigated were two types of transfection reagent: ViaFect and 
Xtremegene, pre-coating the culture surface with Poly-L-lysine and supplementing the 
virus production medium with 4 mM caffeine. The reasons for choosing these conditions 
are as follows: 
 The transfection reagent was chosen because the efficiency of transfection 
directly impacts on virus production. ViaFect and Xtremegene have been shown 
to be the most potent transfection reagents on HEK 293 cells in our lab (data not 
shown). 
 Coating the culture surfaces with Poly-L-lysine was investigated. It has previously 
been demonstrated in our lab that some cell lines have a greater transfection 
efficiency when cultured on Poly-L-lysine e.g. LNCaP cells (data not shown). Also 
disturbing the monolayer of HEK 293 cells during virus production, causing it to 
detach, has a negative impact on HEK 293 cell survival and consequently virus 
production. Coating the culture surfaces with Poly-L-lysine reduces this 
possibility. 
An interesting publication demonstrated that lentiviral titres could be increased 4-fold 
with the addition of 4 mM caffeine to the virus production media (Ellis et al., 2011). The 
proposed mechanism by which caffeine increases viral titre is in part attributed to 
inhibition of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). The results 
indicate (Fig. 47.) that the optimum lentivirus production protocol consists of; coating the 
culture surface with Poly-L-lysine, transfecting with ViaFect and omitting caffeine from 
the viral production media. Also, functional lentiviruses can be sequentially harvested for 
at least three days post transfection, but the virus titre decreases ~2 fold each day. Also 
the best time to harvest virus was 24 hours post-transfection of packaging cells although 
48 hours post-transfection still yielded usable virus. 
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Fig. 47. Optimisation of Lentivirus Titres. 
V = Viafect, X = Xtremegene, P = Poly-L-Lysine, C = Caffeine 
e.g. V-P-C = Viafect reagent used to transfect cells in the absence of both Poly-L-
Lysine and caffeine. 
HEK 293 cells were seeded at a density of 2x105 cells per well of a 24 well plate. 
Culture surfaces were either pre-coated with Poly-L-Lysine or not. The cells were 
allowed to adhere overnight. 2 hours before transfection the media was changed and 
either supplemented with 4 mM caffeine or not. Transfection was performed using 
either Viafect or Xtremegene at a ratio of 2:1 (µl of transection reagent: µg of 
plasmid DNA) and transfection was allowed to proceed for 8 hours before media was 
changed (+/- 4 mM caffeine). Lentiviruses were harvested 24, 48 and 72 hours after 
completion of transfection. Lentiviruses were harvested by aspirating the virus 
containing media from the HEK 293 cells, filtering and freezing. The media was 
replaced +/- 4 mM caffeine. 
Viral titres were determined by performing serial dilutions ranging from neat to 
1:1000 these dilutions were then used to transduce HEK 293 cells. 48 hours after 
transduction cells were harvested and were analysed by flow cytometry 
(incorporating live dead staining).  
Titre/ml = (number of cells seeded at the time of transduction x % live cells positive x 
dilution factor) / transduction volume (ml). 
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4.8.10. Transduction with Lentivirus Results in Stable Transgene Expression in Primary 
Human Prostate Epithelial Cells. 
A demonstration of stable transduction was needed to ensure that cells remained 
expressing the transgene of interest throughout long term experiments. 
Early passage primary human epithelial cells were transduced with lentiviruses at a ratio 
of 2 virus particles per cell and maintained in culture for 3x 1:5 passages which lasted 
approximately 4 weeks. The images (Fig. 48.) demonstrate that the vast majority of 
colonies remained strongly positive for the presence of the transgene without any 
observable loss after 3 passages in culture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 48. Transduction with Lentivirus Results in Stable Transgene Expression in 
Primary Human Prostate Epithelial Cells. 
Passage 1 primary human epithelial cells were transduced with lentiviruses at a ratio 
of 2 viral particles per cell and maintained in culture for three 1:5 passages in the 
presence of feeder cells (STO cells) which lasted approximately 4 weeks.  
A. Transduction with β-glucuronidase (GUS)-159 (GUS-mVenus fusion)   
B. Transduction with LXN-159 (LXN-mVenus fusion)   
For both A. and B., the main-panel is the composite of the upper-right (Fluorescent 
image) and lower-right panels (Bright-field image). 
Images were captured using a 10x objective lens.  Scale bars = 62 μm 
 
 
 
B 
A 
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4.8.11. LXN is a Soluble Pan-cellular Protein 
The subcellular localisation of LXN is a topic of some debate. Our laboratory has previously 
demonstrated for the first time that LXN has an almost exclusively nuclear localisation 
pattern in prostate cell lines (Oldridge et al., 2013). 
In order to circumvent fixation artefacts, live cell confocal imaging utilising LXN-mVenus 
and β-glucuronidase (GUS)-mVenus (cytoplasmic control) protein-fusion lentiviral 
expression vectors was performed using primary human prostate epithelial cells (Fig. 
49A.). Under these conditions LXN-mVenus fusion protein is present in both the nucleus 
and cytoplasm in these cells. This is in contrast to the GUS-mVenus fusion protein which 
is exclusively cytoplasmic. Similar results were obtained for several cell lines (data not 
shown).  
The live cell imaging data using LXN-mVenus fusion agrees with that of endogenous LXN 
detected using two different antibodies (Fig. 49B.) in terms of LXN being able to access 
the nucleus.  However, this data is in contrast to that produced when prostate epithelial 
cells are subcellular fractionated and analysed by western blot (Fig. 49C.). This 
discrepancy is explained by the solubility of nuclear LXN which leaches out of the nucleus 
during the first stage of subcellular fractionation which is disrupting the plasma 
membrane with hypotonic buffer (which causes cells to burst due to osmosis) (Fig. 50.). 
This rapid leaching from the nuclear compartment indicates that LXN is not tethered to 
either DNA or the nuclear matrix and is a reported issue in the literature for other soluble 
nuclear proteins (Stern and Mirsky, 1953). 
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Fig. 49. LXN is a Soluble Pan-Cellular Protein. 
A. Live cell confocal microscopy of primary human epithelial cells transduced with LXN-
mVenus fusion lentiviral vector compared with that of the cytoplasmic GUS-mVenus 
fusion lentiviral vector. Cells were counter stained with Hoechst 33342.  Images were 
taken using a 60x objective lens. 
B. Immunofluorescence imaging of BPH-1 cell probed endogenous LXN using two 
separate antibodies. Images were taken using a 40x objective lens. 
C. Western blot of whole cell, cytoplasmic and nuclear fractions of several cell lines. 
Blots were probed for endogenous LXN, and incorporate α tubulin as a cytoplasmic 
marker and TATA-binding protein (TATA-BP) as a nuclear marker. Over exposed images 
are also included. 
Data generation was in part aided by Evangelia E. Kounatidou. 
A B 
C 
Primary Epithelium LXN-
  176                                         Chapter 4. Results 
 
 
 
 
 
Fig. 50. LXN Leaches out of the Nuclear Compartment During Subcellular 
Fractionation. 
Time lapse fluorescent imaging of primary human epithelial cells transduced with LXN-
mVenus fusion lentiviral vector incubated hypertonic buffer on a microscope slide to 
mimic the first stage of subcellular fractionation cells were counter stained with 
Hoechst 33342. 
Main sub-panel of each panel is fluorescent imaging of LXN-mVenus top right sub-
panel of each panel is brightfield and bottom right sub-panel of each panel is 
fluorescent imaging of Hoechst 33342. 
Coloured circles highlight leaching from nucleus. 
Time is expressed in minutes and all images were taken using a 10x objective lens. 
Scale bar = 90 μm 
Data generation was in part aided by Evangelia E. Kounatidou. 
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4.8.12. Generation of an Interactome for LXN-HA and RARRES1-HA in PC3 Cells 
This section of the report represents collaboration between myself and Robert Seed, and 
it must be stated that Robert Seed was the experimental lead on this project and the 
majority of the work described was performed by him. It is included in this report to 
provide further rational for investigating potential transcriptome changes induced by 
forced overexpression of LXN and RARRES1 in primary prostate epithelial cells. A further 
reason for the inclusion of this data is that I was the sole performer of the attempt to 
validate the RARRES1 interactome by IP with downstream analysis by western blot. 
The experimental approach for analysing potential binding partners of LXN and RARRES1 
utilised the HA tag vectors described and validated in section 5.2.1. This approach was 
taken as the anti-HA antibody is well characterised for IP unlike the anti-LXN and anti-
RARRES1 antibodies. Other important methodological features include: 
 Pre-clearing of the cell-lysate with anti-keratin conjugated sepharose beads to 
reduce these common contaminating proteins as well as nonspecific interactions 
between proteins and the beads themselves. 
 Directly conjugated anti-HA beads obtained and validated by the supplier 
(Sigma). 
 The control IP reaction to which ‘hits’ were compared was decided 
experimentally to be mock transfected PC3 cells. This was chosen over eGFP-HA 
transfection as in these cells eGFP-HA was expressed many-fold greater than 
either LXN-HA or RARRES1-HA. As such eGFP-HA had many non-specific 
interactions which would lead to the inappropriate exclusion of true interactors 
of RARRES1 and LXN.  
 Before liquid chromatography–mass spectrometry (LC-MS) the 
immunoprecipitated proteins were run on a full length polyacrylamide gel which 
was subsequently dissected into small fragments and digested with trypsin. 
 A validation sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) gel for each IP was performed, which allowed visualisation of the bait by 
coomasie staining. 10% of immunoprecipitated fractions were used for this 
analysis. An example of this analysis is shown for LXN in (Fig. 51.). 
 Analysis of the interactome for both proteins was augmented by eliminating 
common ‘sticky’ proteins by use of the contaminant repository for affinity 
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purification–mass spectrometry database (the CRAPome) (Mellacheruvu et al., 
2013). 
 At least three IP reactions with PC3 cells transfected with the target-HA vector 
and at least three mock transfected control IP reactions were generated and 
validated before being analysed by LC-MS. Hits were then analysed for the 
frequency of detection in mock and target IPs as well as spectral counts observed. 
 
The results of these analyses for LXN and RARRES1 interactomes are shown in (Fig. 52A. 
and B.), respectively. An important finding of this series of experiments is that unique 
interactors of LXN are present within the nucleus (cyclin-dependent kinase 12, zinc finger 
and BTB domain-containing protein 4, Smith-Magenis syndrome chromosomal region 
candidate gene 8 protein, Transcription factor IIIB 90 kDa subunit and Zinc finger protein 
583) which indicates that LXN may indirectly modulate transcription. The pan-cellular 
profile of LXN localisation is also corroborated by the aforementioned nuclear hits, 
cytoplasmic hits (calcium binding protein 39 and O60930-Ribonuclease H1) and Abnormal 
spindle like microcephaly-associated protein which has been shown to be located to the 
nucleus and cytoplasm. However, it must be noted that the spectral count of LXN is many-
fold greater than that of the potential interactors. 
The RARRES1 ‘hit-list’ is enriched for proteins resident to the endoplasmic reticulum 
membrane (the published location of RARRES1 in prostate cells (Oldridge, 2012). These 
potential interactors include; Aspartyl/asparaginyl beta-hydroxylase, Dolichyl-
diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunits, Mannosyl-
oligosaccharide glucosidase and Neuropathy target esterase. Perhaps surprisingly 
Importin-7 (IPO7), which is reported to be resident in the nucleus and cytoplasm, was the 
most abundant unique hit. This indicates that RARRES1, similarly to LXN, has the potential 
to indirectly affect transcription. 
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Fig. 51. Example of a Gel Clean-Up of Eluate Prior to LC-MS and Diagnostic Gel 
Validation Successful Bait IP. 
Mock-transfected (UT) and LXN-HA transfected (LXN) PC3 cells were lysed with RIPA 
and precleared with anti-keratin conjugated sepharose beads were 
immunoprecipitated with anti-HA conjugated sepharose beads. The resulting 
precipitation was washed 5x with high salt RIPA (300 mM NaCl) to remove non-
specific binding proteins. Interacting proteins were eluted with Laemmli sample 
buffer under reducing conditions. The resulting eluate was run on a polyacrylamide 
gel, which was subsequently dissected and trypsinised before being analysed by LC-
MS. Before proceeding to LC-MS a quality control (QC) gel was made containing 10% 
of the eluate which was stained with coomasie to allow visualisation of the bait 
(LXN-HA) and hence validation of the IP. 
 
LXN-HA ~ 30 kDa 
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B 
Fig. 52. LXN (A) and RARESS1 (B) Potential Interactors. 
2x106 PC3 cells transfected with either LXN-HA, RARRES1, or mock transfected were 
lysed with RIPA and precleared with anti-keratin conjugated sepharose beads were 
immunoprecipitated with anti-HA conjugated sepharose beads. The resulting 
precipitation was washed 5x with high salt RIPA (300 mM NaCl) to remove non-
specific binding proteins. Interacting proteins were eluted with Laemmli sample 
buffer under reducing conditions. The resulting eluate was run on a polyacrylamide 
gel, which was subsequently dissected and trypsinised before being analysed by LC-
MS. Common ‘sticky’ proteins were eliminated from the hit-list by comparison to the 
CRAPome database. 
 
A 
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4.8.13. Unsuccessful Attempt to Validated RARRES1 Interactome Through Co-IP of 
Importin 7 in PC3 Cells Transfected with RARRES1-HA Plasmid and Subsequent 
Immunoprecipitation Using anti-HA Antibody. 
In an attempt to validate the RARRES1 interactome generated in section 4.8.12, co-
immunoprecipitation (Co-IP) experiments were performed with downstream analysis by 
western blot. 2x106 PC3 cells transfected with, RARRES1, or mock transfected were lysed 
with RIPA and precleared with anti-keratin conjugated sepharose beads. The IP was 
performed using anti-HA conjugated sepharose beads.  
From (Fig. 53.) it can be seen that the IP has been successful (large band corresponding 
to RARRES1-HA in the elution from the +ve but not the control. The IPO7 antibody 
successfully detects a band of approximate molecular weight of IPO7 (120 kDa) in the 
input and the flow through. However, there is no IPO7 detection in the eluate of the 
RARRES1-HA transfect sample. Therefore the interaction between RARRES1 and IPO7 has 
not been validated. It should be noted that the lack of RARRES1 detection in the input 
lane was due to the RARRES1 antibody having low affinity. 
Further experimentation to validate the potential RARRES1-IPO7 interaction could be to 
perform a yeast two-hybrid assay (Brückner et al., 2009). This assay relies on the 
generation of two plasmid constructs: construct one would contain RARRES1 fused to the 
binding domain of the transcription factor. Construct two would contain IPO7 fused to 
the activation domain of the transcription factor. If RARRES1 and IPO7 interact then the 
binding domain and activation domain would be in close enough proximity to allow 
transcription of the reporter gene e.g. LacZ. 
A further experiment that would allow investigation of a potential interaction in a 
prostate model would be to conduct a proximity ligation assay (Weibrecht et al., 2010).  
This assay utilises antibodies specific to each protein of the potential interaction in this 
case one antibody specific to RARRES1 and another that is specific to IPO7. The two 
antibodies are pre-conjugated to oligonucleotides that can participate in rolling circle 
DNA synthesis. If the two proteins interact or form part of a protein complex then the two 
oligonucleotides are positioned close enough for rolling circle DNA synthesis to occur 
(upon addition of polymerase). The resulting DNA synthesis can be visualised by utilising 
complimentary fluorescent oligonucleotide probes and downstream fluorescent 
microscopy. 
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Fig. 53. IPO7 – RARRES1-HA Co-IP. 
Representative image of 3 experiments. 
2x106 PC3 cells transfected with, RARRES1, or mock transfected were lysed with RIPA 
and precleared with anti-keratin conjugated sepharose beads were 
immunoprecipitated with anti-HA conjugated sepharose beads. The resulting 
precipitation was washed 5x with high salt RIPA (300 mM NaCl) to remove non-
specific binding proteins. Interacting proteins were eluted with Laemmli sample 
buffer under reducing conditions 
Blots were probed with anti-IPO7 (sigma) and anti-RARRES1 (HPA) (sigma). 
+ = transfected with RARRES1-HA. 
- = mock transfected control. 
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4.8.14. Transcriptome Profiling of Primary Prostate Epithelial Cells – Transduced with 
LXN, RARRES1 or GUS (Control) Gene Lentiviral Vectors 
Before analysis of the four primary samples presented in (Fig. 54. and 55.) a pilot 
experiment (data not shown) was performed using a single primary sample. This pilot 
study showed that GUS over-expression did not significantly alter the transcriptome 
relative to an un-transduced control, validating GUS as a control gene. Also 48 hours post-
transcription showed the largest trend of transcriptome changes when LXN or RARRES1 
were overexpressed relative to GUS overexpression. 
Four passage-zero cultures derived from biopsies of normal areas of the prostate were 
used, each of the four patient samples was split into three populations each of which 
were transduced with LV vectors with a MOI of three (either pDest-298-GUS, pDest-298-
LXNwt or pDest-298-RARRES1wt). Before progression to microarray analysis each of the 
12 samples (four patient samples and three viruses) were quality controlled in the 
following ways: 
 Confirmation of transgene overexpression at the mRNA level by RT-PCR.  
 Confirmation of transgene overexpression at the protein level by western blot 
analysis. 
 Viral integration was assessed using primers specific WPRE that is present in all 
our LV vectors. 
 RIN and yield was measured by Agilent 2100 Bioanalyzer analysis. 
The samples were then shipped on dry ice to Eurofins Laboratories Ltd (Broadoak 
Business Park, Ashburton Rd W, Manchester M17 1RW) who performed the generation 
of a labelled cDNA libraries and microarray hybridisation. The data was then exported 
back and analysed using TAC console V3.0. 
All QC data (Fig. 54. and 55.) indicated that the experiment was performed correctly and 
to a high standard: 
 Transduction efficiency ~90% as monitored by eGFP positive cells 
 Overexpression confirmed at both mRNA and protein level 
 RIN was 10 for all samples and yield was at least 3-fold excess than the minimum 
requirement. 
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Fig. 54. Assessment of the Effects of LXN Overexpression on Gene Expression in 
Primary Prostate Epithelia.  
 
A. QC data showing physiologically acceptable viral integration events 
B. QC data showing successful overexpression of LXN mRNA across a time course 
C. QC data showing successful overexpression of LXN protein across a time course 
with fold expression calculated using densitometry and normalised to GUS 
transduced control in D. 
E. Data showing that LXN was significantly overexpressed in our transcriptome arrays 
F., G., H. a Volcano plot, Heat map and gene-chart respectively demonstrating the 
small number of genes that are non-significantly up or down-regulated in response 
to LXN overexpression. 
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Fig. 55. Assessment of the Effects of RARRES1 Overexpression on Gene Expression 
in Primary Prostate Epithelia.  
 
A. QC data showing physiologically acceptable viral integration events  
B. QC data showing successful overexpression of RARRES1 mRNA across a time 
course. 
C. QC data showing successful overexpression of RARRES1 protein across a time 
course with fold expression calculated using densitometry and normalised to GUS 
transduced control in D. 
E. Data showing that RARRES1 was insignificantly overexpressed in our transcriptome 
arrays. 
F., G. a Volcano plot and Heat map and gene-chart respectively, demonstrating the 
small number of genes that are insignificantly up or down-regulated in response to 
RARRES1 overexpression. 
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4.9. Discussion 
Evidence from our lab has strongly indicated that LXN and RARRES1 are co-regulated in 
primary prostate epithelial cells of both benign and malignant origin (Birnie et al., 2008). 
A re-analysis of microarray data published by (Birnie et al., 2008) showed a correlation 
exists between both genes - Pearson’s Correlation R2=0.9186 (Fig. 33.). Subsequent data, 
generated by (Oldridge et al., 2013) showed two very important things: firstly, both genes 
are induced by the atRA (a known differentiation-inducing agent of prostate cultures 
(Peehl et al., 1993)) and secondly, epigenetic control of these genes is mediated by DNA 
methylation (at CpG islands located within the promoter regions) in several prostate cell 
lines (Oldridge et al., 2013). Interestingly, this epigenetic control mechanism was not 
observed in primary prostate epithelial cells, or near-patient xenografts (Oldridge, 2012). 
Given the precedence for epigenetic regulation of these genes and the differential 
expression of RARRES1 and LXN mRNA and protein through differentiation, it was 
hypothesised that an alternative epigenetic control mechanism may be active in primary 
prostate epithelial cells. As these genes are in close proximity to one another, epigenetic 
control in the form of histone modification, leading to changes in chromatin status (from 
heterochromatin to euchromatin as cells differentiate) seemed the most likely candidate. 
As such ChIP was employed in order to investigate this proposed regulatory mechanism. 
 
4.9.1. Validation of a ChIP Protocol to Provide Proof of Principle for Epigenetic Control 
of RARRES1 and LXN by Histone Modification in Cell Lines 
Before attempting to investigate a role for epigenetic regulation of RARRES1 and LXN in 
primary prostate epithelial cells (which like all primary in vitro models, are complicated 
by intra-patient variability and relative difficulty in working with) it was deemed prudent 
to start with well-established prostate cell lines. These laboratory ‘work horses’ are easy 
to handle, have low intra sample variability and can be cultured with ease to provide an 
abundance of material. Moreover, the expression profile with regard to RARRES1 and LXN 
was known (Oldridge, 2012). It was therefore possible to pick a high and low expresser of 
LXN and RARRES1 and compare the chromatin status at the LXN and RARRES1 loci in these 
cells as a proof of principle pilot experiment. The caveat was that as DNA methylation had 
been discovered to regulate expression of these genes, it is possible that any further 
epigenetic regulation could be superfluous and therefore absent.  
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Our laboratory had validated several ChIP grade antibodies, which included anti-
H3K27me3 (marker of inactive heterochromatin), anti-H3K4me3 (marker of active 
euchromatin) and anti-RNApol II (marker of transcription) as well as suitable active 
(GAPDH) and inactive (PDYN) control genes to which target gene enrichment by the 
aforementioned antibodies could be compared (Pellacani et al., 2011). A series of primer 
pairs, covering the putative promoter regions and downstream of the transcription start-
sites were designed and validated for their suitability for qPCR downstream of ChIP. 
 As the end goal was to investigate the chromatin status of primary epithelial cells, which 
are grown in the presence of mouse feeder cells (STO), and the potential to analyse 
samples derived from near-patient xenografts, a further validation of the human:mouse 
specificity ratio was incorporated alongside traditional parameters, such as efficiency, R2, 
sensitivity and specificity (single amplicon). Armed with these resources and the same 
ChIP protocol used in the study (Pellacani et al., 2011) a series of ChIP experiments were 
performed to interrogate and compare the chromatin status of RARRES1 and LXN 
promoter regions in LNCaP and PNT2C2 cell lines. 
The result of this analysis showed that the chromatin generated from both LNCaP and 
PNT2C2 cells was sonicated sufficiently (enriched for 200-500 bp fragments) after 
empirical optimisation of sonication time necessary for each sample. The control genes 
gave the expected enrichment profiles for each antibody used; GAPDH was enriched by 
anti-H3K4me3 and anti-RNApol II and was not enriched by anti-H3K27me3, on the other 
hand PDYN was enriched by anti-H3K27me3 but not by anti-H3K4me3 or anti-RNApol II. 
This result confirmed that the ChIP experiment was performed correctly. In the case of 
PNT2C2 cells it was found that all of the RARRES1 promoter sequences analysed were 
enriched by anti-H3K4me3 antibody especially at -175 and 1000 bp from the transcription 
start site. Indicating that this region of DNA is in an active ‘open’ conformation. This is 
verified by a relatively modest enrichment of these sequences by the anti-RNApol II 
antibody which indicated this gene is actively transcribed in these cells. The data matches 
the RARRES1 expression profile generated by (Oldridge, 2012) which shows that RARRES1 
is elevated in the PNT2C2 cell line. In contrast, LNCaP promoter regions, covering the 
RARRES1 promoter, was not enriched by any of the antibodies used, indicating that the 
chromatin is neither open nor closed (termed poised chromatin) and that the gene is not 
being actively transcribed, which is agreement with the (Oldridge, 2012) study which 
showed that this cell line does not express RARRES1 and transcriptional repression is 
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achieved through promoter hypermethylation (Oldridge et al., 2013, Oldridge, 2012). In 
the case of LXN in both cell lines the situation is rather more difficult to define.  In PNT2C2 
cells there is a modest enrichment of all three marks indicating that the gene is being 
actively transcribed (in agreement with previous data (Oldridge, 2012)) but that the 
chromatin is in an ambiguous state, again this can be due to epigenetic control through 
DNA methylation being the dominant mechanism. The results of LXN promoter 
enrichment by anti-H3K27me3 and anti-H3K4me3 in LNCaP are very similar to that of 
PNT2C2, however there is a noticeable reduction in enrichment by anti-RNApol II which 
is to be expected given that this cell line expresses LXN mRNA many fold less than PNT2C2.  
4.9.2. Establishing and Validating a µChIP Method for the Interrogation of Chromatin 
Status in Rare Cell Populations such as the SC Fraction 
There are several difficulties that exist when attempting to characterise any form of 
regulation in primary human prostate SC, not least of which are the complex culture 
systems used to maintain this undifferentiated population, but the most significant hurdle 
that needed to be overcome is that this population is exceedingly rare, accounting for less 
than 0.1% of total cells (Collins et al., 2001, Collins et al., 2005) . This means that in a fully 
confluent 10 cm dish containing approximately 2 million cells only 2000 will be selected 
as having a SC phenotype (through  MACS selection for SC antigen CD133). Accordingly, 
one can only hope to obtain approximately 12 ng of chromatin from such a population. A 
traditional ChIP protocol, such as the one used to generate the data shown for the cell 
lines typically uses 20 µg per immunoprecipitation and is therefore not suitable for this 
application. 
A µChIP method devised and validated by (Collas, 2011) is capable of performing a single 
ChIP reaction and subsequent downstream analysis by qPCR from as few as 100 cells. This 
method was adopted and a series of ‘scale-down’ experiments (from 20 µg to 2 ng per 
immunoprecipitation) were conducted to determine the sensitivity of this assay with ever 
diminishing amounts of input chromatin (as well as to gain experience with the new 
method), with the express aim of being able to perform µChIP from as little as 2 ng of 
chromatin. The approach of scaling-down the input of previously validated chromatin 
rather than preparing chromatin from different amounts of cells was chosen in order to 
reduce variables allowing a targeted investigation of the IP and qPCR analysis steps. 
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The first major difference between the ChIP and µChIP protocol was the use of magnetic 
capture beads (as opposed to sepharose beads) in the latter. The use of magnetic capture 
particles as opposed to sepharose led to a ~10 fold reduction in non-specific binding 
events when coupled to the same control anti-IgG. By reducing the background binding 
the ‘signal to noise’ ratio and therefore the sensitivity of the assay is improved. It was 
decided, that magnetic beads would be used for all subsequent ChIP experiments 
regardless of scale. Interestingly, it was found that 200 ng of chromatin had a greater 
background signal compared with 20 µg. This can be potentially explained by the 
background binding following a non-linear binding curve, and the reduction in the input 
due to dilution following linear kinetics i.e. all nonspecific binding sites were saturated at 
200 ng of chromatin/IP. Experimentally this could be investigated by generating a 
background binding curve using many dilutions of chromatin allowing the identification 
of the chromatin concentration that is sufficient to saturate the non-specific binding sites 
present on bead and antibody (which are finite), indicated on the background binding 
curve as an upper-plateau.  
An unexpected result was the observed increase in signal for the two histone marks 
(H3K27me3 and H3K4me3) when the starting chromatin was reduced to 200 ng and 
below. This indicates that with 20 µg of initial chromatin, the capture antibodies were 
beyond the point of saturation by these very abundant marks, and that the decrease in 
signal as a % of input, compared with 200 ng, is a function of increased input without 
further antibody capture (due to saturation). The human genome contains approximately 
3 billion base pairs and is approximately 6 pg/cell, nucleosomes occur approximately 
every 200bp, and therefore 20 µg of chromatin contains approximately 5x1013 
nucleosomes which equals 1x1014 H3 molecules. A caveat to this is that not all of the 
1x1014 H3 molecules will be positive for H3K27me3 or H3K4me3. In contrast, the signal 
for RNA pol II did not dramatically increase when chromatin levels were reduced, 
indicating that the capture antibody was not being saturated by 20 µg chromatin. 
However, an increase in signal was observed when changing from sepharose to magnetic 
capture particles. This could be due to reduced background, enhanced antibody coupling 
and/or enhanced surface area of the smaller magnetic particles.  
The results of these experiments show that a µChIP protocol has been successfully 
adapted and validated within our laboratory and is suitable for use with the current 
antibodies used in the ‘traditional’ high chromatin/IP ChIP experiments. However, there 
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was one more obstacle that needed to be overcome before the protocol was complete. 
This was to find the means to ensure that the chromatin obtained from ~2,000 cells was 
appropriately fragmented prior to IP.  
As described previously, the sonication step while seemingly unimportant is critical to 
avoid both false positive and false negative results. Under-sonication results in large 
chromatin fragments with the potential for IP of target sequences through antibody 
interaction with a mark that is potentially kilobases or even megabases away. Conversely 
over-sonication results in chromatin fragments that are smaller than the amplicons used 
in the downstream detection of target sequences. Traditional ChIP methodology utilises 
a sonication control in which DNA from a sample of sonicated chromatin is extracted and 
its size is assessed by agarose gel electrophoresis. Obviously such small amounts of DNA 
~2ng can’t be readily visualised and the size determined. The µChIP method circumvents 
this problem through the use of qPCR using a 100 bp and a 300 bp amplicon (Dahl and 
Collas, 2008). Due to the sensitivity of qPCR such low levels of starting material pose no 
problem. Purely due to the function of size, the 300 bp template is broken at a greater 
rate than the 100 bp template. Accordingly, the qPCR ratio of the 100 bp to the 300 bp 
products increases as a function of sonication cycles (Dahl and Collas, 2008). While the 
genomic location of the 100 bp and 300 bp amplicons should be inconsequential it was 
decided that the 100 bp amplicon could be placed within the 300 bp amplicon (in this case 
both amplicons are resident in the coding region of the β-actin gene) to account for any 
sequence specific vulnerabilities to sonication (the 100 bp and 300 bp PCR reactions were 
performed as two separate reactions). By performing a side by side comparison of the 
qPCR and gel-based sizing methods it was found that the first incidence of a 4:1 ratio in 
100 bp to 300 bp product ratio yielded chromatin that was optimally enriched for the 
desired level of fragmentation (200-500 bp). An interesting observation not documented 
by (Dahl and Collas, 2008) was that the 100 bp : 300 bp ratio falls after excessive 
sonication i.e. 4.63 at 60 cycles (determined to be optimal) to 2.04 at 80 cycles and then 
rises again to 6.64 at 130 cycles. This phenomenon may be in part explained by reaching 
the point in which there is accumulation of DNA fragments that are too small to be 
amplified by the 100 bp primers (this point was already reached much earlier for the 300 
bp amplicon).  
It can be concluded that a µChIP protocol suitable for use with the low abundance SC 
fraction has been validated. 
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4.9.3. Chromatin Status of the RARRES1 and LXN Promoter Sequences in Primary 
Prostate Epithelial Cells  
This study is the first attempt to characterise the role that histone modifications play in 
the epigenetic regulation of RARRES1 and LXN in primary human epithelial cells, 
specifically in the basal layer hierarchy (SC, TA and CB cells).  
As with cell line experiments it was found that the control genes gave the expected 
enrichment profiles for each antibody used; GAPDH was enriched by anti-H3K4me3 and 
anti-RNApol II and was not enriched by anti-H3K27me3, on the other hand PDYN was 
enriched by anti-H3K27me3 but not by anti-H3K4me3 or anti-RNApol II. This analysis 
confirmed that the ChIP experiment was performed correctly and that subsequent 
analysis of the relative enrichment of the RARRES1 and LXN promoter sequences is valid. 
By comparing the relative enrichment by each mark it can be seen that there is no 
significant difference between the different basal cell fractions (SC, TA and CB cells) with 
regard to H3K27me3, H3K4me3 and RNApol II enrichment in the promoters of RARRES1 
and LXN. This result was unexpected, especially the RNApol II data, that one would expect 
to correlate with the differential expression of both RARRES1 and LXN mRNA published 
by (Oldridge et al., 2013). It is possible that the expression levels of these genes are fine-
tuned by downstream epigenetic control mechanisms e.g. differential mRNA stability for 
these genes in the different cell fractions, or potentially mediated by either miRNA 
regulation or poly-A tail length, resulting in an accumulation of mRNA species in the more 
differentiated CB cells versus the SC fraction over time. Alternatively, the differing results 
between the two studies could be attributed to patient heterogeneity as different 
samples were used.  
In the case of RARRES1 it was found that there was no significant enrichment of RNApol 
II when compared to the negative control gene for this mark – PDYN (0.63% vs 0.52% 
average across all samples). This result indicates that this gene is not expressed in these 
cells which is in contrast to data published by (Oldridge et al., 2013) In agreement with 
the data presented in here, recent data generated in our laboratory (Robert Seed- 
personal communication) using RT-PCR on the panel of patient samples published in 
(Rane et al., 2015)) showed that RARRES1 was only detected at significant levels in CD24+ 
luminal cells (sorted directly from patient biopsies and stromal cells (Fig. 56.). 
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There is evidence that these genomic regions exist in an intermediate state between 
‘open’ euchromatin and ‘closed’ heterochromatin, as both genes in all samples tested 
were significantly enriched above the relevant negative control gene, albeit not to the 
same extent as a relevant positive control gene for both H3K27me3 and H3K4me3. This 
intermediate state is an observed phenomenon termed bivalent chromatin (Voigt et al., 
2013). Bivalent chromatin is defined as a region of DNA with interacting histone 
complexes which are positive for both activating and repressing marks (Voigt et al., 2013). 
Usually these marks are mutually exclusive allowing the chromatin to exist in either an 
open or closed conformation allowing or preventing transcription, respectively. In the 
case of bivalent chromatin, both marks exist together (Voigt et al., 2013). This chromatin 
can be described as being ‘poised’ for either activation or repression of the gene by 
removal of one of the opposing histone modifications allowing the cell to rapidly alter the 
expression of a gene (Lesch and Page, 2014). As such, this bivalent chromatin regulates 
gene expression in embryonic stem cells (Harikumar and Meshorer, 2015). Another 
instance where bivalent chromatin is observed is in genomic imprinting (Kacem and Feil, 
2009). Genomic imprinting is an epigenetic phenomenon in which cells express a single 
allele of a gene in a temporal or cell specific manner i.e. the allele inherited from the 
father is expressed while the allele expressed by the mother is silenced (Bartolomei and 
Tilghman, 1997). Of specific relevance to this study is that the most common opposing 
marks that are found in regions of bivalent chromatin are H3K27me3 and H3K4me3 which 
are the marks used in this investigation (Harikumar and Meshorer, 2015). 
 
 
 
 
 
 
 
 
 
 
Fig. 56. RARRES1 Expression in a Cohort of Primary Samples.  
RT-PCR for RARRES1 mRNA normalised to several ‘housekeeping’ genes, samples 
used in this analysis were from the date set presented in (Rane et al., 2015) Data 
provided by Robert Seed (personal communication). 
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4.9.4. Establishment of a Lentiviral Overexpression System to Study the Effects of LXN 
and RARRES1 Overexpression in Primary Prostate Epithelia 
Previous attempts to generate and utilise LV transduction in our laboratory were plagued 
by several technical hurdles which precluded the routine use of this system (Frame et al., 
2010). These limitations included: promoter silencing was observed in several cell lines 
(P4E6, BPH-1, PC3), low titres and perhaps the most importantly - low infection efficiency 
in primary cultures (Frame et al., 2010). 
Here we present a functioning and highly optimised and validated protocol including a 
method for estimating integration number. Several LV plasmid backbones are now 
available in our laboratory which facilitated further experiments in this project and also 
other projects within the laboratory e.g.  The E74 like ETS transcription factor 3 (ELF3)-
mVenus fusion was used by Leanne Archer to identify its location after several 
immunofluorescence approaches on both native and un-tagged plasmid over expression 
systems gave variable and unsatisfactory data which were at odds with the literature (Do 
et al., 2006) (personal communication).  
Future work aimed at further improvement of the LV production methodology developed 
as part of this report could be through investigation of viral titres achieved through the 
use of alternative packaging cells such as WinPac (Sanber et al., 2015). The major inherent 
advantage of the WinPac cell line is the continuous production of LV vectors as opposed 
to three days with HEK293FT cells which were used in this project. Also the use of LV-
concentration should also be investigated. This approach would reduce unwanted 
secreted products (and serum) from the viral supernatant. 
4.9.5. LXN is a Soluble Pan-Cellular Protein 
Data published by (Oldridge et al., 2013) showed that LXN is exclusively nuclear in the 
LNCaP cell line and primary prostate epithelial cells. However, the experimental design 
used in this study had several short-comings, anti-LXN antibody used detection was not 
validated for use in immunofluorescence. This led to the utilisation of an anti-HA and LXN-
HA transfection to define subcellular localisation of LXN. Plasmid transfection leads to un-
physiological overexpression of LXN-HA protein (+ve control in Fig. 55C.). This 
overexpression is especially high when one considers efficiency in this sample is ~30%. It 
has been demonstrated that lentiviral transduction results in a less extreme level of LXN 
overexpression. The gross overexpression is likely due to many copies of the plasmid 
entering single cells within the transfected population. 
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A confounding set of results in the investigation of LXN localisation was that attempts to 
confirm immunofluorescence findings by cellular fractionation coupled to western blot 
found exclusive localisation to the cytoplasm (Fig. 49C.) i.e. the two methods give 
conflicting results. To circumvent these experimental limitations, the use of LXN-mVenus 
fusion LV vectors, coupled to confocal microscopy in a live-cell imaging approach, was 
used to settle this experimental quandary. The use of live-cell imaging was chosen to 
examine the localisation in an unbiased manner. Also the serendipitous discovery that 
GUS-mVenus fusion had an exclusively cytoplasmic distribution in all cell types used 
provided an excellent control for the identification of a nuclear localisation. The results 
of this analysis confirmed that LXN has the ability to access the nucleus however in 
contrast to previous studies – LXN was found not to be exclusively nuclear but rather pan-
cellular. When subcellular fractionation coupled to downstream western blot analysis was 
performed on the same samples used for the live cell imaging experiments, it was found 
that the LXN-mVenus fusion protein was exclusively cytoplasmic (data not shown), 
mimicking previous data generated by LXN-HA transfection. Therefore I decided to 
investigate if the experimental approach of nuclear cytoplasmic fractionation was giving 
artefactual data. By analysing the first lysis step in preparing the separate cell fractions 
(only lyses the cell membrane but not the nuclear envelope) it was seen that LXN-mVenus 
and therefore, native LXN, is so soluble that it leaches out of the nucleus at this stage of 
the subcellular fractionation protocol. This result clearly demonstrates that nuclear 
cytoplasmic fractionation by this method is not suitable for determining the localisation 
of this protein in these cells. Therefore immunofluorescence and confocal imaging data 
should take precedence. 
Whilst leaching of nuclear proteins into the cytoplasm is a well reported phenomenon, 
future work to confirm LXN localisation by a second method could utilise a recent method 
developed by (Nabbi and Riabowol, 2015). The protocol described in this report involves 
a rapid fractionation method using selective dissolution of the cytoplasmic membrane 
(but not the nuclear membrane) using a combination of low-concentration non-ionic 
detergent and rapid centrifugation to reduce the leaching events which occurs in a time-
dependent manner. (Nabbi and Riabowol, 2015).  
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4.9.6. Identification of Potential LXN and RARRES1 Interacting Partners in Prostate 
Epithelial Cells 
The first attempt to generate an interactome for RARRES1 and LXN in a prostate model 
(PC3 cells) is presented in this report. This analysis identified many unique ‘hits’ for both 
proteins. In the case of LXN several of the potential protein interactors have a reported 
nuclear distribution. This corroborates the LXN localisation profile described in this report 
and data previously published by our laboratory (Oldridge et al., 2013). The evidence for 
the pan-cellular localisation of LXN identified for the first time in this report is further 
strengthened by the identification of both nuclear and cytoplasmic potential interactors 
of LXN.  A report by (You et al., 2014) in leukaemic cells, identified Ribosomal Protein S3 
(RPS3), as an LXN-interacting protein. Initial identification of the LXN-RPS3 interaction 
was identified by mass spectrometry subsequently validated by reciprocal Co-IP. 
Interestingly, RPS3 is shown in the literature to be located mainly in the cytoplasm with 
small amounts in the nucleus but in cells undergoing apoptosis in response to hydrogen 
peroxide treatment RPS3 translocates to the nucleus. As such this report, while 
identifying that the LXN-RPS3 interaction serves to prevent RPS3 translocation to the 
nucleus in response to DNA damage it does leave the door open for LXN to shuttle RPS3 
from the nucleus to the cytoplasm. Perhaps more importantly the exclusively cytoplasmic 
distribution of LXN reported in the (You et al., 2014) study demonstrates that LXN can 
access the cytoplasm. 
Similarly to LXN, the ‘hit-list’ generated of potential RARRES1 interactors corroborates the 
observed localisation of RRARES1 in this report and the data published previously by our 
laboratory (Oldridge et al., 2013). RARRES1 interactors also reside in the endoplasmic 
reticulum including, Aspartyl/asparaginyl beta-hydroxylase, Dolichyl-
diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunits, Mannosyl-
oligosaccharide glucosidase and Neuropathy target esterase. 
Initial attempts to validate either data set by IP coupled to western blot has proved 
unsuccessful. In the case of RARRES1 the validation attempt has only focused on one hit 
IPO7 (albeit the most abundant in terms of spectral counts). It must be stated that other 
hits should be investigated before a definitive conclusion on this data set is to be made, 
especially those that show through gene ontology - localisation to the endoplasmic 
reticulum membrane. 
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Future work on the identification of LXN and RARRES1 interactors could utilise lentiviral 
vectors discussed extensively in this report, to generate a more physiological interactome 
through interrogation of primary prostate epithelial culture model. Furthermore this 
experimental approach could theoretically be used to analyse the interactome generated 
in CaP and normal cells derived from the same patient. This experimental approach may 
lead to novel binding events in either system which may shed light on how LXN and 
RARRES1 elicit their effects.  
 
4.9.7. Understanding the Effects of LXN and RARRES1 Overexpression on Gene 
Expression in Primary Prostate Epithelia 
This is the first attempt to look at transcriptional changes induced by LXN or RARRES1 
overexpression in primary prostate epithelial cells. The rationale behind performing 
transcriptomic profiling in cells overexpressing either LXN or RARRES1 is multi-layered: 
 These genes have been shown to effect fundamental processes in CaP 
progression namely, colony formation, cell migration and invasion. 
 The confirmed localisation of LXN to the nucleus 
 Mass-spectrometry data which shows that potential binding partners of LXN and 
to a lesser extent RARRES1 are in the nucleus. 
It was decided that the most appropriate model for investigating transcriptional 
regulation by LXN and RARRES1 was the use of well validated lentiviral vectors. These 
vectors have been shown to transduce primary prostate epithelial cultures in a stable and 
highly efficient manner. This experimental approach was favoured over plasmid 
transfection as lentiviral vectors have been shown to transduce primary prostate 
epithelial culture with much greater efficiency than plasmid transfection. Additionally this 
approach allows MOI and therefore level of expression to be more tightly controlled. LV 
generated from pDEST-298 backbone (co-expression of eGFP) was used as this system 
allows visualisation of transduction efficiency and intensity across samples. 
Downstream analysis of transcriptional changes was performed through Affymetrix 
microarray technology. This approach was chosen as it is a well validated system for 
measurement of transcriptome changes in our cell culture model (Birnie et al., 2008). 
Specifically the Affymetrix GeneChip® Human Transcriptome Array 2.0 was used. This 
microarray contains >6.0 million distinct probes covering coding and non-coding 
transcripts. 70% of the probes on this array cover exons for coding transcripts, and the 
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remaining 30% of probes on the array cover exon-exon splice junctions and non-coding 
transcripts.  
No significant alterations that exceeded the traditional cut-off of 2-fold change compared 
to control were seen for either LXN or RARRES1 overexpression. In the case of RARRES1 
analysis even RARRES1 itself was not significantly overexpressed vs control, even though 
RARRES1 as analysed by targeted RT-PCR and western blot with appropriate controls 
showed several thousand fold over expression of RARRES1 compared to GUS-transduced 
control (Fig. 55B. and D.). As a result, the validity of the whole dataset for both genes is 
cast into doubt and the ability (or lack of) of LXN or RARRES1 overexpression to elicit 
transcriptional changes in primary prostate epithelial cells remains unanswered. 
An alternative to microarray profiling is RNA sequencing (RNA-seq) (Zhao et al., 2014). 
RNA-seq is a powerful technique for transcriptomic analysis which relies on massively 
parallel ‘next generation’ sequencing technologies such as ilumina’s HiSeq 2500 
Technology. The advantage of RNA-seq vs microarray technology include: 
 Greater dynamic range. 
 The ability to detect novel transcripts and mRNA variants such as those arising 
from: splicing events, alternative promoter usage and sequence variation within 
the sample compared to reference genome (Zhao et al., 2014). 
 Enhanced signal to noise through lower background. 
However, it is not without disadvantages: 
 Increased sample requirements - especially important if rare cell populations 
such as the SC fraction are to be analysed. 
 Complicated library preparation. 
 Biases during sample preparation and sequencing that must be accounted for 
when analysing the data generated (Roberts et al., 2011). 
It is widely accepted that RNA-seq will eventually overtake microarray approaches as the 
assay of choice (Zhao et al., 2014). As such future attempts to investigate transcriptomic 
changes induced by LXN and RARRES1, could be facilitated by utilisation of RNA-seq. This 
approach would preclude any issues regarding the ability of microarray probes to reflect 
RT-PCR (RARRES1 probe is capable of detecting endogenous RARRES1 mRNA but this was 
below the level of detection in un-transduced and GUS-transduced samples) and western 
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blot QC data which showed massive (thousand-fold) expression of RARRES1 in cells 
transduced with RARRES1 LV compared to those transduced with the control (GUS LV). It 
must be noted that both LXN and RARRES1 are only covered by a single probe set each 
(on the microarray used). Also as GUS is not a human sequence it is not covered by any 
Affymetrix probes thus precluding expression analysis of this control by this approach.  
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5. Overall Discussion: Integration of the Research into Emerging Paradigms of Cancer 
Treatment and Future Directions of the Research 
 
5.1. Differentiation Therapy as a Strategy to Treat Cancer 
Traditional cancer therapies are cytotoxic in nature- aiming to kill cancer cells directly. 
Unfortunately, these treatments often fail and the cancer recurs. Reasons for treatment 
failure include; toxicity and drug resistance often attributed to the properties of CSCs 
(discussed in section 1.4.1.). In contrast, ‘differentiation therapy’ describes a form of 
therapeutic strategy for the treatment of malignancies, through hyper-activation of 
endogenous differentiation pathways (Cruz and Matushansky, 2012). Differentiation 
leads to maturation of the cancer cells and subsequent loss of several key properties of 
cancer such as self-renewal potential and resistance to apoptosis (Xu et al., 2014). This 
strategy is by no means new, having been initially proposed in 1961 (Pierce and Verney, 
1961). However, due to a relatively recent wave of evidence supporting the CSC 
hypothesis of cancer, it has now been investigated in many cancers including: several 
forms of leukaemia, and solid tumours such as breast, colon and CaP (Walczak et al., 2001, 
Munster et al., 2001, Castaigne et al., 1990, Xu et al., 2014). 
There are many different differentiation inducing agents. The main strategies include: 
interference of signal transduction and transcription, CSC targeting and modulation of the 
epigenome and miRNA expression.  
Targeting signal transduction: It has been shown that mesenchymal stem cells (MSCs) are 
the progenitors of malignant fibrous histiocytoma (MFH) (Matushansky et al., 2007). 
Furthermore, elevated Dickkopf-related protein 1 (DKK1) (a Wnt inhibitor), mediates the 
transformation of MSC to the MFH phenotype (Matushansky et al., 2007). Importantly, 
restoration of Wnt signalling caused reversion to the MSC phenotype and loss of tumour 
cell properties through differentiation into connective tissue lineages (Matushansky et 
al., 2007). 
Peroxisome proliferator-activated receptor (PPAR)-γ agonists: PPAR-γ is member of the 
PPAR transcription factor superfamily. PPARs are nuclear receptors that elicit their effects 
on transcription by interaction with RXRs in a heterodimeric conformation (Tontonoz et 
al., 1997). PPAR-γ is involved in the regulation of key cellular functions such as cell 
proliferation, differentiation and apoptosis (Grommes et al., 2004). Agonists of PPARγ are 
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well established inducers of differentiation. They have been shown to induce 
differentiation in several types of cancer cell lines, including: monocytic leukaemia, 
breast, colorectal, non-small-cell lung cancer, and CaP (Zaytseva et al., 2011, Cruz and 
Matushansky, 2012). In the latter, treatment of the PC-3 cells (high expression of PPARγ), 
with troglitazone (synthetic PPARγ agonist of the thiazolidinediones class) resulted in a 
potent reduction of proliferation (Kubota et al., 1998). 
Modulation of posttranscriptional modification of histone proteins: Modification of the 
‘histone code’ and subsequent accessibility of the chromatin to transcription machinery 
is known to play a crucial role in development, cellular differentiation and programed cell 
death. Importantly, aberration of this control mechanism is implicated in oncogenesis. 
Histone deacetylation, performed by HDACs, results in transcriptional silencing of 
tumour-suppressor genes in several cancers. Concordantly, HDACI, have been shown to 
induce differentiation in several cell lines (Gallinari et al., 2007, Marks et al., 2001). A 
breakthrough for differentiation therapy through modulation of the histone code is 
Vorinostat for treatment of cutaneous T cell lymphoma which has been approved by the 
Food and Drug Administration (FDA). 
Modulation of the miRNA expression profile of cancer cells is another strategy for forcing 
differentiation of cancers cells. One of the key advantages of this approach is that a single 
miRNA targets multiple mRNA species. Supporting the potential of miRNA modulation 
comes from the reintroduction of miR-1 and miR-124 resulted in inhibition of growth 
through induction of differentiation (Lim et al., 2005). Additionally the CSC fraction can 
be directly targeted e.g. upregulation of miR-145 leads to differentiation through the 
mechanism of repressing octamer-binding transcription factor 4 (OCT4) in human 
endometrial adenocarcinoma cells (Wu et al., 2011b). Alternatively, elimination of 
miRNAs required for the maintenance of CSC ‘stemness’ is another strategy e.g.  miR-21 
(Yu et al., 2013).  
Hypermethylation of CpG islands present in the promoters of tumour-suppressor genes 
is a well-described mechanism of gene silencing in cancer. CpG island methylation is 
performed by DNA methyltransferases. Two of the first epigenetic drugs used in AML 
were the nucleoside analogues 5-azacytidine and 5-aza-20deoxycytidine (Schenk et al., 
2014). Which are examples of DNA methyltransferase inhibitors (DNMTi). The mechanism 
of DNMTi action is through DNMTi incorporation into the DNA, where they complex with 
the DNA methyltransferases (Schenk et al., 2014). Covalent coupling of DNMTi to DNA 
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methyltransferases results in the degradation of the enzyme and subsequent loss of CpG 
island hypermethylation in cancer and re-expression of tumour suppressor genes. 
Retinoids have been shown to control differentiation, proliferation and apoptosis through 
interaction with nuclear retinoic acid receptors (RAR and RXR). The best example of a 
retinoid as a differentiation promoting agent is atRA. As well as the effects of atRA on 
transcription discussed previously, there are also extra-nuclear effects of this agent. Non-
classical functions of atRA include activation of extracellular signal-regulated kinases 
(Erks) via PI3K and Proto-oncogene tyrosine-protein kinase Src (Src) kinases in neuronal 
cells leading to repression of Oct4 (Al Tanoury et al., 2013). Although the non-genomic 
effects of atRA are not fully understood, it is clear that these effects have to be taken into 
consideration when evaluating the response to retinoids (Schenk et al., 2014). 
The first successful clinical application of differentiation therapy was provided when atRA 
was used to treat acute promyelocytic leukaemia (APL) (Castaigne et al., 1990, Schenk et 
al., 2014, Stone et al., 1988). This breakthrough resulted in APL being a curable disease 
rather than a fatal one. atRA treatment resulted in the terminal differentiation and loss 
of long-term proliferative capacity and eventually induction of apoptosis (Schenk et al., 
2014). Incorporation of chemotherapy and up-front use of atRA in combination with 
arsenic trioxide led to complete remission rates in excess of 93% with patients achieving 
5-year overall survival rates approaching 100% (Schenk et al., 2014). Mechanistically, 
most APL patients, have the chromosomal translocation t(15;17) producing a fusion of 
RARα and promyelocytic leukaemia gene (PML)  (Cruz and Matushansky, 2012). atRA 
treatment induces  dissociation of PML-RARα/HDAC interaction and subsequent 
degradation of PML-RARα (Cruz and Matushansky, 2012). Ultimately this leads to the 
reactivation of myeloid differentiation processes in APL cells (Schenk et al., 2014, Stone 
et al., 1988). The very successful use of atRA in the treatment of APL validates the concept 
of differentiation therapy. It also provides the rationale for differentiation therapy in the 
treatment of other cancers. 
Unfortunately, there are currently no other differentiation-inducing agents that mirror 
the effectiveness of atRA treatment of APL. The major reason for this is that APL 
represents a simple karyotype disease, characterised by the presence of the PML-RARα 
gene. Thus, the reversal of one pathway is sufficient to reverse the tumourigenicity of APL 
and induce normal differentiation. Solid tumours on the other hand, are heterogeneous 
with respect to cell proliferation, differentiation and most importantly – epigenetic and 
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genetic abnormalities. For solid tumours, the application of differentiation therapy has 
been further compounded by the absence of developmental models of cancer 
progression that correlate cancer subtypes to stages of normal development.  
Most solid tumours are now viewed as aberrantly-differentiated heterogeneous tissues 
containing a hierarchy of cells that originate from CSCs. Due to this intra-tumour 
heterogeneity it is perhaps naïve to believe that a single agent can elicit a cure. 
Accordingly, combined regimens with different targets are likely to have greater efficacy. 
Such combinations can take the form of two or more differentiation promoting agents or 
the combination of differentiation therapy with conventional radiation or chemotherapy 
(Sung and Waxman, 2007, Vainstein et al., 2012).  
Mechanistically, ‘combined regimens’ can exert additive or even synergistic effects in 
many ways. One example is retinoid resistance of many solid tumours which limits the 
effectiveness of atRA treatment. HDACI can increase the expression of retinoid receptors 
and therefore the combination of HDACI with atRA is logical (Ferrara et al., 2001, David 
et al., 2010, Xu et al., 2014). CSCs are resistant to traditional cytotoxic cancer therapies. 
By inducing differentiation of CSCs one could hope to sensitise these cells to the 
traditional therapy and thus achieved greater efficacy (Cruz and Matushansky, 2012, Xu 
et al., 2014). 
Both LXN and RARRES1 have been shown to be regulated by atRA, hypermethylation of 
CpG islands and modulation of the histone code. These proteins have also been shown to 
have tumour suppressive roles in several malignancies. The upregulation of LXN and 
RARRES1 through differentiation promoting agent(s) has the potential to improve patient 
outcomes in CaP and other cancers particularly when administered in combination with 
a traditional cytotoxic therapy to destroy the bulk tumour. This bivalent assault of the 
main population of tumour cells and the CSC fraction has the potential benefit of reducing 
tumour burden, reducing metastatic potential, resistance to therapy and relapse rates (all 
of which are attributed to CSCs).  
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5.2. Targeted Medicine as a Means to Improve Outcomes in Cancer 
Every patient is unique and accordingly every patient’s cancer is unique. This well-
established paradigm is the root cause of the inter-patient variability seen with regards 
to: prognosis, tumour response, clinical presentation, treatment tolerance and risk of 
metastasis. Recent advances in molecular profiling technologies, biomarkers and drugs 
which exploit ‘molecular weaknesses’ of cancer have precipitated a trend towards a 
targeted medicine approach for the treatment of cancer. Targeted medicine is a term 
used in this report to encompass several distinct but overlapping terms which include: 
 Precision medicine - Genomic profiling to inform and guide treatment decisions. 
 Stratified medicine - The use of diagnostic tests for grouping of patients based 
risk, prognosis and/or response to therapy. 
 Personalised medicine - Profiling of an individual at the level of the genome, 
transcriptome and/or proteome - used to direct healthcare on a patient by 
patient basis. 
The ultimate goal of targeted medicine strategies is to provide patients with the most 
suitable therapeutic intervention at the correct time. Traditional ‘one-dose-fits-all’ 
approach to clinical intervention has proven unsatisfactory in many diseases with 
response rates in oncological disorders the most disappointing (Spear et al., 2001). 
The inter- and intra-heterogeneity of cancer is a fundamental problem that has resulted 
in poor response rates to therapeutic intervention. Cancer is characterised by mutations, 
and mutation is a random process (although specific mutations can be preferentially 
selected and therefore enriched in certain disease types). This randomness combined 
with a unique starting point i.e. an individual’s genome and epigenome is unique, 
increases the spectrum of driver mutations that are present even within a single subtype 
of cancer. This situation is further complicated by the observed multi-focal nature of 
many cancers i.e. a patient may present with CaP but in fact the cancer is composed of 
several distinct clones, each exploiting a different genomic lesion. Current ‘omics’ 
technology allows the molecular interrogation of the cancer genome in direct comparison 
to the genome of normal cells. This approach enables the detection of aberrant genes 
and pathways, and the patient to be treated accordingly. 
Targeted medicine offers several advantages to both the patient and healthcare system. 
These include: 
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 Accurately defining prognosis - reducing ‘over-treatment’ and waiting time for 
patients with aggressive disease (Jackson and Chester, 2015). 
 Reduced administration of drugs which are unlikely to be of benefit - reduced 
exposure to side-effects for patients and reduced expenditure for the health care 
system (Bell, 2013).  
Targeted medicine is currently employed in many disease settings (Bell, 2013). One of the 
most well-known examples of targeted medicine is the identification of heredity genetic 
factors which increase the life time risk of breast cancer- breast cancer 1 (BRCA1) and 
breast cancer 2 (BRCA2) (Jackson and Chester, 2015, Struewing et al., 1997, Cho et al., 
2012). By predicting that a disease is likely to occur within an individual or within a sub-
group of the population, clinicians are able to monitor the patient (by regular 
mammography) allowing early diagnosis. Also, if risk management dictates, prophylactic 
surgery or other intervention can be administered. 
Sub-classification of cancer types based on molecular profiling of somatic mutations has 
already begun in several cancer fields leading to targeted therapeutic strategies being 
employed. 
Molecular profiling of breast cancer has resulted in the identification of a subtype of the 
disease defined by overexpression of the human epidermal growth factor receptor 2 
(HER2) oncogene. Commonly this is a result of genomic amplification of HER2 which can 
be identified by FISH. This driver mutation, which is present in approximately 20-30% of 
breast cancer patients, can be targeted by treatment with trastuzumab (Rodríguez-
Antona and Taron, 2015, Vogel et al., 2002). The use of targeted medicine in this setting 
has been shown to reduce disease recurrence in HER2 positive breast cancer by 40% 
(Pinto et al., 2013). 
In colorectal cancer patients with WT Kirsten rat sarcoma viral oncogene homolog (KRAS) 
(approximately 60% of colorectal cancer patients) which is a downstream signalling 
molecule of epidermal growth factor receptor (EGFR) have been shown to respond to 
treatment with cetuximab (Jackson and Chester, 2015). Cetuximab is a monoclonal 
antibody directed against EGFR. Importantly patients with mutant KRAS do not respond 
to cetuximab treatment and therefore can be triaged in an appropriate manner (Jackson 
and Chester, 2015, Karapetis et al., 2008). 
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In malignant melanoma, the presence of oncogenic murine sarcoma viral oncogene 
homolog B (BRAF) mutation which is present in approximately 66% of malignant 
melanoma patients has been shown to predict increased aggressiveness and resistance 
to traditional chemotherapy (Tsai et al., 2008). Additionally and most significantly, the 
presence of BRAF mutations has been shown to predict disease sensitivity to the Raf 
inhibitor vemurafenib (Tursz et al., 2011, Jackson and Chester, 2015). Accordingly, 
treatment of this disease subtype with vemurafenib led to a reduction of disease 
progression in 74% of a patients and a reduction of overall mortality of 63% (Chapman et 
al., 2011). 
Application of a targeted medicine approach to the treatment of CaP is currently 
hampered by the high level of molecular heterogeneity of the disease. However, several 
common molecular abnormalities have been identified which include: TMPRSS2/ERG 
fusions, loss of PTEN, mutations affecting the PI3K pathway and perturbations of AR 
signalling. 
As part of the COU-AA-302 CaP trial (Abiraterone acetate in metastatic CRPC in 
chemotherapy naïve patients) it was found that patients who have fusion of TMPRSS2 to 
ERG sequences together with interstitial deletion of sequences 5′ to ERG (2+EDel) variant 
of TMPRSS2/ERG translocation had an increased benefit from Abiraterone treatment 
(Ryan et al., 2015). 
Perturbations of the AR signalling pathways and the increased efficacy of 2nd generation 
ADT in patients with AR amplification has already been discussed. However, it has also 
been shown that the expression of AR-V7 splice variant predicts resistant to enzalutamide 
but also susceptibility to galeterone, (an androgen receptor therapy) (Maughan and 
Antonarakis, 2015). 
It has been shown that 19% of CRPC patients have a DNA repair pathway alterations, 
including 12.7% of patients with a hereditary BRCA2 mutation (Mullane and Van Allen, 
2016, Agalliu et al., 2007). It was subsequently shown that the use of the poly ADP ribose 
polymerase inhibitor (olaparib) in patients with DNA repair gene mutations resulted in a 
response rate of 87.5% (14 out of 16 patients) (Mateo et al., 2015, Mullane and Van Allen, 
2016). 
It can be seen that the revolution of targeted medicine is currently gathering momentum 
- buoyed by success seen in several disease types and oncological disorders. This trend is 
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set to continue as high-throughput sequencing technologies are expected to become 
more accessible to healthcare providers, as technological progress is driving a fall in cost 
(Fig. 57.) (Cho et al., 2012). This information explosion must be accompanied by a 
concomitant increase in bioinformatics and data processing capability for maximum 
benefit to be realised. 
Currently we are in an era of targeted medicine which relies on targeted tests to identify 
a particular molecular lesion within a patient and matching this incomplete ‘molecular 
signature’ with the most appropriate therapy available. It is at this juncture that the qPCR 
assay described in this report would be most applicable to determining prognosis and 
response to therapy. As deep sequencing improves particularly in the resolution of minor-
populations present within a tumour biopsy, it is expected that our understanding, and 
detection, of deregulated pathways will increase (Cho et al., 2012, Bell, 2013). This 
information as well as being used to triage patients, will also feed forward to the 
pharmaceutical industry, allowing the generation of therapeutic agents that exploit these 
abnormalities. Additionally, reducing costs and increasing the through-put of diagnostic 
methodologies will enable target medicine to be utilised in more patients. Further 
progress in targeted medicine, in the longer-term, will likely benefit from the integration 
of many ‘omics’ data e.g. genomic, epigenomic, transcriptomic and proteomic 
approaches to further-refine molecular diagnosis and disease phenotypes. 
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Fig. 57. Cost of Sequencing a Human-Sized Genome.  
The cost of sequencing decreased from 2001 to 2007. This was followed by dramatic 
fall in cost upon technique evolution from 1st generation to 2nd generation 
technology in January 2008. The cost of sequencing continued to decrease following  
2008.  
From: (Cho et al., 2012)  
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5.3. Future Directions of the Research 
5.3.1. Future Directions: Utilising the GAAR Assay in a Clinical Setting  
The field of biomarker research has often focused on the utilisation of liquid biopsies due 
to less invasive sampling methodologies when compared to a tissue biopsy approach. In 
this regard a collaboration was initiated with the Medical University of Innsbruck to 
explore the possibility of analysing XCA and GAAR status of circulating tumour cells (CTC).  
Unfortunately with current methodology of CTC enrichment from liquid biopsies in CaP 
and the vanishingly small numbers of CTCs recorded in the literature the project was 
quickly abandoned. However should the technology for CTC purification from liquid 
biopsy be improved, then such a study had the potential to allow urologists to quickly and 
easily monitor the patient’s suitability and responsiveness to ADT. A proposed study 
design devised in collaboration with Frédéric Santer is shown in (Fig. 58.). The proposed 
study design advocates the use of whole-genome sequencing in parallel to utilisation of 
the GAAR qPCR assay. While this would provide an enormous amount of additional 
information a more AR-targeted approach would be to use targeted sequencing of the AR 
alleles and/or investigation of AR mRNA species such as AR-V7. 
With current methodology of CTC isolation which is plagued by high levels of cellular 
contamination particularly by white blood cells, as such analysis by FISH would be the 
preferred methodology.  
A more achievable way of establishing usefulness of this assay in a clinical setting would 
be through performing a retrospective trial. As the assay is compatible with FFPE tissue 
then historical archived samples of repeated patient biopsies could be used and 
compared against known outcomes. The goal of this trial would be to predict: 
1. Which patients are likely to be at risk of developing a clinically relevant CaP? 
 
2. Out of the patients that failed first line ADT, which ones responded to subsequent 
total androgen blockade through second line ADT therapeutics, such as 
Enzalutamide. 
 
This approach is dependent on the availability of multiple biopsies from different stages 
of treatment, for each patient in the trial which has serious logistic problems, but would 
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provide genuine insights into the development of castration resistance, and its 
relationship to GAAR and XCA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 58. Proposed Trial Design for Monitoring ADT Resistance Through the use 
of the AR Assay Described in this Report by Analysing CTCs Isolated from Liquid 
Biopsies. 
Enza = Enzalutamide 
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5.3.2. Future Directions: Potential qPCR Assay Modifications   
The assay described in this chapter has several advantages over FISH in terms of being 
amenable to high-throughput screening compared to competitor technologies such as 
FISH and whole genome sequencing. However, there are several modifications that could 
result in significant streamlining, specificity and sensitivity gains as well as increasing 
usefulness of the assay in the case of CaP patient stratification.  
Use of TaqMan® to allow multiplexing - TaqMan® assays utilise a 3rd probe in the PCR 
reaction which binds to the target sequence in-between the forward and reverse primers. 
This 3rd probe is chemically labelled at the 5’ end with a fluorescent reporter dye and a 
quencher is present at the 3’ end. When the 3rd probe is bound to its complementary 
sequence and included into the PCR product the reporter and quencher are cleaved by 
the 5′ to 3′ activity of the DNA polymerase. This cleavage releases the reporter dye from 
the quencher and hence fluorescence is observed which is proportional to product 
amplification. By utilising different reporter dyes it is possible for multiple PCR reactions 
to be performed simultaneously e.g. AR reported by FAM, DMD reported by Texas Red 
and GAPDH reported by NED reporter dye. By converting the assay to a ‘triplex’ would 
theoretically lead to a reduction in assay preparation and sample usage (template DNA) 
by a factor of three. Additionally, through the use of a 3rd probe, specificity of the assay 
would also increase. 
Use of Digital PCR - Digital PCR is a relatively new version of quantitative PCR and is 
depicted in (Fig. 59.) (Thermofisher, 2016). The defining feature of digital PCR vs 
traditional methodology is the partitioning of the sample into many parallel reactions (all 
in the same well). Upon partitioning some reactions will contain the template molecule 
and others will not, during the reaction each partition is measured for fluorescence 
accumulation akin to traditional qPCR (partitions which do not contain the target 
template will not be positive for fluorescence accumulation). Following PCR analysis, the 
number of positive and negative partitions is used to calculate, in absolute terms, the 
number of target molecules in the starting sample. The key advantages of digital PCR vs 
traditional qPCR are increased precision by using more PCR replicates without extra assay 
preparation and the elimination of the need for a ‘reference’ reaction and standards. 
Incorporation of a sister assay such as ‘primer walking’ or an additional set of PCR probes 
specific for the ligand binding domain of AR (frequently truncated in CaP) to detect AR 
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mutations resulting in androgen independent AR activity and/or relaxed ligand specificity. 
This would allow patients with AR mutations to be stratified and treated accordingly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 59. Overview of Digital PCR. 
From: (Thermofisher, 2016) 
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5.3.3. Future Directions: Increasing the Likelihood of Detecting Changes in Chromatin 
Status in the RARRES1 and LXN Genes through Experimental Modifications  
 
It is possible that changes in chromatin status at the RARRES1 and LXN genes in the 
prostate epithelium could be more thoroughly characterised through direct selection of 
cellular phenotypes from primary prostate tissue (without culture). This experimental 
design would preclude any artefactual changes in chromatin structure that may occur in 
in vitro cell culture. Another advantage of this experimental approach is that it would 
allow the interrogation of the most differentiated luminal cell population. Currently our 
laboratory are unable to maintain the terminally differentiated quiescent luminal fraction 
in culture. 
Another possibility to enhance the potential identification of regulation through histone 
modifications would be to expose cells, differentially, to the known inducer of RARRES1 
and LXN - atRA. This form of cellular manipulation has the potential to enhance the 
differences between tested samples to a greater extent than that achieved through 
‘enforced’ differentiation in our culture system. A potential caveat to this approach is that 
atRA is known to induce differentiation which would deplete the SC population in the 
+atRA condition and may preclude analysis of this fraction. Even so, this approach should 
be considered for future studies on the epigenetic regulation of RARRES1 and LXN. 
5.3.4. Future Directions: Increasing the Likelihood of Detecting Changes in Chromatin 
Status in the RARRES1 and LXN Genes through an Enhancement of the µChIP Protocol 
 
The µChIP protocol used in this study has proven effective, allowing interrogation of 
epigenetic regulation from as little as 2 ng of chromatin/IP. This is incredible sensitivity, 
when one considers that 2 ng of chromatin can theoretically be derived from as few as 
330 cells. However, no method can ever be considered perfect and incremental gains can 
still be made.  
One possibility to enhance the current protocol is through use of ‘hard’ plastic sonication 
tubes. Harder plastics have been shown to transfer ultra-sonic waves more efficiently 
than softer plastic tubes, allowing the chromatin to be sheared more evenly and by fewer 
sonication cycles. Although hard plastic sonication tubes (such as those made from 
polystyrene) were advocated by the Collas protocol (Collas, 2011, Dahl and Collas, 2008), 
it was deemed a low-priority optimisation step given that many things had to be validated 
and that soft polypropylene tubes had proven to be adequate in previous publications 
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from our laboratory. The plastic tubes that I would advocate the use of in any further 
µChIP optimisation would be TPX® Polymethylpentene (PMP) tubes from Diagenode to 
improve sonication and shearing efficiency. As these tubes have been validated for use 
on the Bioruptor® Standard sonicator which is currently use for fragmenting chromatin in 
our laboratory. 
Another possibility is to completely avoid sonication altogether through use of enzymatic 
digestion of chromatin to yield the desired chromatin fragment lengths (Duband-Goulet, 
2016). The advantage of enzymatic digestion versus sonication is that enzymatic digestion 
is less ‘harsh’ than sonication. This property has the potential to preserve the integrity of 
the chromatin and antibody epitopes leading to enhanced efficiency, which may be even 
more apparent when trying to detect transcription factor-DNA interactions which are 
weaker than that of histone-DNA interactions. 
One of the main limiting factors in antibody-based biological assays is the affinity and 
specificity of the capture antibody itself. The assays presented here used validated and 
well published antibodies against canonical marks. However, as no direct comparison was 
made to other capture antibodies it is possible that more effective antibodies are 
available which through increased affinity have the potential to increase IP efficiency. 
5.3.5. Future Directions: Bivalent Chromatin or Mono-allelic Expression? 
 
A very recent publication by (Shema et al., 2016) attempted to address the issue of 
bivalent chromatin, specifically the question to address was ‘do opposing marks exist on 
the same histone molecule or is one allele enriched for one histone mark and the other 
allele enriched for the antagonistic histone mark?’ 
ChIP is incapable of answering this question.  Although, the sequence that is enriched for 
the mark of interest can be obtained, it cannot provide information on the allele from 
which that sequence was derived (Rane et al., 2015). Moreover, ChIP is incapable of 
deciding whether a nucleosome is modified by two (or more) marks simultaneously, as 
the immunoprecipitations for each mark are performed in separate reactions and hence 
interrogate different nucleosomes populations. On the other hand, MS can detect the 
presence of two antagonistic marks on the same histone tail but it does not provide 
information on the sequence in which these modifications are associated with (Sidoli and 
Garcia, 2015). Through the use of sequential ChIP and MS it is possible to identify 
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coexistence of the opposing marks. However, it is not possible to definitely identify an 
individual bivalent-nucleosome which would be the best evidence of bivalent chromatin. 
The method that was established and validated by this group uses a single molecule 
approach and involves the isolation of mono-nucleosomes and labelling them with 
fluorescent biotinylated oligonucleotides (Shema et al., 2016). The labelled nucleosomes 
are captured on polyethylene glycol (PEG) and streptavidin coated slides. After capturing, 
the nucleosomes are then incubated with fluorescently labelled antibodies to histone 
modifications of interest. Total internal reflection microscopy is then used to record the 
position of each nucleosome along with the presence of histone modifications - indicated 
by antibody binding (Shema et al., 2016).  
5.3.6. Future Directions: Potential Transcription Factor and miRNA Regulators of LXN 
and RARRES1 Loci 
Transcription factors that have the potential to co-regulate LXN and RARRES1 have been 
identified in silico using the Genomatix bioinformatics suite, including PromoterInspector 
MatInspector and ModelInspector (Table. 8.). This list was refined based on expression 
profiles of prostate epithelial cells of benign and malignant origin conducted by (Birnie et 
al., 2008) (Fig. 60.). Through this analysis, four lead candidates: hepatoma-derived growth 
factor (HDGF), DNA damage-inducible transcript 3 (DDIT3), nuclear factor erythroid 2-
related factor 1 (NFE2L1) and activating transcription factor 4 (ATF4) have been 
discovered which merit experimental analysis through either knockdown or ChIP 
experiments. 
 Similarly, miRNAs with predicted binding sites on both LXN and RARRES1 mRNA 3’ 
untranslated region (UTR)s have been identified (Table. 9). This in silico analysis was 
performed using microrna.org and mirwalk online tools bioinformatics tools. Alongside 
this analysis, the expression levels of the identified potential miRNA regulators in SC, TA, 
CB and PrEC cell populations and BPH, CaP and CRPC disease types. The miRNA data base 
published by (Rane et al., 2015) was used for expression analysis. Experimental validation 
of regulation by these miRNAs can be conducted through a 3’ UTR luciferase reporter 
assay (Jin et al., 2013). This assay involves the generation of a DNA construct consisting a 
strong promoter, 3’UTR of RARRES1 or LXN, and luciferase DNA sequence (construct 1). 
A separate DNA construct containing potential miRNA identified by software screen 
(construct 2). Cells can then be transfected with either (construct 1) or (construct 2) alone 
  215                       Chapter 5. Overall Discussion 
or the combination of (construct 1) and (construct 2). Interference by the miRNA will lead 
to a reduction in luminescence and hence confirmation of regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcription Factor p-value 
Hepatoma-derived growth factor-HDGF 0.000222 
Germ cell nuclear factor GCNR - NR6A1 0.003169 
C/EBP homologous protein CHOP-DDIT3 0.007845 
Zinc Finger Protein 628 - ZNF628 0.008663 
Nuclear Factor, Erythroid 2-Like 1- NFE2L1 0.008831 
Activating Transcription Factor 4-ATF4 0.009516 
Paired Box 1-PAX1 0.009516 
    
Table. 8.  Potential Transcriptional Co-regulators of LXN and RARRES1.  
Transcriptional co-regulators of LXN and RARRES1 were predicted using several tools 
of the online bioinformatics suite: Genomatix, including PromoterInspector 
MatInspector and ModelInspector.  This data was combined and the most significant 
‘hits’ are tabularised with the corresponding p-value. 
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Table. 9.  Potential Post-Translational Co-regulators of LXN and RARRES1.  
Post-translational co-regulators of LXN and RARRES1 were predicted using 
microrna.org and mirwalk. miRNA expression in the prostate epithelia of potentially 
important miRNAs was investigated using an ‘in-house’ miRNA expression database 
Rane et al (2015). This data was combined and shown in the table. 
SC. Stem Cell, TA. Transit Amplifying Cell, CB. Committed Basal Cell, PrEC. Normal 
Human Prostate Epithelial Cells, BPH. Benign Prostatic Hyperplasia, PCa. Prostate 
Cancer and CRPC. Castration-resistant Prostate Cancer 
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6. Conclusions  
The aim of developing a qPCR based method for the identification and quantification of 
AR gene amplification has been comprehensively met. The assay described in this report 
can distinguish between male (one copy of AR) and female (two copies) DNA and is 
sensitive enough to detect the presence of a duplication of the AR gene even if only 20% 
of the sample harbours the duplication. It is therefore suitable for the interrogation of 
heterogeneous biopsy samples. The inclusion of DMD as an X-encoded control gene has 
expanded the applicability of this assay by allowing simultaneous detection of XCA which 
is common in hormone naïve CaP (~25%) and is a poor prognostic indicator. Assay 
validation was performed using ten blinded samples (five positive and five negative) in 
which the GAAR status was independently verified by FISH. All GAAR positive samples 
were identified and none of the GAAR negative samples were misidentified. GAAR and 
XCA were detected in at least two near-patient xenografts derived from CRPC tissue. One 
such passage zero xenograft (H455X) exhibited an inferred XCA of four and a GAAR of 
seven relative to patient-derived lymphocyte DNA. The assay was subsequently shown to 
be compatible with DNA derived from FFPE tissue. Detection of GAAR and XCA in near-
patient xenografts derived from CRPC tissue is strong evidence that these genetic 
abnormalities are present in cells capable of tumour reconstitution in vivo. This new 
method has several advantages over FISH including a shorter ‘turnaround time’ and it is 
more amenable to high throughput scaling. The technique has the potential to triage 
patients according to their GAAR and XCA status, allowing an improved personalised-
medicine approach for the treatment of CRPC. 
In order to facilitate further study of RARRES1 and LXN overexpression, particularly in 
primary prostate epithelial cells, lentiviral vector production using Gateway™ cloning and 
viral particle generation was established, validated and optimised. This allowed the 
production of viral titres in excess of 1x107 IU/ml. These vectors stably transduced 
primary prostate epithelial cells with high efficiency and transgene silencing was not 
observed. This is in contrast to a published, previous attempt to utilise lentiviral vectors 
by our lab, which were limited by low titres, low transduction efficiency and promoter 
silencing. Lentiviral vectors permitted the analysis of changes in gene expression induced 
by RARRES1 and LXN overexpression and analysis of the intracellular localisation of LXN. 
I have investigated the intracellular localisation of LXN utilising confocal microscopy of 
live cell imaging of mVenus tagged LXN and subcellular fractionation. The results of this 
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analysis show that in primary prostate epithelial cells that LXN is a pan-cellular protein 
capable of accessing both the cytoplasm and the nucleus. 
ChIP was used to investigate the role that posttranslational modification of histone 
proteins plays in the epigenetic regulation of RARRES1 and LXN. It was discovered that 
RARRES1 is epigenetically regulated through histone protein modifications in PNT2C2 
cells. In order to investigate this regulatory mechanism in primary prostate SCs, a µChIP 
method was established and validated. This allowed the first targeted study of LXN and 
RARRES1 promoter regions. The results of this analysis provided evidence for ‘poised 
chromatin’ (a characteristic of embryonic stem cells) in both the LXN and RARRES1 
promoters which were both enriched above the IgG control by anti-H3K27me3 (inactive 
mark) and anti-H3K4me3 (active mark) relative to negative control genes (GAPDH for 
H3K27me3 and PDYN for H3K4me3). 
Progress has been made on the identification of LXN and RARRES1 interactors, to this end 
MS was used to generate a ‘hit list’ for both proteins. Whilst both data sets remain un-
validated, the LXN hits agree with the newly discovered pan-cellular distribution and the 
RARRES1 hits agree with the published localisation of RARRES1 to the endoplasmic 
reticulum membrane. 
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Appendices 
Appendix 1. Patient samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample ID Pathology
H024 CaP 4+3=7
H027 CaP 5+4=9
H042 CaP 3+4=7
H110 CaP 3+4=7
H135 CaP 5+4=9
H217 CaP 3+4=7
H220 CaP 3+4=7
H224 CaP 4+5=9
H226 BPH
H227 BPH
H229 CaP 4+4=8
H427 CaP 4+5=9
H455 CRPC
H460 CaP 4+5=9
H493 CaP 4+5=9
H521 CaP 3+4=7
H530 CaP 4+4=8
H533 BPH
HaCaP CRPC
Y018 CRPC
Y019 CRPC
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Appendix 2. Primers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Forward Reverse
Annealing 
Temperature °C
AR TCATTATCAGGTCTATCAACTCTT GTCATCCCTGCTTCATAACATTTC 58
DMD TTGGTTGCCAGTTATGGGCT CCAGCTGTCATGCAAAACCC 58
GAPDH ATGCTGCATTCGCCCTCTTA GCGCCCAATACGACCAAATC 58
LXN PP1 TCCAGTATGCAAGCGAAGCA CGCTGGGATTGCATCTTTCG 55
LXN PP2 GACAGTGTCTGCAAAGCAAA TACCATCTGTCTGCTTGCCC 58.5
LXN PP3 TCCTGGACTGCACATATAATGACA AAACTGGCTGTAGCTCACCT 55
LXN PP4 CCCGGGACTGTTTTCACCTT GAAAGTGCTGCCCCTTACCT 55
LXN PP5 AGCCCCTCCAACCAAATGAG GGTGATACTTATGTCCTCTTCCTGG 58.5
RARRES1 PP1 GCTGCGGCCTGCCCCTTTCTC ACTTGGCGTTTCCCCTGCGGTTTC 58.5
RARRES1 PP2 ACCACCCACTGGCAAAAAGA TGCTAGGCACTCCCAACATC 58.5
RARRES1 PP3 ATGACTGGGTTCTGGGAGGT GATCAGCGGATCCTGGAGTT 55
RARRES1 PP4 TAATTGCAGTCCACCACGCT ATCAGACGCCAGCATTAGCA 58.5
RARRES1 PP5 CCTAGTCCAACAGAGCAGTGA CCCTTCTTTAGGCTCTGGGC 58.5
GAPDH(ChIP) CCTAGGTGGGGGACGTTTCTTTC AACGGCTGCCCATTCATTTCCTTC 58.5
PDYN AGGGCTTTGGTGGTGTTC AGTGCCCCCCTCTGGATGTTAC 55
Sequence 
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Appendix 3. Antibodies 
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Appendix 4. Plasmids 
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Appendix 5. IgH and EBV Testing of Xenogratft Models 
 
 
 
 
 
 
 
 
 
A = IGH rearrangements in a PDX panel. PCR amplification of VJD regions using a 
multiplex PCR. W = water control. + = positive control (B cell lymphoma clonal control). - 
= negative control (prostate epithelial primary culture).暨Rearrangements in  Y042, 
H016, H042, H084, H027, H288, H050, H024 are within the valid size range (310-360bp). 
FR2-JH: H084, H027, H288, H050, H024 are within the valid size range (250-295bp). FR3-
JH: Y042, H016, H084, H082, H087, H460, Y018, H050, H024 are within the valid size 
range (100-170bp). DH-JH: H084, H087, H493, Y056 are within the valid size range (110-
290 and 390-420bp). DH7-JH: valid size range is 100-130bp.   
 
Clonality was evaluated by PCR for V-J gene rearrangements of the IgH locus using the 
IdentiClone™ diagnostic kit from Invivoscribe.  The assay employs multiple consensus 
DNA primers that target conserved genetic regions within the IgH locus.  The test 
includes 6 master mixes targeting the conserved framework (FR) of the variable (V) 
regions and the conserved joining (J) regions, as well as the diversity (D) and joining 
regions.  PCR products were loaded onto a non-denaturing 6% polyacrylamide TBE gel 
and visualised under UV light using GeneSnap ID software (Syngene). 
B = EBV testing of xenograft samples. Xenograft samples were interrogated for presence 
of EBV by PCR using primers specific for Epstein–Barr nuclear antigen 1 (EBNA1).psPCR 
products were loaded on to a 1.5% Agarose TBE gel and visualised under UV light using 
GeneSnap ID software (Syngene). Lane guide is shown in C. 
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Abbreviations 
Abbreviation Description 
°C Degree(s) Celsius 
18S 18S ribosomal RNA 
2+Edel  
Fusion of TMPRSS2 to the ERG sequence together with 
interstitial deletion of sequences 5′ to ERG 
ADP Adenosine diphosphate 
ADT Androgen deprivation therapy 
AF Activation function 
Akt Serine/threonine Kinase 1 
ALL Acute lymphoblastic leukaemia 
AML Acute myeloid leukaemia 
APL Acute promyelocytic leukaemia  
AR Androgen Receptor 
ARE Androgen response element 
AR-V7  Androgen-receptor splice variant 7 
ATF4 Activating transcription factor 4 
ATP Adenosine triphosphate  
atRA All-trans retinoic acid 
attB  Site of site-specific recombination B 
attP Site of site-specific recombination P 
attR Site of site-specific recombination R 
B cell B lymphocyte 
BALB/c   Albino, laboratory-bred strain of the house mouse 
BCA Bicinchoninic acid 
bcl-2 B-cell lymphoma 2  
BCR/ABL  
Fusion gene juxta positioning the Abl1 gene on chromosome 9 
(region q34) to a part of the BCR (“breakpoint cluster region”) 
gene on chromosome 22 (region q11) 
BM Basement membrane 
BMP Bone morphogenetic protein 
bp Base pairs 
BPH Benign prostatic hyperplasia 
BRAF Murine sarcoma viral oncogene homolog B 
BRCA1 Breast cancer 1 
BRCA2 Breast cancer 2 
BRDU 5-bromo-2’-deoxyuridine 
BSA Bovine serum albumin  
CAIS Complete androgen insensitivity syndrome  
Camp  Cyclic adenosine monophosphate 
CaP Prostate cancer 
CARN Castration-resistant Nkx3.1-expressing cells 
CB Committed basal cell 
ccb Bacterial death gene 
CD Cluster of differentiation  
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cDNA Complementary DNA 
ChIP Chromatin immunoprecipitation 
CI Confidence interval  
CIN Chromosomal instability  
CK Cytokeratin 
c-met Tyrosine-protein kinase Met 
c-Myc  Avian myelocytomatosis viral oncogene homolog 
CNL Chronic neutrophilic leukaemia  
CO2 Carbon dioxide 
Co-IP Co-immunoprecipitation 
CPA Carboxypeptidase A 
CpG A cytosine base followed immediately by a guanine base  
CPI Carboxypeptidase inhibitor 
cPPT Central polypurine tract 
cPSA Complexed PSA 
Cq Quantification cycle 
CRAPome The contaminant repository for affinity purification 
CREB  Camp response element-binding protein 
CRE-LOX  
Site-specific recombinase technology utilising Cre recombinase 
and Lox  sequence both derived from bacteriophage P1 
CRPC Castration-resistant prostate cancer 
CSC Cancer stem cell 
Ct Threshold cycle 
CTC Circulating tumour cells 
CYP17 Cytochrome P450 17alpha hydroxylase/17,20 lyase 
D10 DMEM + 10% FCS 
DAPI 4’,6-diamidino-2-phenylindole 
DBD  DNA-binding domain 
ddH20 Double distilled water 
DDIT3  DNA damage-inducible transcript 3 
DEPC Diethylpyrocarbonate 
DHFR Dihydrofolate reductase  
DHT 5α-dihydrotestosterone 
DKK1 Dickkopf-related protein 1 
DMD Dystrophin 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNMTi DNA methyltransferase inhibitors  
dNTP Deoxynucleotide 
dsDNA Double-stranded DNA 
DTT Dithiothreitol 
EB1 End-binding protein-1  
EBV Epstein–Barr virus 
E.Coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
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EGF Epidermal growth factor 
eGFP Enhanced GFP 
EGFR Epidermal growth factor receptor  
EGTA 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic 
acid 
ELF-3 E74 like ETS transcription factor 3 
EMA European medicines agency 
EMT Epithelial–mesenchymal transition  
env  HIV virulence gene – env 
ER Oestrogen receptor 
ERG ETS-related gene 
Erks Extracellular signal–regulated kinases 
ESR1 Oestrogen receptor alpha 
EZH2 Enhancer of zeste homolog 2 
FAM Fluorescein 
FCS Foetal calf serum 
FDA Food and drug administration 
FFPE Formalin fixed paraffin embedded 
FGF Fibroblast growth factor 
FISH Fluorescent in situ hybridization 
FLAG FLAG epitope tag,  sequence motif = DYKDDDDK 
fmol Femtomole 
Foxa1 Forkhead box protein A1 
fPSA Free PSA  
g/L Gram per litre 
GAAR Genomic amplification of the AR gene  
gag-pol Polyprotein – reverse transcriptase derived from HIV 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GC:AT  Guanine and cytosine to adenine and thymine ratio 
gDNA Genomic DNA 
GFP Green fluorescent protein 
GIN Genomic instability  
GnRH  Gonadotropin-releasing hormone  
gp120 Envelope glycoprotein GP120 
GPCRs G-protein-coupled receptors  
GRK5 G-protein-coupled receptor kinase 5  
GST Glutathione S-transferases 
GUS β-glucuronidase 
Gy Gray 
h Hours 
H&E Haematoxylin and eosin stain  
H1  Histone 1 
H2A Histone 2A 
H2AK119Ub Monoubiquitination of lysine-119 of Histone 2A 
H2B Histone 2B 
H3 Histone H3 
H3K27  Lysine 27 on histone 3 
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H3K27me3 Trimethylation of lysine 27 on histone 3 
H3K36 Lysine 36 on histone 3 
H3K4 Lysine 27 on histone 3 
H3K4me3 Trimethylation of lysine 4 on histone 3 
H3K79 Lysine 79 on histone 3 
H3K9 Lysine 9 on histone 3 
H3K9ac Acetylation of lysine 9 on histone 3 
H3K9me2 Dimethylation of lysine 9 on histone 3  
H4  Histone 4 
H4K20 Lysine 20 on histone 4 
H4K20me3 Trimethylation of lysine 20 on histone 4 
HA  Hemagglutinin 
HAT Histone acetyltransferase 
HCl Hydrochloric acid 
HDAC Histone deacetylases 
HDACI Histone deacetylase inhibitor 
HDGF Hepatoma-derived growth factor 
HER2 Human epidermal growth factor receptor 2 
HGPIN High-grade PIN  
HIS Polyhistidine-tag 
HIV Human immunodeficiency virus  
HPLC High performance liquid chromatography 
HR Hormone responsive  
HRP Horseradish peroxidase 
HSC Hematopoietic stem cell 
HSP Heat shock protein 
IF Immunofluorescence 
IgG Immunoglobulin G 
IGH  Immunoglobulin heavy chain locus 
IL Interleukin 
IP Immunoprecipitation 
IPO7 Importin-7  
IU/ml Infectious units per millilitre 
kb Kilobase 
KCl Potassium chloride 
kDa Kilo Dalton 
Ki67 Antigen KI-67  
KRAS Kirsten rat sarcoma viral oncogene homolog 
KSFM Keratinocyte serum-free medium 
LB Lysogeny broth  
LBD Ligand-binding domain  
LC-MS Liquid chromatography–mass spectrometry 
LiCl Lithium chloride 
Lin  Lineage markers 
lncRNA Long non-coding RNA 
LTR Long terminal repeat 
LV Lentivirus 
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LXN Latexin 
M Molar 
MACS Magnetic-activated cell sorting 
Mek  Mitogen-activated kinase 
MFH Malignant fibrous histiocytoma  
mg Milligrams 
min Minutes 
miR Mature form of the miRNA 
miRNA microRNA 
ml Millilitre 
mm Millimetre 
Mm  Millimolar 
MOI Multiplicity of infection  
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA Messenger RNA 
MS Mass spectrometry  
MSCs Mesenchymal stem cells  
mTOR Mechanistic target of rapamycin 
MTX Methotrexate 
mVenus Modified version of yellow fluorescent protein  
MW Molecular weight 
NaAc Sodium acetate 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NCBI National center for biotechnology information 
NED Reporter dye used in TaqMan assays 
NF κβ Nuclear factor kappa-light-chain-enhancer of activated B cells 
NFE2L1 Nuclear factor erythroid 2-related factor 1  
ng Nanogram 
ng/ml Nanogram per millilitre 
NHS National health service 
NICE The national institute for health and care excellence 
Nkx3.1 Homeobox protein Nkx-3.1 
nM Nanomolar 
nm Nanometre 
NOD/SCID Nonobese diabetic/severe combined immunodeficiency 
NP-40 Tergitol-type NP-40 
ns Non-significant 
NTD Amino-terminal domain 
OCT4 Octamer-binding transcription factor 4 
OG Oncogenes 
p53 Tumour protein p53 
p63 Tumour protein p63  
PAP Prostatic acid phosphatase 
psPAX2 
Lentiviral packaging plasmid containing Gag, Pol, Rev 
sequences 
PBS Phosphate-buffered saline 
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PCA3 Prostate cancer gene 3 
PCNA Proliferating cell nuclear antigen  
PCR Polymerase chain reaction  
pDEST Destination plasmid  
PDGFRB  Platelet derived growth factor receptor beta 
PDK1 Phosphoinositide-dependent kinase-1 
Pdonr-221  
Gateway™ cloning plasmid containing Puc origin for high 
plasmid yields and universal M13 sequencing  sites 
PDX Patient-derived xenograft 
PDYN Neoendorphin-dynorphin-enkephalin prepropeptide gene 
PEG Polyethylene glycol  
PGE2 Prostaglandin E2 
pH Potential of hydrogen 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIN Prostatic intraepithelial neoplasia 
PIP2 Phosphatidylinositol 4,5-bisphosphate  
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PIPES piperazine-N,N′-bis(2-ethanesulfonic acid) 
PML Promyelocytic leukaemia 
PMP Polymethylpentene 
PP2A Serine/threonine-protein phosphatase 2A 
PPAR Peroxisome proliferator-activated receptor 
PPP2CB 
Serine/threonine-protein phosphatase 2A catalytic subunit 
beta isoform 
Pre-miRNA  Precursor microRNA 
Pri-miRNA Primary miRNA 
PSA Prostate-specific antigen 
PSMA Prostate-specific membrane antigen  
PTEN Phosphatase and tensin homolog 
PURO-R  Puromycin-resistance gene 
QC Quality Control 
qPCR Quantitative polymerase chain reaction  
R10 RPMI + 10% FCS 
R2 Statistical measure of closeness of fit to a regression line 
RA Retinoic acid 
Raf Proto-oncogene serine/threonine-protein kinase  
RAG2 Recombination activating gene 2  
RAR Retinoic acid receptor 
RARE Retinoic acid response element 
RARRES1 Retinoic acid receptor responder 1 
Rb Retinoblastoma protein  
rev 
Regulatory protein Rev,  essential for post-transcriptional 
transport of the un-spliced and incompletely spliced viral 
mRNAs from nuclei to cytoplasm 
RIN RNA integrity number 
RIPA Radioimmunoprecipitation assay  
RISC RNA-induced silencing complex 
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RNA Ribonucleic acid 
RNA pol II RNA polymerase II 
RNase Ribonuclease 
RNA-seq  RNA sequencing 
RPLPO  60S acidic ribosomal protein P0  
RPM Revolutions per minute 
RPMI Roswell park memorial institute-1640 medium 
RPS3 Ribosomal protein S3 
RRE Rev responsive element 
rRNA  Ribosomal RNA 
RT Room temperature 
RT-PCR Reverse transcription polymerase chain reaction 
RXR Retinoid X receptor 
S100P S100 calcium-binding protein P 
SC Stem cell 
Sca-1 Stem cells antigen-1 
SDS Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
secs Seconds 
SHH Sonic hedgehog  
SIN Self-inactivating configuration 
SLPI Secretory leukocyte protease inhibitor 
SOC Super optimal broth with catabolite repression 
SP Side population 
SQ Starting quantity 
Src Proto-oncogene tyrosine-protein kinase Src 
ssDNA Single-stranded DNA 
SV40 Simian vacuolating virus 40 
T cell T lymphocyte 
TA Transit amplifying cells 
TAE Tris-acetate-EDTA 
TAF TBP-associated factor 
TAQ Thermus aquaticus 
TBP TATA-binding protein  
TBST Tris-buffered saline with 0.1% Tween 20 
TCF T cell factor  
TE  Tris-EDTA 
TIC Tumour initiating cells 
TMPRSS2 Transmembrane protease, serine 2 
TMPRSS2-ERG  Fusion of TMPRSS2 gene to the ERG gene 
TRAIL Tumour necrosis factor-related apoptosis-inducing ligand 
TRAMP Transgenic adenocarcinoma of the mouse prostate 
Tris (HOCH2)3CNH2 
tRNA Transfer ribonucleic acid 
Trop2 Tumour-associated calcium signal transducer 2 
TSG Tumour suppressor genes  
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TURP Transurethral resection of the prostate 
U/ml Unit per millilitre 
UGE Urogenital sinus epithelium  
UK United Kingdom 
USM Urogenital sinus mesenchyme 
UTR Untranslated region 
UV Ultraviolet 
V Volt 
v/v Volume per volume 
V5 
Epitope tag derived from the RNA polymerase α subunit of 
simian parainﬂuenza virus type 5 
VSV-G Vesicular stomatitis Indiana virus – protein G 
w/v Weight per volume 
WFDC1 WAP four-disulphide core domain 1 
Wnt Wingless-related integration site protein 
WPRE 
Woodchuck hepatitis virus post-transcriptional regulatory 
element 
WT Wild type  
x g Times gravity – units of relative centrifugal force 
XCA X chromosome aneuploidy 
α2β1 Collagen receptor 
γC  Common gamma chain 
γH2AX Phosphorylation on serine 139 of histone H2A variant X 
µChIP Micro chromatin immunoprecipitation 
μg Microgram 
μg/ml Microgram per millilitre 
μl Microlitre 
mM Micromolar 
μm Micrometre 
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